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ABSTRACT 
Parkinson’s disease (PD) is a neurodegenerative movement disorder characterized by the loss of 
dopaminergic neurons in the substantia nigra of the midbrain. Although the aetiology of PD is still not 
fully understood, it is thought to involve a combination of environmental and genetic factors. To date, 
a number of PD-causing genes have been found. The PINK1 gene is of particular interest for this study, 
and mutations in this gene result in autosomal recessive inheritance of early onset PD. PINK1 plays a 
vital role in mitochondrial quality control and homeostasis, and in its absence it is thought to result in 
an accumulation of dysfunctional mitochondria in neurons, culminating in neuronal cell death. Whilst 
pharmacological and surgical interventions are available for PD, the current options exhibit adverse 
side effects with long term treatment. There is a great need to develop new treatments with i. less side 
effects and ii. that can simultaneously target the multiple pathways associated with this disorder. One 
molecule is curcumin, the core component of the curry spice turmeric, which is well known for its 
antioxidant and anti-inflammatory properties and has already been studied for its possible 
neuroprotective role in Alzheimer’s disease. 
The aim of the present study was to create a cellular model of PD by decreasing the expression of 
PINK1 in SH-SY5Y neuroblastoma cells. Thereafter, we aimed to test the protective effects of curcumin 
on this model in the presence and absence of a known stressor, paraquat. This study also aimed to detect 
possible copy number variation (CNV) in PINK1 (and other PD-causing genes) in a cohort of South 
African patients with PD, in order to obtain patient-derived fibroblasts to verify the results obtained 
from the original cellular model. 
PINK1 was knocked down using siRNA (Qiagen, USA) in SH-SY5Y neuroblastoma cells, and the 
knock down was verified by quantitative real time PCR (qRTPCR) and western blotting. Thereafter, 
PINK1 siRNA cells and control cells were separated into four treatment groups: i. untreated, ii. treated 
with 25µM paraquat for 24hours, iii. pre-treated with 2µM curcumin for 1hour then treated with 25µM 
paraquat for 24hours, or iv. treated with 2μM curcumin for 1hour, and various parameters of cellular 
and mitochondrial function were measured. Cell viability was measured by an MTT assay. Western blot 
analysis was performed using cleaved PARP and full-length caspase 3 markers to detect levels of 
apoptosis, and LC3-II and p62 markers to detect autophagic flux. Mitochondrial respiration experiments 
were completed on the Seahorse XF Analyser using the Mito Stress Test Kit and the Glycolysis Stress 
Test. Flow cytometry was utilised to measure mitochondrial membrane potential (MMP) using the JC-
1 fluorochrome, and mitochondrial network was analysed by fluorescent microscopy. For CNV 
detection, MLPA was performed on 210 South African PD patients and putative mutations were verified 
by qRTPCR on the Lightcycler 96. 
PINK1 was successfully knocked down at a gene and protein expression level. The PINK1 siRNA cells 
exhibited a significant decrease in cell viability (p=0.0036), and an increase in apoptosis (p=0.0144). A 
decrease in PINK1 expression also resulted in significantly decreased MMP (p=0.0008), mitochondrial 
respiration (p=0.0015), ATP production (p=0.002) and glycolytic capacity (p=0.0445). No significant 
changes were observed in the connectivity of the mitochondrial network, but autophagic flux was 
significantly increased in the PINK1 siRNA cells, as detected by increased LC3-II levels (p=0.0152). 




As expected, paraquat-treated cells exhibited decreased cell viability, increased apoptosis, decreased 
MMP, autophagic flux, and a more fragmented mitochondrial network. Paraquat treatment therefore 
successfully acted as a stressor on the cells. Curcumin pre-treatment followed by paraquat treatment 
rescued cell viability in control cells (p=0.003), and significantly decreased apoptosis in PINK1 siRNA 
cells (p=0.0018). Curcumin protected mitochondrial dysfunction in PINK1 siRNA cells by increasing 
MMP (p=0.0472) and maximal respiration (p=0.0014), as well as significantly increasing MMP 
(p=0.0307) and maximal respiration (p=0.032) in control cells. Additionally, curcumin treatment 
resulted in increased autophagic flux (p=0.0017) in stressed control cells. These results highlight a 
protective effect of curcumin against paraquat and against the damaging effects on the mitochondria in 
cells with decreased PINK1 expression.  
 
Lastly, MLPA analysis did not reveal any PINK1 CNV mutations in a total of 210 South African PD 
patients, and fibroblasts were therefore not obtained. A number of false positive mutations were 
identified that were not verified by qRTPCR. A common polymorphism M192L resulting in a false 
positive PARK2 exon 5 deletion was found in a number of patients, all of whom were of Black or Mixed 
Ancestry ethnic groups. One patient was shown to harbour a heterozygous deletion in PARK2 exon 4. 
 
In conclusion, PINK1 siRNA-mediated knock down in SH-SY5Y neuroblastoma cells can be used as 
a model of PD to study aspects of mitochondrial dysfunction. Furthermore, curcumin should be 
considered as a possible therapeutic target for PD, as it exhibits protective effects against paraquat at a 
mitochondrial level. Given the low toxicity of curcumin, and the fact that it is already part of a dietary 
regimen in most populations worldwide, further studies on elucidating its biochemical and cellular 
properties are therefore warranted. The use of natural compounds such as curcumin as therapeutic 
agents is currently a topical and fast-growing area of research, and holds much promise for clinical 
application in various diseases including neurodegenerative disorders such as Alzheimer’s disease and 
PD.   





Parkinson se siekte (PD) is 'n neurodegeneratiewe beweging versteuring wat gekenmerk word deur die 
verlies van dopaminergiese neurone in die brein. Hoewel die etiologie van PD nog nie ten volle verstaan 
is nie, is daar denke dat dit 'n kombinasie van die omgewing en genetiese faktore behels. Tot dus ver is 
daar nog net ‘n aantal gene wat PD-veroorsaak gevind. Die PINK1 geen is van besondere belang vir 
hierdie studie, en mutasies in dié geen veroorsaak outosomale resessiewe oorerwing van vroeë aanvang 
PD. PINK1 speel 'n belangrike rol in die mitochondriale gehaltebeheer en homeostase, en in sy 
afwesigheid is dit gedink om te lei tot 'n opeenhoping van disfunksionele mitochondria in die neurone, 
wat kulmineer in neuronale sel dood. Terwyl farmakologiese en chirurgiese ingrepe beskikbaar is vir 
PD, die huidige opsies wys duidelike newe-effekte met lang termyn behandeling. Daar is 'n groot 
behoefte om nuwe behandelings te ontwikkel met i. minder newe-effekte en ii. wat gelyktydig die 
verskeie paaie wat verband hou met hierdie versteuring kan teiken. Een molekule is curcumin, die hoof 
komponent van die kerrie spesery borrie, wat wel bekend is vir, sy anti-oksidant en anti-inflammatoriese 
eienskappe, en is reeds bestudeer vir sy moontlike beskermende rol in Alzheimer’s se siekte. 
 
 
Die doel van hierdie projek is om 'n sellulêre model van PD te skep deur die vermindering van die 
uitdrukking van PINK1 in SH-SY5Y neuroblastoom selle. Ons daarop gemik om die beskermende effek 
van curcumin te toets in die teenwoordigheid en afwesigheid van 'n bekende stressor, parakwat in ons 
model. ‘n Additionele doelwit is om moontlike kopiegetal variasie (CNV) in die PINK1 gene (en ander 
PD veroorsaakende gene) op te tel in 'n groep van die Suid-Afrikaanse pasiënte met PD. Die doel van 




SH-SY5Y neuroblastoom selle was gekweek, en PINK1 is platgeslaan deur gebruik te maak van siRNA 
en HiPerfect Transfectie Reagens (Qiagen, VSA). Klop van PINK1 is bevestig deur kwantitatiewe real 
time PCR (qRTPCR) en westelike klad. Daarna, PINK1 siRNA selle en beheer selle was óf i. nie 
behandel nie, ii. behandel met 25 um paraquat vir 24 uur per dag, iii. vooraf behandel met 2μM curcumin 
vir 1 uur dan behandel met 25 um paraquat vir 24 uur per dag, of iv. behandel met 2μM curcumin vir 1 
uur, en verskeie parameters van sellulêre en mitochondriale funksie is gemeet. Lewensvatbaarheid van 
die selle is gemeet deur 'n MTT toets. Westerne klad analise is uitgevoer met behulp van gekleefde 
PARP en vollengte caspase 3 merkers om die vlakke van apoptose te meet, en LC3-II en p62 merkers 
was gebruik om autophagic vloed op te spoor. Mitochondriale respirasie eksperimente is voltooi op die 
Seahorse XF Analyser met behulp van die Mito Stres Test Kit en die Glikolise Stres Toets. 
Vloeisitometrie is gebruik om mitochondriale membraan potensiaal (MMP) te meet met behulp van die 
JC-1 fluorochrome en die mitochondriale netwerk is geanaliseer deur fluorescent mikroskopie. Vir 
CNV opsporing, was MLPA uitgevoer op 210 Suid-Afrikaanse PD pasiënte en vermeende mutasies is 
bevestig deur qRTPCR op die Lightcycler 96. 
 
 
PINK1 is suksesvol platgeslaan op 'n geen en proteïen uitdrukking vlak. Die PINK1 siRNA selle betoon 
'n beduidende afname in lewensvatbaarheid sel (p = 0.0036), en 'n toename in apoptose (p=0.0144). 'n 
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Afname in PINK1 uitdrukking het ook daartoe gelei na ‘n beduidende vermindering in MMP 
(p=0.0008), mitochondriale respirasie (p=0.0015), ATP produksie (p=0.002) en glikolitiese kapasiteit 
(p=0.0445). Geen beduidende veranderinge is waargeneem in die verbinding van die mitochondriale 
netwerk nie, maar autophagic vloed het aansienlik toegeneem in die PINK1 siRNA selle, soos 
waargeneem deur verhoogde vlakke in LC3-II (p=0.0152). 
 
 
Soos verwag betoon, paraquat behandelde selle ‘n afname in sel lewensvatbaarheid, verhoogde 
apoptose, afname in MMP, autophagic vloed, en 'n meer gefragmenteerde mitochondriale netwerk. 
Parakwat behandeling het dus suksesvol opgetree as 'n stressor op die selle. Curcumin vooraf-
behandeling gevolg deur paraquat behandeling het sel lewensvatbaarheid gered in beheer selle 
(p=0.003), en aansienlik verminderde apoptose in PINK1 siRNA selle (p=0.0018) betoon. Curcumin 
beskerm mitochondriale disfunksie deur die verhoging van MMP (p=0.0472, p=0.0307) en maksimale 
respirasie (p=0.0014, p=0.032) in beide PINK1 siRNA en beheer selle. Additioneel, het curcumin 
behandeling gelei tot ‘n verhoogde autophagic vloed (p=0.0017) in onderdrukte beheer selle. Hierdie 
resultate beklemtoon die beskermende effek van curcumin teen parakwat en teen die skadelike resultaat 
op die mitochondria in die selle met verlaagde PINK1 uitdrukking. 
 
 
Laastens, MLPA ontleding het nie PINK1 CNV mutasies openbaar in 'n totaal van 210 Suid-Afrikaanse 
PD pasiënte, en fibroblaste is dus nie verkry nie. 'n Aantal vals positiewe mutasies is geïdentifiseer wat 
nie geverifieer is deur qRTPCR. 'n Algemene polimorfisme M192L is in 'n aantal pasiënte gevind wat 
in 'n vals positiewe PARK2 ekson 5 eliminasie ontaard, waarvan almal swart of gemengde afkoms etiese 
groepe is. Een pasiënt het getoon dat 'n heterosigotiese eliminasie in PARK2 ekson 4 bevind is. 
 
 
Ten slotte, PINK1 siRNA-gemedieerde wat platgeslaan is in SH-SY5Y neuroblastoom selle kan gebruik 
word as 'n model van PD om aspekte van mitochondriale disfunksie te bestudeer. Verder moet curcumin 
beskou word as 'n moontlike terapeutiese teiken vir PD, omdat dit beskermende effekte teen parakwat 
op 'n mitochondriale vlak vertoon. Gegewe die lae toksisiteit van curcumin en die feit dat dit reeds ‘n 
deel vorm van die dieët in meeste populasie groepe wêreldwyd, is verdere studies op die biochemiese 
en sellulêre eienskappe daarvan benodig. Die gebruik van natuurlike komposisies, soos curcumin as ‘n 
terapeutiese middel is tans ‘n relevante en vinnig groeiende area van navorsing en toon baie belofte vir 
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Parkinson’s disease (PD) is a neurodegenerative disorder that is characterised by the degeneration of 
the neuromelanin-containing dopaminergic neurons of the substantia nigra pars compacta (SNc). PD 
was first discovered almost two centuries ago in 1817 by Dr. James Parkinson. In his ‘Essay on Shaking 
Palsy’ (Parkinson, 2002), Parkinson described the disease as a movement disorder, with symptoms 
including resting tremor, abnormal posture and gait, and diminished muscle strength.  Today, PD is 
recognised by four cardinal motor symptoms – bradykinesia (slowness of movement), rigidity, resting 
tremor and postural instability (Figure 1.1). Furthermore, patients suffering from PD also present with 
neuropsychiatric and non-motor symptoms including loss of smell, constipation, depression, sleep 
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PD is rare in individuals under the age of 50, and increases with increasing age thereafter. A study 
analysing global incidence rates observed an overall incidence of 12.3 per 100 000, and 44.0 per 
100 000 specifically for individuals over the age of 50 (Van den Eeden et al., 2003). A recent meta-
analysis of 47 studies found that PD prevalence also increased with age, with 40.5 in 100 000 in 40-49 
year olds compared to 1086.5 in 100 000 in 70-79 year olds (Pringsheim et al., 2014). It has also been 
found that there is increased mortality in PD patients compared to controls, and survival is reduced by 
approximately 5% every year of follow up (Macleod et al., 2014). 
 
1.2. Neuropathology of PD 
 
Dopaminergic neurons, found in the SNc, are responsible for the production of the hormone dopamine. 
Dopamine is involved in several pathways in the brain, including reward-motivated behaviour and 
motor control, and can also act as a chemical messenger for the release of other hormones.  Furthermore, 
dopamine-producing neurons also produce melanin, causing these neurons to be pigmented. PD is 
pathologically characterised by the loss of 70 – 80% of the dopaminergic neurons which results in 
depigmentation of the SNc (Figure 1.2A, B). This neuronal loss causes a substantial decrease in 
dopamine production, thus leading to the movement disturbances seen in PD patients.  
 
A second pathological characteristic of PD, and referred to as the pathological hallmark of this disease, 
is the presence of proteinaceous deposits known as Lewy bodies (LBs) in the SNc and several other 
regions of the brain (Figure 1.2C,D). LBs are cytoplasmic protein inclusions composed predominantly 
of alpha-synuclein, neurofilament proteins and ubiquitin (Spillantini et al., 1997). It is hypothesized that 
the formation of LBs occurs prior to PD diagnosis in the dorsal motor nucleus, and progressively moves 
through the brainstem into the SNc and towards the cerebral cortex (Braak et al., 2003). Post mortem 
















Figure 1.2. The pathology of the substantia nigra in Parkinson’s disease. A, B. Cross-section 
images of the midbrain indicating the pigmented substantia nigra and dopamine-producing neurons of 
healthy individuals (top), compared to the loss of pigmentation on the substantia nigra in PD patients 
(bottom). C, D. Animation (C) and histological staining (D) images indicating the presence of a Lewy 
body. Adapted from http://belairecare.com  
 
1.3. Age at onset 
 
The age at onset (AAO) in PD patients is categorised into three sub-groups - juvenile onset PD, early 
onset PD (EOPD) and late onset PD (LOPD). Juvenile onset PD (AAO <20 years) is uncommon, and 
is caused by rare mutations in the genes that cause PD (Section 1.4.2). EOPD (≤40-50 years) is also 
relatively rare with predominantly genetic causative factors. Patients with an AAO over the age of 50 
fall into the LOPD category, and this is thought to be caused by a combination of genetic and 
environmental factors. PD is an age-related disorder, and it has been found that an increase in age is 
one of the strongest risk factors. 
 
1.4. Causes of PD 
 
PD was traditionally considered to be a sporadic disease caused by environmental factors such as 
lifestyle and aging. However, the past eighteen years have been successful in proving the role of genetic 
factors in the cause of this condition. A positive family history is associated with a higher risk of PD 
and the aetiology of this disorder, although not fully understood, is considered to involve an interaction 
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1.4.1. Environmental causes 
 
The search into environmental causes of PD began after an incident in 1982 where heroin users in 
California presented with cases of acute parkinsonism (Langston, 1985). Dr. J.W. Langston identified 
that the cause of these severe symptoms was the presence of the toxic agent 1-methyl-4-phenyl-1,2,3,6-
tetrahydropyridine (MPTP) in the heroin. This discovery led to the development of animal models using 
MPTP, which displayed features of parkinsonism and led to selective degeneration of the dopaminergic 
neurons (Langston, 1985; Miller and DeLong, 1987). 
 
MPTP is able to cross the blood-brain barrier (BBB), where it is converted to its metabolite 1-methyl-
4-pyridinium (MPP⁺) via monoamine-oxidase B (MAO-B). MPP+ acts at the electron transport chain 
(ETC) as a mitochondrial complex I inhibitor, resulting in the disruption of oxidative phosphorylation, 
decreased ATP and increased reactive oxygen species (ROS) production, and ultimately cell death. This 
initial model of PD via the inhibition of complex I led researchers to search for agents with similar 





A meta-analysis determining environmental risk factors found that 11 out of 14 previous studies showed 
a positive association between pesticide exposure and PD (Priyadarshi et al., 2001). A second meta-
analysis including 46 previous studies observed a risk ratio for PD of 1.6 for ever (versus never) for the 
variable pesticide exposure (van der Mark et al., 2011). It is therefore generally accepted that exposure 
to pesticides results in an increased risk of disease onset. Two such pesticides are rotenone and paraquat 
(1,1’-4,4’-bypyridium dichloride). Rotenone has been used as an alternative to MPTP in animal models 
as it also inhibits mitochondrial complex I, causing mitochondrial dysfunction (Alam and Schmidt, 
2002; Sherer et al., 2003; Wrangel et al., 2015). It has been reported that autophagic dysfunction may 
contribute to neurodegeneration (Section 1.5.2; Dehay et al., 2010; Tan et al., 2014; Zhang et al., 2011), 
and rotenone has recently been shown to inhibit autophagic flux and induce lysosomal dysfunction in 




Much interest has been placed on paraquat, and in using paraquat to model PD, because its chemical 
structure closely resembles that of MPP+ (Figure 1.3; Goldman, 2014). Paraquat is one of the most 
widely used nonselective dipyridyl pesticides worldwide, and several studies have associated paraquat 
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use with an increased risk of PD (Hertzman et al., 1990; Kamel et al., 2007; Liou et al., 1997; Tanner 
et al., 2011). Paraquat induces parkinsonian features in animal models through the generation of ROS, 
which results in increased lipid peroxidation, decreased antioxidant levels, and impaired mitochondrial 
function (Costello et al., 2009; McCormack et al., 2002). Like rotenone, paraquat also selectively kills 
dopaminergic neurons. It is thought that the reason for this selectivity is the fact that SNc neurons have 
an increased sensitivity to oxidative stress.  
 
Evidence of the effect of paraquat on complex I has been conflicting. Some studies report that paraquat 
does not inhibit the mitochondrial complex I of the ETC (Mohammadi-Bardbori and Ghazi-Khansari, 
2008; Richardson et al., 2005), whereas other studies report that superoxide production by paraquat 
may be due to its effect on complex I (Fukushima et al., 2002). It has also been suggested that paraquat 
causes inhibition of complexes III and IV (Fukushima et al., 1995). In spite of this, paraquat 
mitochondrial toxicity appears to be caused by its acceptance of electrons from the complexes of the 
mitochondrial ETC, which then rapidly react with molecular oxygen to form free radicals such as the 







Figure 1.3. Structural similarity of MPP+ to paraquat. Taken from Goldman, 2014. 
 
1.4.1.2. Other environmental causes of PD 
 
Although pesticide use is one of the highest environmental risk factors for PD, there are several 
secondary factors that have shown a positive association for increased risk of PD (Priyadarshi et al., 
2001). Well-water can easily become contaminated with pesticides, volatile organic compounds and 
other chemicals, and drinking of this water could increase the risk of onset of disease. Furthermore, 
farming is also known to be a risk factor of PD, as this may result in direct contact with large quantities 
of pesticides through inhalation or absorption by the skin. It is due to both these reasons that rural living 
is also a risk factor (Priyadarshi et al., 2001), as well-water drinking and farming occur more frequently 
in rural areas. All of these factors are closely linked and interrelated to pesticide use, which may be the 
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reason why they are all positively associated with an increased risk of PD. Disease onset has also been 
linked to exposure to heavy metals such as iron, lead, manganese and mercury as well as head injury 
(Huang et al., 2006; Yamin et al., 2003; Jafari et al., 2013; Wirdefeldt et al., 2011), and studies suggest 
a dose-response relationship whereby the greater the number of head injuries, the greater the associated 
risk (Gao et al., 2015). 
 
1.4.2. Genetic causes 
 
Insights into phenotypic variation and disease susceptibility can be made through the study of genetic 
variation between individuals. Such variation includes single nucleotide polymorphisms (SNPs), 
various repetitive elements such as short tandem repeats involving short DNA sequences, small (<1kb) 
insertion/ deletion polymorphisms, and genomic structural alterations known as copy number variation 
(CNV, Feuk et al., 2006). Of the known PD-causing genes, five are linked to autosomal dominant forms 
of the disease (SNCA, LRRK2, VPS35, eIF4G1, CHCHD2), and four with autosomal recessive 
inheritance (parkin, PINK1, DJ-1, ATP13A2). A summary of the PD-associated loci and genes can be 
found in Table 1.1.  
 
1.4.2.1. Autosomal dominant genes 
 
The first known PD-causing gene, SNCA, was discovered in 1997 in a large Italian family that had a 
missense A53T mutation (Polymeropoulos et al., 1997). Since then, point mutations and whole-gene 
multiplications (duplications and triplications) of SNCA have been found in PD families worldwide 
(Ibáñez et al., 2004; Krüger et al., 2000; Singleton et al., 2003). Mutations of SNCA lead to missense 
variations and pathogenic overexpression of the encoded protein, α-synuclein (Corti et al., 2011),  which 
is a major component of LBs, the pathological hallmark of PD (Tu et al., 1998). Since then, several 
other genes have been implicated in autosomal dominant inheritance of PD. LRRK2, for example, is 
responsible for the most common cause of autosomal dominant PD due to the G2019S mutation in exon 
41 (Ozelius et al., 2006; Paisán-Ruíz et al., 2005). VPS35 was recently discovered to be a PD-causing 
gene by two separate studies both using the Next Generation Sequencing (NGS) approach, more 
specifically Whole Exome Sequencing (WES, Vilariño-Güell et al., 2011; Zimprich et al., 2011). The 
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Adapted from Trinh and Farrer, 2013.  Abbreviations:  GBA, glucocerebrosidase; LRRK2, leucine-rich repeat kinase 2; VPS35, vacuolar protein sorting 35; EIF4G1 = eukaryotic 
translation initiation factor 4G1;  PINK1 = PTEN-induced kinase 1;  SNCA =  α synuclein;  UCHL1 = ubiquitin carboxyterminal hydrolase 1;  MAPT = microtubule-associated 
protein tau;  FBOX7 = F-box only protein 7;  DNAJC = DNAJ- Homolog Subfamily C
Gene Locus Inheritance Mutations Protein Protein function 
Juvenile & Early Onset 
Parkin PARK2 Recessive Point mutations;  exonic rearrangements Parkin Cell signalling;  protein degradation and clearance 
PINK1 PARK6 Recessive Point mutations;  rare, large deletions PTEN putative induced kinase Unknown;  possible role in mitochondrial protection during 
oxidative stress 
DJ-1 PARK7 Recessive Point mutations;  large deletions Oncogene DJ-1 Unknown; possible role in cellular protection against oxidative 
stress 
ATP13A2 PARK9 Recessive Point mutations P5 subfamily of ATPases Unknown;  cellular cation homeostasis and maintenance of 
neuronal integrity  
Late Onset 
VPS35 PARK17 Dominant Point mutations Vacuolar sorting protein 35 Transport of proteins from endosomes to trans-Golgi network 
LRRK2 PARK8 Dominant Point mutations Leucine rich repeat kinase 2 Cellular and protein interactions and cell signalling 
SNCA PARK1/4 Dominant Point mutations;  gene duplications and 
triplications 
Alpha synuclein Synaptic vesicle recycling, compartmentalization of 
neurotransmitters 
eIF4G1 PARK18 Dominant Point mutations Eukaryotic translation initiation 
factor 4 gamma 1 
mRNA cap recognition, ATP dependent unwinding of 5’ terminal 
secondary structure; recruitment of mRNA to ribosome 
CHCHD2 - Dominant Point mutations Coiled-coil-helix-coiled-coil-helix 
domain containing 2 
Unknown; possible role in maintaining activity of oxidative 
phosphorylation 
Genes associated with PD 
GBA - - Point mutations Glucocerebrosidase Glucosidase is a lysosomal hydrolysing glucosylceramide, the 
penultimate intermediate in degradation of complex glycolipids 
  
MAPT - - Two distinct haplotypes can be associated 
with PD (H1 and H2) 
Microtubule Associated Protein 
Tau 
Promotion of microtubule assembly and stability 
DNAJC - - Point mutations DNAJ- Homolog Subfamily C Transport of  target proteins from ER to the cell surface 
 
FBOX7 PARK15 Recessive Point mutations F-box only protein 7 Substrate recognition component of a SKP1-CUL1 F-box protein 
E3 ubiquitin ligase complex  
UCHL1 PARK5 Dominant Point mutations Ubiquitin Carboxyl-Terminal 
Esterase L1 
A thiol protease that hydrolyses a peptide bond at the C-terminal 
glycine of ubiquitin 
PLA2G6 PARK14 Recessive Point mutations Phospholipase A2, Group VI Catalyses the release of fatty acids from phospholipids. 
Table 1.1. Summary of Parkinson’s disease-associated loci and genes  
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D620N mutation was confirmed to be disease-causing in familial PD cases with dominant inheritance 
(Bonifati, 2014). Lastly, the eIF4G1 gene mutation was first discovered in a large French family through 
a genome-wide linkage approach (Chartier-Harlin et al., 2011). The missense R1205H and A502V 
mutations are the only two mutations found to date (Chartier-Harlin et al., 2011; Lesage et al., 2012), 
and there are suggestions that mutations in this gene do not cause PD, but are rather rare benign variants 
as they are more frequent in controls than in cases (Nichols et al., 2015). 
 
1.4.2.2. Autosomal recessive genes  
 
Parkin mutations are the most common cause of autosomal recessive early onset PD (Lücking et al., 
2000), and such mutations result in a loss-of-function of the parkin protein. Functionally, parkin acts as 
an E3 ubiquitin ligase, and works in conjunction with E1 ubiquitin activating enzymes and E2 ubiquitin 
conjugating enzymes of the ubiquitin proteasome system (UPS, Section 1.5.1). Parkin is also selectively 
recruited to the outer mitochondrial membrane (OMM) where it is a key player in mitochondrial quality 
control (MQC, Kuroda et al., 2006; Narendra et al., 2008). After parkin, PINK1 (PTEN-induced 
putative kinase 1) mutations, either homozygous or compound heterozygous, account for 1-8% of early 
onset cases (Nuytemans et al., 2010), and are the second most common cause of autosomal recessive 
PD. The PINK1 protein is comprised of a mitochondrial targeting domain, resulting in its localization 
to the mitochondrial membrane (Gandhi et al., 2009). PINK1 plays a pivotal role in MQC together with 
parkin, and this will be discussed in greater detail in Section 1.7. Mutations in the DJ-1 and ATP13A2 
genes are rare causes of early onset autosomal recessive PD. There is speculation that DJ-1 may play a 
role in the PINK1/parkin pathway, but studies have been inconclusive to date (as reviewed in Van der 
Merwe et al., 2015).  
 
1.4.2.3. Copy Number Variation in PD 
 
Originally, CNV was defined as a segment of DNA that is 1kb or larger and is present at a variable 
copy number in comparison with a reference genome (Feuk et al., 2006). More recently, however, CNV 
describes any structural variation, including smaller events less than 1kb in size such as exonic 
rearrangements (Alkan et al., 2011). Classes of CNV include insertions, deletions, multiplications 
(duplications/ triplications), inversions and translocations (Figure 1.4). The discovery and genotyping 
of structural variation has been central to understanding disease associations, and altered expression 
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levels of CNV genes may be responsible for observed phenotypic variability, disease susceptibility and 
complex behavioural traits (Toft and Ross, 2010). In PD, CNV accounts for a number of pathogenic 










Figure 1.4. Illustration of different forms of chromosomal copy number variation including a) 
deletion, b) duplication, c) inversion and d) reciprocal translocation. Taken from 
http://bio1151.nicerweb.com/Locked/media/ch15/chromosome_mutations.html 
 
The most widely used method for CNV detection in PD is Multiplex Ligation-dependent Probe 
Amplification (MLPA), a gene dosage technique that enables the detection of smaller deletions or 
insertions (i.e. a single gene or part of a gene/exon). This approach is PCR-based, and allows for 
simultaneous analysis of multiple genomic regions. Probes for the exons of the gene of interest are 
hybridised to patient and control DNA. After ligation and amplification, the resulting products are then 
analysed by capillary electrophoresis. Comparison of the peak patterns of the patient to that of the 
control allows for the observation of aberrant copy numbers. MLPA has been particularly successful in 
the detection of disease-causing exonic rearrangements in PD patients (Cazeneuve et al., 2009; Kay et 
al., 2010; Keyser et al., 2009; Moura et al., 2012). However, despite the success of this technique in 
CNV detection in PD, a major limitation is the resulting false positives that may occur due to the 
presence of SNPs in the region of the probe sequences. One such example of this phenomenon is due 
to the presence of a polymorphism (c,A574C, p.Met192Leu) in the annealing site of the probe for parkin 
exon 5 (Keyser et al., 2009; Yonova-Doing et al., 2012). This results in incorrect ligation of the probe 
Stellenbosch University  https://scholar.sun.ac.za
12 
 
to the sample, and reduced PCR amplification. To correct for this, quantitative real time PCR (qRTPCR) 
is necessary to verify MLPA results.  
 
The first evidence of genomic variation in PD was the discovery of genomic duplications and 
triplications of the entire SNCA locus (Ibáñez et al., 2004; Singleton et al., 2003). In parkin, the majority 
of CNV observed in PD patients are large exonic deletions, although exonic duplications and 
triplications have also been found to a lesser degree. Despite the large amount of CNV observed in 
parkin, CNVs in other autosomal recessive forms of PD such as PINK1 and DJ-1 are far less frequent.  
To date, a deletion of exons 4 – 8 in PINK1 has been observed in a Sudanese family (Cazeneuve et al., 
2009), an exon 6 – 8 deletion in a Japanese family (Li et al., 2005) and a whole gene deletion in an 
Italian patient (Marongiu et al., 2007). A large study performed on 51 Iranian families with inherited 
PD found two families with homozygous PINK1 exon 4 and exon 5 deletions respectively.  To date, no 
CNVs have been observed in LRRK2, EIF4G1, VPS35 and ATP13A2. 
 
1.5. Mechanisms implicated in PD 
 
To date, the pathogenic mechanisms of PD have not yet been fully established. However, growing 
evidence suggests that the specific neuronal cell death of the SNc neurons occurs by way of multiple 
apoptotic processes, including oxidative stress and mitochondrial dysfunction, proteolytic stress and the 
UPS, and dysfunction of the autophagic pathway. This section will focus on each of these aspects in 
greater detail to further elucidate and understand the underlying mechanisms that may be involved in 
PD pathogenesis.  
 
1.5.1. The Ubiquitin Proteasome System 
 
The UPS is both a general and precise means for the disposal and removal of unwanted proteins in the 
cell that are either mutant, misfolded, damaged, terminally modified, or over-accumulated (Lehman, 
2009). Interestingly, a common feature of neurodegenerative diseases such as PD, AD, prion diseases, 
tauopathies, motor neuron disease, spinocerebellar ataxia and amyotrophic lateral sclerosis is the 
accumulation, aggregation and deposition of abnormal proteins in the brain of patients with these 
disorders (Ciechanover and Brundin, 2003; Taylor et al., 2002). The resulting accumulation of damaged 
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and unwanted proteins leads to the formation of insoluble aggregates that are deposited in disease-
specific inclusions (Taylor et al., 2002). For example, LBs are the result of a build-up of proteins in 
neuronal cells of PD patients. These observations led to the hypothesis that dysfunction in the UPS may 
be the primary cause, or one of the causes, of many of these neurological diseases.  
 
The UPS is managed by three enzymes – namely an E1 ubiquitin-activating enzyme, E2 ubiquitin-
conjugating enzymes, and E3 ubiquitin-ligating enzymes, of which parkin is an example. Initially, E1 
activates ubiquitin in an ATP-dependent manner. Thereafter, E2 transfers the activated ubiquitin to the 
unwanted protein substrate that has been bound to E3, which subsequently attaches the ubiquitin to the 
protein. Additional activated ubiquitin molecules are added to the previous ubiquitin to form a 
polyubiquitin chain that acts as a label or tag on the unwanted protein. The protein is then recognised 
by the 26S proteasome, which unfolds and breaks down the complex into peptides and ubiquitin 












Figure 1.5. The Ubiquitin Proteasome System. Governed by the three enzymes - E1 ubiquitin-
activating enzymes, E2 ubiquitin-conjugating enzymes and E3 ubiquitin-ligating enzymes, the UPS is 
responsible for the removal of damaged proteins from the cell via the 26S proteasome. Taken from 
Moore et al., 2003. 
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Dysfunction of the UPS is thought to be a mechanism of PD pathogenesis in both familial and sporadic 
PD, providing a link between sporadic and familial forms of the disorder (Moore et al., 2003). In 
sporadic cases, the structure and function of the 26S proteasome is altered in patients compared to 
controls, resulting in poor removal of unwanted proteins from the cell (Olanow and McNaught, 2006; 
McNaught et al., 2003). Alternatively, dysfunction of the UPS in familial PD is governed by mutations 
in either the parkin or the SNCA genes. Mutations in SNCA leads to a build-up of the α-synuclein 
protein, resulting in increased α-synuclein-positive aggregates. Multiplications (duplications and 
triplications) of the gene cause a three or four fold production of α-synuclein, and missense mutations 
increase the potential for the protein to misfold and aggregate (Olanow and McNaught, 2006). 
Interestingly, an accumulation of α-synuclein can also induce proteasomal damage, which can create a 
‘domino-effect’ of increased α-synuclein and inability of the UPS to remove them due to the damaged 
proteasome caused by the α-synuclein (Snyder et al., 2003). 
 
Mutations in parkin result in the loss-of-function of the parkin protein or a decrease in parkin enzyme 
activity, which cause substrates linked to parkin to accumulate in the cell. This has been shown to occur 
in the brains of PD patients and in parkin knockout mice (Ko et al., 2006, Ko et al., 2005). Studies in 
Drosophila and cell models of PD have revealed that accumulation of the parkin substrate Pael-R results 
in cell death, which is prevented by presence of parkin (Imai et al., 2003, Imai et al., 2000; Takahashi 
and Imai, 2003). Similarly, another substrate of parkin, FAF1, also accrues and results in cell death in 
SH-SY5Y cells, but this is abolished when parkin is present (Sul et al., 2013). Therefore an absence of 
functional parkin as a result of a mutation may cause the accumulation of unwanted and damaged 
proteins, thus resulting in cell death and ultimately disease onset. 
 
1.5.2. The Autophagy-Lysosome Pathway 
 
Autophagy is defined as the global process by which intracellular components are degraded by 
lysosomes (Dehay et al., 2010). Cell survival is essentially only possible if there is a healthy balance 
between the formation and degradation of cellular proteins. Such degradation is carried out in 
partnership by two pathways – the afore-mentioned UPS, and the Autophagy-Lysosome Pathway 
(ALP). Autophagy can be separated into three processes, namely Chaperone Mediated Autophagy 
(CMA), microautophagy, and macroautophagy. CMA involves the selective targeting of cytosolic 
proteins to the lysosomal lumen for degradation. Microautophagy occurs when the lysosomal 
membrane invaginates and pinches off small vesicles of cytoplasm for digestion. Lastly, 
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macroautophagy (henceforth known as autophagy) is the large-scale degradation of cytoplasmic 
constituents, and will be the primary focus in this section. 
 
Whilst the UPS is involved in highly selective degradation of short-lived intracellular and plasma 
membrane proteins, and misfolded/damaged proteins, autophagy encompasses the removal of long-
lived stable proteins, large membrane proteins, and protein complexes that are too large to fit though 
the 26S proteasome. Furthermore, autophagy is the only process responsible for the degradation of aged 
or dysfunctional organelles. Various signalling pathways can either activate or inhibit autophagy, 
including the mTOR pathway, the Insulin/Akt pathway and the AMP kinase pathway (Chu, 2010). 
Known stresses that induce autophagy include nutrient and growth factor deprivation, and the presence 
of protein aggregates and damaged organelles (Nixon, 2006). 
 
Initiated by these stresses, a double-sided isolation membrane will form around the damaged proteins 
or organelles and fuse to form an autophagosome (Figure 1.6). Once fully formed, the autophagosome 
then fuses with the lysosome, a cytoplasmic membrane-enclosed vacuole that contains a wide variety 
of hydrolytic enzymes, to form the autolysosome (also known as the autophagolysosome). Collectively, 
autophagosomes and autolysosomes can be referred to as autophagic vacuoles (AVs). At the formation 
of the autolysosome, the contents of the AV are degraded by the hydrolytic enzymes and recycled to 
provide amino acids and energy (Figure 1.6). 
 
 
Figure 1.6. The Autophagy-Lysosome pathway. This illustration indicates the removal of cellular 
waste via the formation of an autophagosome and an autolysosome through the actions of Atg gene 
products Atg5-Atg12, LC3 and p62. Taken from www.bio-med.com. 
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In order to test the cells for autophagy, markers such as LC3-II (microtubule-associated protein 1 light 
chain 3) and p62 (SQSTM1/sequestosome) are used. Upon induction of autophagy, LC3-I is conjugated 
to phosphatidylethanolamine (PE) to generate LC3-II (Barth et al., 2010). The PE group then promotes 
integration of LC3-II into lipid membranes at the phagophore and autophagosomes, and LC3-II is 
subsequently degraded once the autolysosome is formed (Figure 1.6). The amount of LC3-II present in 
the sample correlates with the amount of autophagosome present in the sample (Mizushima, 2007).  
 
The detection of an increased level of LC3-II or p62 is not always indicative of autophagy induction, 
but could also be representative of reduced autophagosome turnover and a blockade in autophagosome 
maturation (Zhang et al., 2013). Therefore, in order to distinguish between the two, autophagic flux 
needs to be measured. Autophagic flux is defined as the rate at which intracellular material is transported 
via the autophagic pathway to the lysosomes, and is measured by the difference in the amount of LC3-
II/p62 before and after the addition of lysosomal inhibitors such as Bafilomycin A1 (BafA1). These 
inhibitors prevent the degradation of LC3-II by the lysosome, by preventing the fusion of the 
autophagosome with the lysosome. Therefore, if LC3-II and p62 is increased after the addition of 
BafA1, then there is an efficient autophagic flux. However if LC3-II remains at the same level after 
BafA1 treatment this is indicative of a defect in the process prior to lysosomal degradation.  
 
An increase in autophagic flux indicates an increase in the rate of autophagy and clearance of damaged 
organelles and proteins, whereas a lower flux suggests a slower clearance rate, and therefore possible 
accumulation of these unwanted organelles and proteins in the cell. There is some ambiguity when 
using p62 as a measure for autophagic flux, because p62 is regulated at transcriptional and post-
translational levels. Therefore if an autophagic inducer such as BafA1 activates p62 transcription, the 
increased autophagic flux may not be sufficient to clear intracellular p62. Therefore this measure of 
autophagy needs to be taken into consideration, and it is recommended to measure both LC3-II and p62 
when determining autophagic flux (Puissant et al., 2012). 
 
1.5.2.1. Autophagy and PD pathogenesis 
 
Despite its role in cell survival, autophagy has been implicated in various other processes including 
programmed cell death (PCD) and neurodegenerative disorders (Scott et al., 2007). Dysfunction can 
occur at various stages of the autophagic pathway, resulting in failure to protect the cell from damaged 
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and toxic proteins and organelles. For example, failure of autophagosome formation, failure of 
autophagosome fusion with the lysosome or deficiency of hydrolytic enzymes in the lysosome can all 
result in accumulation of dysfunctional substrates. Interestingly, an early study revealed an increase in 
the number of AVs and related structures of autophagy in the neurons of the substantia nigra from PD 
patients (Anglade et al., 1997). Cell models of PD induced by the addition of MPP+ and rotenone also 
found increased AV presence compared to controls (Chu et al., 2007; Dagda et al., 2008; Zhu et al., 
2007). Furthermore, several mouse models have shown that inhibition of the autophagy-related genes 
Atg5 and Atg7 leads to the formation of ubiquitinated cellular inclusions and neuronal cell loss (Hara 
et al., 2006; Komatsu et al., 2006). These studies confidently implicate autophagy in neurodegeneration 
and PD pathogenesis. Mitochondrial autophagy, or mitophagy, is a form of autophagy selective for 
degradation of mitochondria, and will be discussed in Section 1.7. 
 
1.5.2.2. Programmed Cell Death  
 
PCD is described as the regulated death of a cell in any form, mediated by an intracellular program. 
Apoptosis, or Type I PCD, is characterised by the condensation of chromatin, nuclear fragmentation, 
cell shrinkage, and plasma membrane blebbing (the formation of protrusions in the membrane). Two 
pathways are known to be responsible for apoptosis – the extrinsic, or death receptor pathway, and the 
intrinsic, or mitochondrial pathway (Figure 1.7). Both pathways are controlled by caspases, which are 
either ‘initiator’ caspases (-2, -8, -9, -10) that start the apoptotic cascade, or ‘effector’ caspases (-3, -6, 
-7) that disassemble the cell. Briefly explained, death signals such as cellular stress, ROS and DNA 
damage result in the release of mitochondrial inter membrane space proteins conducive to 
Mitochondrial Outer Membrane Permeabilisation (MOMP), which is regulated by the Bcl family of 
proteins. MOMP causes the release of cytochrome c, which together with APAF-1 and pro-caspase 9 
forms the apoptosome complex in the cytoplasm. This complex activates (cleaves) caspase 9 which in 
turn activates the effector caspases 3 and 7. The cascade accumulates in the activation (cleavage) of 
PARP (Poly ADP-ribose) which then results in dismantling of cellular structures and death. The 
extrinsic pathway is also initiated by death signals that activate death receptors at the plasma membrane. 
This results in the recruitment and activation of pro-caspases 8 and 10 which in turn activate the effector 
caspases. 
 
Cleaved PARP is generally used as a marker of apoptosis in immunoblotting procedures. An increase 
in the levels of cleaved PARP is indicative of an increase in apoptosis. Any other caspase can be used 
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to further verify these results, but caspase 3 is predominantly used. Cleaved caspase 3 works in a similar 
manner to cleaved PARP, whereby when increased it signifies an increase in apoptosis. However, full-
length caspase 3 is reduced when it is cleaved into its active form, and therefore increased levels of full-














Figure 1.7. Summary of apoptotic cell death. The extrinsic (death receptor) pathway is initiated at 
the plasma membrane, and the intrinsic (mitochondrial) pathway at the outer mitochondrial membrane. 
Both pathways result in the cleavage and activation of PARP from the caspase cascade which activates 
apoptosis. Adapted from www.mdpi.com  
 
In comparison to apoptotic cell death, autophagic cell death (also known as Type II PCD) is fast 
becoming a point of interest in neurodegenerative diseases. Neurons destined for elimination internalise 
their cytoplasmic components into autophagic compartments to effect self-degradation, and this is 
known as autophagic cell death (Nixon, 2006). The observation of advanced autophagy in PD led to the 
hypothesis that although autophagy is a protective mechanism for cell survival, it may also be a 
mechanism for cell suicide. Both PCD processes have been linked to similar molecular mechanisms 
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and proteins. For example, p53 has been shown to act as an inducer of both apoptosis and autophagy 
(Thorburn, 2007), and the P13K/Akt pathway is an inhibitor of both processes (Arico et al., 2001). 
Furthermore, Beclin-1 which is involved in the formation of AVs, physically interacts with Bcl-2, a key 
regulator of apoptosis (Liang et al., 1999). These similarities suggest that autophagy and apoptosis may 
be more similar than was previously thought, although it must not be forgotten that the primary role of 
autophagy is cell protection. Nevertheless, it is clear that both processes are part of PD pathogenesis 
and should be further investigated. 
 
1.5.3. Mitochondrial Dysfunction and PD 
 
Mitochondrial dysfunction was first implicated in the development of PD through studies on pesticides 
and neurotoxins (e.g. MPTP, rotenone) that disrupt complex I of the ETC on the inner mitochondrial 
membrane (IMM). Post mortem studies on the SNc from PD patient brain samples revealed a significant 
decrease in complex I activity (Schapira et al., 1998, Schapira et al., 1990; Sherer et al., 2002). 
Furthermore, as previously mentioned, various genes known to cause PD, such as parkin, PINK1 and 
DJ-1, play a role in mitochondrial function. 
 
1.5.3.1. Structure and function of the mitochondria 
 
Mitochondria are elongated, rod-shaped organelles consisting of the OMM, the intermembrane space 
(IMS), the IMM, and the mitochondrial matrix (Figure 1.8). All four respiratory chain complexes and 
the ATP synthase (also known as complex V) of the ETC are situated on the IMM, which is the site of 
oxidative phosphorylation in mitochondrial respiration. Cristae are folds formed by the IMM in order 
to increase the surface area, and are vital for rapid and efficient energy production (Sherwood, 2015). 
The mitochondrial structure facilitates efficient functional capacity of the organelle. Structural defects 
such as swelling of the mitochondria or dysregulation of the mitochondrial network generally leads to 















Figure 1.8. Electron micrograph of a mitochondrion. Taken from: http://www.tutorvista.com 
 
The mitochondrion is a vital intracellular organelle found in all tissue types and it is responsible for one 
of the cell’s key survival functions – the production of energy in the form of ATP. Mitochondria are 
also responsible for several other secondary functions, including regulation of cellular metabolism and 
respiration, signalling, cellular differentiation, cell death, control of the cell cycle and cell growth, and 
storage of calcium ions.  
 
Mitochondrial respiration is defined as the series of metabolic processes by which all living cells 
produce energy through the oxidation of organic substances. Glycolysis is the first step of the process 
and occurs in the cytosol of all cells. It involves the breakdown of one molecule of glucose into two 
three-carbon molecules of pyruvate via a series of enzyme-controlled reactions. In glycolysis, a net 
yield of two ATP molecules for one molecule of glucose is produced. The pyruvate produced during 
glycolysis is used in the Krebs cycle (which also produces two ATP molecules) to make products 
needed for oxidative phosphorylation, the final step of mitochondrial respiration, which produces 34 
ATP molecules per molecule of glucose (Figure 1.9). This is notably higher than the amount produced 
during glycolysis, signifying that glycolysis is less efficient in energy production than oxidative 
phosphorylation. Should oxidative phosphorylation be dysfunctional, then glycolysis assumes the role 
of the primary source for ATP. An example of when this occurs is in the absence of oxygen (when the 
cells are undergoing anaerobic respiration), oxidative phosphorylation cannot proceed, and glycolysis 
is then responsible for ATP production. Alternatively, if any of the five electron transport chain 















Figure 1.9. An overview of cellular respiration. For every molecule of glucose, two molecules of 
ATP are produced from glycolysis and the Krebs cycle, and 34 ATP molecules are produced via 
oxidative phosphorylation. Taken from http://www.uic.edu/.  
 
Oxidative phosphorylation occurs on the IMM via five enzyme complexes (complex I, complex II, 
complex III, complex IV and ATP synthase/complex V; Figure 1.10). NADH (reduced nicotinamide 
adenine dinucleotide) and FADH₂ (reduced flavin adenine dinucleotide) act as carrier molecules, 
transporting hydrogen ions from the matrix to the inner membrane. NADH releases the hydrogen 
protons at complex I, whereas FADH₂ releases the protons at complex II. Once the protons are released, 
high energy electrons are extracted from the hydrogen. The hydrogen ions then move through the 
complexes and into the IMS, whilst the electrons move through the ETC via ubiquinone and cytochrome 
c and other specific electron carriers. When the electrons reach complex IV, they are passed to O₂, the 
final acceptor, and H₂O is formed. As the electrons move, energy is released which aids in the 
movement of more hydrogen ions into the IMS. The high concentration of hydrogen ions in the IMS 
then leads to a density gradient from the IMS to the matrix, forcing the hydrogen ions to move from the 
IMS into the matrix through the ATP synthase complex. This leads to the activation of ATP synthase, 
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Figure 1.10. Oxidative phosphorylation at the mitochondrial inner membrane. This is shown in steps 1-9. This process involves the movement of electrons from the 
electron donors NADH and FADH₂ through a series of complexes, resulting in the movement of proton’s to the IMS. This creates a high proton gradient, which in turn forces 
the hydrogen ions to move from the IMS into the matrix through the ATP synthase complex which drives the conversion of ADP and Pi into ATP 
e¯, electron; NADH, reduced nicotinamide adenine dinucleotide; FADH₂, reduced flavin adenine dinucleotide; IMS, Intermembrane space; H+, proton; ADP, adenosine 
diphosphate; Pi, inorganic phosphate; ATP, adenosine triphosphate. Taken from: Sherwood, 2015
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The term ‘mitochondrial dysfunction’ can be widely used to include dysfunction in the generation of 
ATP, the production of ROS, involvement in apoptosis, and incorrect transport to areas in the cell 
(Brand and Nicholls, 2011). Mitochondria are the main producers of ROS in the cell as a by-product of 
respiration. ROS are part of the free radical family, which are molecules that have a shortage of electrons 
in their outer orbital. An example of such a molecule is oxygen, because it has two unpaired electrons 
in its outer orbital. ROS are scavengers, because in order to find stability they need to extract electrons 
from neighbouring molecules to complete their own outer orbital (Beal, 2003). This leads to oxidation 
of neighbouring molecules. For example, when oxygen adds an extra electron, it becomes the 
superoxide anion (O₂˙¯), which is also a free radical. When there is a complex I deficiency or any other 
deficiency in the respiratory chain, the amount of electrons lost to oxygen significantly increases, 
resulting in an increase in the levels of ROS. A cell undergoes oxidative stress when there is an 
imbalance between the production of ROS and the cell’s ability to detoxify or neutralize the effect with 
antioxidants. Excessive ROS production and oxidative stress is toxic to the cell as they cause protein, 
lipid and DNA damage. 
 
A second example of mitochondrial dysfunction is alterations in the mitochondrial rate of respiration. 
There is a constant fluctuation in the amount of energy required by tissues and cells, and the production 
of energy is controlled by a feedback system at the mitochondria with regulators of oxidative 
phosphorylation that determine either basal or maximal respiration. Basal respiration is the rate at which 
mitochondria function when cells only require a part of their total bioenergetic capacity. In comparison, 
maximal respiration is performed when the cell is in need of great amounts of energy in response to 
stress or an increased workload. The difference between ATP produced by oxidative phosphorylation 
at basal and at maximal respiration is defined as spare respiratory capacity (Desler et al., 2012). Spare 
respiratory capacity is able to provide cells with an extra burst of energy in response to stress, however 
if this is not available it will result in cell damage and death. This form of mitochondrial dysfunction 
whereby there is an exhaustion of spare respiratory capacity due to inconsistent respiration has been 
associated with cardiovascular and neurodegenerative disease (Nicholls, 2008; Yadava and Nicholls, 
2007). It would therefore be appropriate to study these aspects of mitochondrial respiration in PD 
models, as it could further elucidate how mitochondrial dysfunction may be a cause of PD pathogenesis. 
 
Mitochondrial membrane potential (MMP) has also been implicated as a cause of mitochondrial 
dysfunction and apoptosis. Membrane potential is defined as the difference in electric potential between 
both sides of a membrane. A voltage difference is created by the constant movement of protons and 
ions across the membrane. The MMP across the IMM is produced by the proton gradient formed during 
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oxidative phosphorylation (Gottlieb et al., 2003). As a core component of the proton motive force, the 
MMP is responsible for the synthesis of ATP by producing the force that pumps protons through the 
ATP synthase complex to generate ATP. Collapse of the MMP can compromise both the production of 
ATP and the integrity of the cell. If there is a loss of MMP, the permeability of the mitochondria 
becomes active via the mitochondrial Permeability Transition Pore (PTP). Opening of the PTP causes 
an inlet of solutes and water which result in swollen mitochondria. This in turn causes cytochrome c 
leakage and the onset of the caspase cascade and apoptosis.  
 
It is clear that the MMP is essential for cell survival. In an intact and stable state, MMP is responsible 
for oxidative phosphorylation and ATP maintenance. However, a decrease in MMP results in the 
depolarisation of the mitochondria and can cause spontaneous cell death (Ly et al., 2003). Measurement 
of MMP is performed by staining the cells with the JC-1 (5,5’,6,6’ tetrachloro – 1,1,3,3’ 
tetraethylbenzimidazol-carbocyanine iodide) fluorochrome. JC-1 is a lipophilic cation that is capable 
of entering selectively into the mitochondria and forming JC-1 aggregates upon membrane polarisation. 
These aggregates cause a shift in emitted light and a colour change from green to orange as the 
mitochondrial membrane becomes more polarised, which can be measured by means of flow cytometry.  
 
1.5.3.2. Mitochondria are dynamic organelles 
 
Recent studies have shown that mitochondria are not static organelles with primary and secondary 
functions, but are highly dynamic, and are involved in processes such as movement, fusion, fission and 
mitophagy (Detmer and Chan, 2007). In most tissues, but especially in neuronal tissue, healthy 
mitochondria are transported towards areas with a high energy demand. In contrast, damaged or 
dysfunctional mitochondria move away from these areas into less demanding spaces of the cell. 
Movement can also promote morphological transitions in the mitochondria depending on the cell type. 
This is controlled by fusion and fission. Fusion and fission play major roles in maintaining the 
mitochondria, which is done by controlling the integrity of the mitochondria, the electrical and 
biochemical connectivity, the turnover of the mitochondria, and the protection of mtDNA (Berman et 
al., 2008).  
 
Fusion is the merging of the double membranes of two mitochondria, resulting in a larger single 
organelle (Figure 1.11A). Alternatively, fission is the division of one mitochondrion into two smaller 
mitochondria, a healthy one and an ‘impoverished one’, which is tagged for degradation whilst the 
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healthy mitochondrion remains in the cell. Although these processes are not fully understood, fusion is 
controlled by the mitofusins (Mfn1 and Mfn2) and Opa1 on the OMM, whereas fission occurs via Drp1 
and Fis1 (Figure 1.11A). The removal of unhealthy mitochondria in the cell is controlled by mitophagy, 
which is governed in part by the PINK1/parkin pathway (Section 1.7). The balance of fusion and fission 
is therefore vital in the maintenance of functional mitochondria and cellular requirements (Burbulla et 
al., 2010) and an imbalance can lead to autophagy and cellular apoptosis.  
 
Detection of mitochondrial fusion or fission in cells is done via analysis of the mitochondrial network 
(Figure 1.11B). Mitochondria form tubular networks, and when they are predominantly undergoing 
fusion they appear joined together, resulting in a highly connected network (Legros et al., 2002). 
Alternatively, when the majority of the mitochondria are undergoing fission to rid the cell of damaged 
mitochondria, the network appears fragmented and broken. Knock down models in Drosophila have 
revealed that knock down of Drp1 and Fis1 results in elongated, connected mitochondria, whereas 
knock down of Opa1 and Mfn1/2 result in fragmented mitochondria (Deng et al., 2008; Ziviani et al., 
2010). Conversely, overexpression of these proteins resulted in opposite effects to the knock down. The 










Figure 1.11. Mitochondrial fusion and fission mechanisms that form the mitochondrial network. 
A. Fusion is governed by the Mfn and Opa1 proteins, whereas fission occurs via Drp1 and Fis1. B. 
Image of the mitochondrial network stained with the red MitoTracker dye, and the nucleus stained with 
blue Hoechst dye. Mitochondria that have been fragmented from the network are shown by the arrows. 
Taken from www.mindsofmalady.com 
A B 
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1.6. Treatment strategies 
 
The current treatment for PD is through the administration of Levodopa, a dopamine precursor. 
Levodopa is a highly effective drug, as it can cross the BBB where it is converted into dopamine via a 
chemical reaction involving the enzyme aromatic L-amino acid decarboxylase (AAD), thus increasing 
the concentrations of dopamine in the central nervous system. Although Levodopa is a successful 
dopamine-replacement therapy, the long term effects of this drug on PD patients include motor 
fluctuations, dyskinesia, toxicity and loss of efficacy (Fahn et al., 2004).  
 
Another treatment option for PD is deep brain stimulation (DBS) therapy. DBS is a surgical procedure, 
whereby electrodes are implanted into either the subthalamic nucleus or the globus pallidus within 
specific brain circuits, or neuronal loops, for modulation of the activity of those circuits. The electrodes 
are connected to an implanted pulse generator that is responsible for delivery of continuous stimulation, 
and the current produced then acts as either a suppressor or a driver of neuronal activity (Lozano et al., 
2011). Risks of DBS include the small chance of a haemorrhage or stroke, depression and personality 
changes, paraesthesia’s, dysarthria, motor contractions and infection. However, this treatment option is 
continually expanding and improving, and studies show that the clinical benefits of DBS outweigh the 
risks involved (Deuschl et al., 2006; Follett et al., 2010). 
 
 
1.6.1. Natural remedies  
 
Herbal or natural remedies are fast becoming a preventative treatment or cure for diseases ranging from 
cardiovascular, diabetes, cancer and even the common cold (Kincheloe, 1997). It is thought that herbal 
medicines are less toxic than pharmaceutical agents, and the value of traditional medical systems 
continue to attract more media and public attention each year (Elvin-Lewis, 2001). A survey in the 
United States spanning seven years found a substantial increase in the use of alternative medicine 
therapies (Eisenberg et al., 1998). A second study observed that almost 40% of patients claimed to have 
used over the counter natural remedies to treat or prevent a health condition (Bennett et al., 2012), and 
this was reiterated in another study observing that more than one third of American adults use herbal 
remedies (Johnston, 2004).  
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The World Health Organisation estimates that 80% of the world’s population use herbs as their primary 
method for health care needs (Winslow and Kroll, 1998). These studies have resulted in a greater focus 
over the past two decades on understanding these remedies and the side effects thereof, so that sufficient 
information and research can be obtained in order to deem these products safe for use. The use of 
medicinal plants in treatment of diseases has been limited by the lack of scientific data. Furthermore, 
research is needed to determine whether these types of products may be vital in preventing diseases that 
Western medicine is unable to do. The following section will focus on a detailed explanation on the 
natural compound curcumin, as it was investigated as a possible therapeutic agent in a cellular model 






Curcumin is derived from the Curcuma longa plant (Figure 1.12), a plant of the ginger family, and is 
the core component of the golden yellow curry spice turmeric. It was first described by Vogel & 
Pelletier in 1815, and more than 100 years later its biological characteristics and antibacterial activity 
were identified (Schraufstätter and Bernt, 1949). Since then, curcumin has gained considerable interest 
as a potential therapeutic aid, and has been shown to have anti-inflammatory, antioxidant, antimicrobial 
and anticarcinogenic activities (Anand et al., 2007). In addition to cell and animal models, phase I 
clinical trials have also shown that curcumin can be used to treat a variety of diseases including cancers, 
neurodegenerative diseases, cardiovascular disease, diabetes, allergy, asthma, bronchitis, inflammatory 
bowel disease, rheumatoid arthritis, renal ischemia, scleroderma, psoriasis and acquired 
immunodeficiency disease (AIDS; Aggarwal and Harikumar, 2009).  
 
In patients with Alzheimer’s disease (AD), curcumin was shown to enhance amyloid β (Aβ) uptake in 
macrophages (Fiala et al., 2007; Zhang et al., 2006). These results led to a 6-month clinical pilot study 
of curcumin in patients with AD, however no protective effect of curcumin was observed in comparison 
to the placebo group (Baum et al., 2008). Despite this, there were increased levels of Aβ in serum of 
patients who received curcumin, indicating that curcumin is able to disaggregate the Aβ-deposits in the 
brain. Longer studies are needed on AD patients to properly understand the effect of curcumin in vivo. 
A stage 2 18-month double-blind placebo-controlled clinical trial is currently ongoing to study the 
effects of curcumin on age-related cognitive decline. To date, there have been no clinical trials of 
curcumin exposure in PD patients. However, given its anti-inflammatory and antioxidant properties, 
further studies on PD are warranted.  
 
 
























Figure 1.12. Images representing the various forms of turmeric. A. The Curcuma longa plant 
exhibits lengthy, rectangular shaped leaves with white spike flowers. The roots are rhizomes 2-7cm in 
length. B. The turmeric powder comes from the roots or rhizomes of the Curcuma longa plant, and is 




Initial animal studies found that curcumin decreases the formation of inflammatory compounds such as 
prostaglandins and leukotrienes (Huang et al., 1991; Kunchandy and Rao, 1990), and it was later 
discovered that the mechanism through which curcumin stops inflammation is by blocking JNK (Jun 
N-terminal kinase, Chen and Tan, 1998). JNK is responsible for the activation of various transcription 
factors in response to environmental stress, specifically NFκB, which plays a regulatory role in 
mediators of inflammation such as inflammatory cytokines (TNFα), chemokines, adhesion molecules, 
enzymes and kinases (Aggarwal and Harikumar, 2009). JNK also promotes cell death by activating Bcl-
2. By inhibiting the activation of JNK, curcumin rescues the cell from apoptosis and tumorigenesis 
(Gupta et al., 2012; Pan et al., 2012). It was also found that curcumin blocks various other agents of 
B 
A 
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inflammation such as IκBα kinase and AKT, which further results in the inhibition of activation of 
NFκB and its gene products, ultimately providing protection against various diseases (Aggarwal et al., 
2007a, Aggarwal et al., 2005; Kamat et al., 2007; Siwak et al., 2005). A complete list of the 
inflammatory pathways inhibited by curcumin can be found in Figure 1.13. It has been shown in these 
studies that curcumin is able to suppress inflammation through multiple pathways and thus provide vital 




















Curcumin is largely known for its capacity as an antioxidant, through the scavenging of ROS and the 
inhibition of free radical generation (Manikandan et al., 2004). Furthermore, by inhibiting lipid 
degradation, peroxidation and cytolysis, curcumin is able to prevent oxidative cellular injury (Cohly et 
al., 1998). It has been suggested that this mechanism works through antiapoptotic and antioxidant 
properties exerted through the Bcl2-mitochondria-ROS pathway, and via the down regulation of NFκB 
(Chen et al., 2006; Ortiz-Ortiz et al., 2010). The human brain is highly oxidative, and consumes up to 
20% of the body’s oxygen. Through its antioxidant properties, curcumin would therefore be able to 
protect the brain against neurological disorders such as AD and PD by decreasing oxidised proteins and 
IL-1β. Interestingly, prevalence studies have indicated that there is a lower prevalence of 
neurodegenerative disorders in India, a country known for its high consumption of turmeric as a popular 
curry spice, compared to Westernised countries such as America. In particular, one study found a 4.4 
fold reduced prevalence of AD in India compared to America (Ganguli et al., 2000). Furthermore, there 
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is a lower prevalence of PD in India compared to European countries (Muthane et al., 1998). Whilst 
this may be due to worse health care facilities and under researched areas of this developing country, it 
is tempting to consider that this may also be due to the high intake of turmeric and curcumin amongst 
this population. 
 
To date, both animal and cell models of neurodegeneration have shown the protective effects of 
curcumin. In AD, curcumin reduced Aβ– induced oxidative stress in PC12 cells (Kim et al., 2001). 
Similarly, a MPP⁺ model of PD in PC12 cells revealed that curcumin treatment protected the cells by 
inducing the anti-apoptotic protein Bcl2 and prevented dissipation of the MMP (Chen et al., 2006). A 
study on SH-SY5Y neuroblastoma cells affected with α-synuclein toxicity found that curcumin 
treatment protected the cells against this toxicity. Furthermore, it was revealed that curcumin reduced 
levels of intracellular ROS, and inhibited the activation of caspase 3 which ameliorated signs of 
apoptosis in the cells (Wang et al., 2010). Overexpression of A53T mutant α-synuclein in SH-SY5Y 
resulted in decreased LC3-II formation and autophagosomes, and ultimately inhibition of autophagy. 
Curcumin treatment to the cells reduced the levels of accumulated A53T α-synuclein and further 
rescued autophagy (Jiang et al., 2013).  
 
Animal models of AD have shown that curcumin reduces the levels of oxidised proteins (Baum, 2004; 
Lim et al., 2001), inhibits the formation and aggregation of Aβ (Ono et al., 2004; Yang et al., 2005), 
and also reduces amyloid levels and plaque burden (Yang et al., 2005). Initial mouse models of PD 
induced by 6-OHDA (6-hydroxydopamine) and MPTP resulted in decreased levels of dopamine, which 
were rescued by curcumin treatment (Rajeswari, 2006; Zbarsky et al., 2005). More recently, a study by 
Liu and colleagues analysed the effect of curcumin on both a rotenone-induced Drosophila model of 
PD, and a rotenone-induced SH-SY5Y cellular model of PD (Liu et al., 2013). Treatment with curcumin 
significantly reduced dopaminergic neuronal loss and ameliorated PD-like symptoms in the Drosophila 
such as improvement in fly survival and prevention of locomotor impairment. In the PD cell model, 
curcumin reduced intracellular and mitochondrial ROS levels, and decreased apoptosis by inhibiting 
caspase 3 and caspase 9 activation (Liu et al., 2013). The previous work done on curcumin in animal 
and cell models have shown curcumin to play an essential role in the prevention of dopaminergic neuron 
loss, reduction of ROS, apoptosis and alleviation of autophagy. However the mechanism behind this 
drug is still unknown, and further work needs to be performed at a molecular level to determine how 
curcumin is able to protect cells against insult. 
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1.7. The role of PINK1 in PD pathogenesis 
 
Since PINK1 is the focus of the present study, the following section will discuss this gene and its protein 
function in greater detail. PINK1 contains 8 exons spanning 1.8kb, and encodes a 581 amino acid 
serine/threonine protein kinase (Figure 1.14). Valente and colleagues first discovered a homozygous 
G309D missense and a W437X nonsense mutation in families with autosomal recessive, early onset PD 
(Valente et al., 2004). PINK1 mutations, either homozygous or compound heterozygous, are the second 
most common cause of autosomal recessive PD after parkin, and include point mutations, small 
insertions or deletions, genomic deletions and complex large rearrangements (Corti et al., 2011; 
Marongiu et al., 2007). 
 
The PINK1 protein is comprised of a catalytic serine/threonine kinase domain as well as a mitochondrial 
targeting domain (Figure 1.14), resulting in its localization to the mitochondrial membrane (Gandhi et 
al., 2009). Studies have shown that PINK1 has autophosphorylation activity, and mutations in this 
protein have differential effects on its ability to phosphorylate protein substrates (Beilina et al., 2005; 
Silvestri et al., 2005). PINK1 is present in the cell in two forms – a cleaved, inactive protein of 55kDa, 
and a full-length, stable, functional protein of 65kDa. In healthy mitochondria, PINK1 translocates to 
the IMM via the TOMM20 machinery, where it is cleaved and rapidly degraded by the mitochondrial 
inner membrane rhomboid protease presenilin-associated rhomboid-like protease (Jin et al., 2010; 
Meissner et al., 2011) as well as other mitochondrial proteases MMP, m-AAA and ClpXP (Van Laar 
and Berman, 2013). Conversely, when the mitochondria are damaged or dysfunctional, the MMP is 
lowered, thereby inhibiting mitochondrial import of PINK1 by the TOMM machinery (Corti and Brice, 
2013). This results in the accumulation of full-length PINK1 on the OMM where it plays a pivotal role 
with parkin in the removal of damaged mitochondria from the cell via the PINK1/parkin pathway 
(Becker et al., 2012; Song et al., 2013).  
 
PINK1 is a multifunctional protein that is also required for cellular functions other than MQC, such as 
mitochondrial trafficking, Ca²+ signalling and autophagic degradation. It is fundamental in maintaining 
mitochondrial homeostasis and protecting the cell against stress-induced apoptosis through the 
regulation of the mitochondrial networks, decreasing mitochondrial oxidative stress and modulating 
autophagy (Van der Merwe et al., 2015). Mutations in PINK1 have been implicated in causing 
mitochondrial structural defects such as alterations in mitochondrial morphology and network 
(Grünewald et al., 2009), as well as functional defects such as an increase in ROS production, a decrease 
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in the levels of ATP and a decrease in respiratory complex activity (Grünewald et al., 2009; Piccoli et 
al., 2008). Despite its predominant role in MQC, PINK1 has also been shown to be secondarily involved 
in pathways such as the UPS and autophagy, and is therefore a protein of great interest to further 
understand the mechanisms behind PD pathogenesis.  
 
Figure 1.14. Schematic representation of PINK1. Deletions (red lines) and frame shift mutations (red 
arrows) are shown above the transcript. The protein organisations below the transcript highlight the 
mitochondrial targeting domain (yellow, MTS), the kinase domain (green) and the putative 
transmembrane region (TM, blue). Missense mutations are shown below the protein (blue arrows). 
Taken from Corti et al., 2011. 
 
1.7.1. Animal models 
 
Several animal knockout models of PINK1, specifically in Drosophila, have shown mitochondrial 
dysfunction, as well as muscle and dopaminergic neuron degeneration (Park et al., 2006). Results from 
loss-of-function PINK1 mutant flies revealed locomotion defects in flight ability and climbing speed 
and abnormal muscle structure such as swollen, enlarged mitochondria with a loss of the OMM and 
fragmented cristae. Functionally, energy depletion was noted due to a decrease in ATP levels of mutant 
Stellenbosch University  https://scholar.sun.ac.za
33 
 
flies. Studies in animal models other than Drosophila include mice, zebrafish and more recently 
murines. PINK1-deficiency in zebrafish revealed a developmental delay, decreased neuronal 
populations, and developmental retardation of dopaminergic neurons, that were rescued by PINK1 
injection (Anichtchik et al., 2008; Xi et al., 2010). In comparison, knock out studies of PINK1 in mice 
have interestingly shown no neuronal degeneration or PD phenotype, but rather defects in mitochondrial 
respiration in complexes II-IV (Gautier et al., 2008; Kitada et al., 2007), which may suggest that PINK1 
functions differently in mammalian models of the disease.  
 
Interestingly, animal knockout models of parkin also revealed changes in the mitochondria in 
comparison to the wild-type controls. A study on a Drosophila parkin knockout model found that 
mitochondrial defects were a common characteristic of pathology, and morphological differences such 
as irregular & dispersed myofibrillar arrangements and swollen and malformed mitochondria with 
disintegration of cristae were observed (Greene et al., 2003). These flies exhibited reduced lifespan, 
locomotor defects and male sterility. Due to the highly similar phenotypes in parkin and PINK1 
knockout flies, it was hypothesized that these two proteins may play similar roles in the cell, or possibly 
even function through a common mechanism. Studies indicate that parkin overexpression rescues the 
detrimental phenotype found in PINK1 knock out models, whereas PINK1 overexpression did not show 
any changes to the phenotype in a parkin knock out model (Clark et al., 2006; Park et al., 2006; Yang 
et al., 2006). Therefore it was determined that parkin and PINK1 function through a common pathway 
known as the PINK1/parkin pathway, where parkin acts downstream of PINK1.  
 
Animal models of PINK1 mutants also reveal loss of complex I activity, decreased MMP, defective 
mitochondrial morphogenesis and swollen mitochondria (Clark et al., 2006; Park et al., 2006; Yang et 
al., 2006). This has led to the hypothesis that these phenotypic changes may be a consequence of 
dysfunctional fusion/ fission machinery. Initial studies in Drosophila showed that when PINK1 is over-
expressed, fission appears to be promoted, however when under-expressed, fusion appears to take over 
(Clark et al., 2006; Park et al., 2006; Yang et al., 2006). When parkin or PINK1 are knocked out, 
elongated mitochondria were observed (similar to what can be seen when Drp1/Fis1 are knocked out 
and Opa1/Mfn are overexpressed), whereas when overexpressed, mitochondrial fragmentation 
proceeded (Figure 1.15, Ziviani et al., 2010). PINK1 mutant flies displayed dysfunction of the 
dopaminergic neurons, mitochondrial aggregates and tubular structure. Either overexpression of the 
pro-fission protein Drp1, or under-expression of the pro-fusion protein Opa1 restored the dopamine 
levels and suppressed mitochondrial aggregation indicating that PINK1 may act through Drp1 to 
regulate fission (Deng et al., 2008; Poole et al., 2008; Yang et al., 2008). Missense mutants of parkin 
and PINK1 exhibited a loss of mitochondrial integrity due to reduced mitochondrial fission (Poole et 
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al., 2008). These animal models have conclusively shown that the PINK1/parkin pathway promotes 












Figure 1.15. PINK1 and parkin activity either promotes mitochondrial fission or inhibits fusion 
in Drosophila. Mitochondrial network staining using Rhodamine 123 indicates that knock down of 
parkin or PINK1 results in increased mitochondrial connectivity (similar to Drp1/Fis1 knock down), 
and parkin or PINK1 over expression results in network fragmentation (similar to Drp1/Fis1 over 
expression). Taken from Ziviani et al., 2010. 
 
1.7.2. Cell models and primary cultures 
 
Several cell lines have been used to establish alternative models of PD, including HeLa, M17, SH-
SY5Y, COS1, COS7, HEK293T, human fibroblasts and more recently induced pluripotent stem cells 
(iPSCs). An initial study investigating the PINK1/parkin interaction in mammalian cells performed 
RNA-interference mediated down regulation of PINK1 and subsequent overexpression of parkin in a 
HeLa cell line, and confirmed that parkin and PINK1 act in a common physiological and pathological 
pathway (Exner et al., 2007). Subsequent PINK1 knock down studies in cell cultures show cells that 
exhibit mitochondrial dysfunction such as decreased MMP, increased ROS levels, enlarged 
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mitochondria with decreased number of cristae and complex I respiratory dysfunction (Dagda et al., 
2009; Gegg et al., 2009; Hoepken et al., 2007; Wood-Kaczmar et al., 2008).  
 
Interestingly, whilst PINK1 knock down cells similarly exhibited damaged mitochondria as observed 
in Drosophila models, increased fragmentation rather than increased connectivity was exhibited in 
HeLa, SH-SY5Y and M17 cells (Figure 1.16, Dagda et al., 2009; Exner et al., 2007; Lutz et al., 2009; 
Sandebring et al., 2009). Conversely, in parkin-mutant fibroblasts the mitochondria appear more 
branched and connected compared to controls in some cases (Grünewald et al., 2010; Mortiboys et al., 
2008), whereas other cases revealed increased fragmentation in patient-derived fibroblasts (Pacelli et 
al., 2011) or no changes (van der Merwe et al., 2014). Overexpression of parkin or PINK1 in SH-SY5Y 
cells was able to suppress mitochondrial fragmentation induced by Drp1, thus implicating both parkin 
and PINK1 as pro-fusion proteins in mammalian cells (Lutz et al., 2009). These contradictory results 
may be due to the fact that cancer-derived cell lines and fibroblasts are actively dividing and therefore 
may lack the characteristics of post-mitotic neurons. It has also been suggested that cells may need an 
additional stressor in order for changes in the mitochondrial network to occur. Despite this drawback, 
studies on cell lines such as these are vital to tease out the mechanisms of genes and signalling pathways. 
 
 
Figure 1.16. Representative examples of normal or altered (truncated or fragmented) 
mitochondrial morphologies in HeLa cells following down regulation of PINK1 using siRNA. 
Taken from Exner et al., 2007.  
 
 
A second observation in PINK1-deficient cell cultures is the effect of PINK1 on cellular and 
mitochondrial autophagy. Aggregates reminiscent of autophagosomes that appeared lysosomal in 
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nature were observed in PINK1 knock down models of SH-SY5Y cells and mice neurons (Wood-
Kaczmar et al., 2008). This was verified in a similar study using SH-SY5Y cells that revealed an 
elevated number of AVs and lysosomes in PINK1 knock down cells that were not present in control or 
PINK1 overexpressed cells (Dagda et al., 2009). This was further tested using the LC3-II marker of 
autophagy, which was shown to be increased when PINK1 is under expressed (Figure 1.17). These 
studies suggest that a loss of PINK1 promotes autophagy in cell cultures. However it is still unknown 
whether autophagy is compensating for cell damage to ensure cell survival, or aiding in cell suicide, as 
some studies have shown that there is a decreased level of mitochondria in PINK1 knock downs (Dagda 
et al., 2009), whereas other studies indicate mitochondrial elimination when PINK1 is overexpressed 
(Kawajiri et al., 2010). It is clear that future studies should be conducted to determine whether an 










Figure 1.17. Knock down of PINK1 increases autophagy. Confocal microscopy of MitoTracker Red-
labelled mitochondria in control and three PINK1 shRNA lines expressing LC3-II (green) indicates an 
increase in LC3-II in all three knock down lines compared to the control. LC3-II is colocalised with the 
mitochondria, indicating an increase in mitophagy. Taken from Dagda et al., 2009. 
 
A third and increasingly popular method for understanding the mechanisms involved in the 
PINK1/parkin pathway is the use of iPSCs, which have the capacity to differentiate into any cell from 
the human body (Badger et al., 2014). In the case of PD, patient fibroblasts carrying mutations in the 
PD-causing genes are obtained, cultured, and differentiated using various growth factors into 
dopaminergic neurons. A study investigating mitochondrial dysfunction in PINK1 mutant PD patients’ 
iPSCs revealed an increase in ROS levels and a decrease in the production of the antioxidant glutathione 
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synthase (Cooper et al., 2012). Furthermore, an initial study on mutant PINK1 iPSCs to observe the 
mechanism of the PINK1/parkin pathway found that when the mitochondria were depolarised, parkin 
recruitment to the OMM was impaired in the mutant PINK1 iPSCs compared to control iPSCs (Seibler 
et al., 2011). Interestingly, observations in patient fibroblasts have differed compared to the iPSCs 
differentiated, indicating the importance of studies to be done in both cell cultures (Rakovic et al., 2013). 
Future studies should also focus on mitochondrial structure and network in iPSCs to further understand 
the mechanism of the PINK1/parkin pathway. 
 
1.7.3. Mechanism of the PINK1/parkin pathway to date 
 
A breakthrough study by Narendra and colleagues revealed in HEK293 cells that after the addition of 
the mitochondrial membrane inhibitor CCCP (carbonyl cyanide 3-chlorophenylhydrazone), parkin was 
recruited to the OMM (Narendra et al., 2008). A second study showed that PINK1 is also recruited and 
accumulates at the OMM of dysfunctional mitochondria with low membrane potential and that PINK1 
expression at the OMM is necessary for parkin recruitment (Narendra et al., 2010). Therefore, despite 
conflicting observations in animal models, cell cultures and iPSCs, the current mechanism of the 
PINK1/parkin pathway is thought to occur as follows:  
 
An interaction between parkin and PINK1 is initiated by the depolarisation of mitochondria, which 
recruits full-length PINK1 to the OMM (Pickrell and Youle, 2015; Narendra et al., 2010). Co-
immunoprecipitation experiments have determined that parkin and PINK1 are involved in a direct 
interaction, whereby PINK1 phosphorylates parkin and activates its E3 ligase activity at the OMM 
(Geisler et al., 2010; Kawajiri et al., 2010; Kim et al., 2008; Sha et al., 2009; Shiba et al., 2009; Um et 
al., 2009). Once phosphorylated, parkin then ubiquitinates mitochondrial substrates including fusion 
proteins Mfn1 and Mfn2 (Gegg et al., 2010). Mfn1 and Mfn2 are now tagged for degradation via the 
UPS, and once they have been removed, the balanced regulation between fusion and fission is 
compromised, resulting in a shift towards increased fission. This then initiates fragmentation of the 
mitochondrial network and therefore isolation of dysfunctional mitochondria, which are subsequently 
removed by mitophagy, thereby keeping the cell in a healthy state (Figure 1.18). If either parkin or 
PINK1 is mutated or down regulated, the dysfunctional mitochondria will remain in the cytoplasm, 
creating an environment of oxidative stress ultimately resulting in cell death (Devireddy et al., 2015). 
It is thought that parkin has limited activity in the absence of PINK1, and this activity is potentiated 
through PINK1 expression (Xiong et al., 2009). 





Figure 1.18. Hypothetical schematic representation of the mechanism behind the PINK1/parkin 
pathway. Taken from Matsuda et al., 2013. 
 
1.8. The present study 
 
This study involves the creation of a PINK1 siRNA-mediated knock down model of PD in an SH-SY5Y 
neuroblastoma cell line in order to gain insight into PD pathogenesis. By decreasing the gene and protein 
expression levels of PINK1 compared to a normal wild type control and studying its physiological 
effects, this may provide insight into the physiological function of PINK1. Furthermore, this study 
investigated the potential rescue effects of curcumin, an antioxidant and anti-inflammatory compound, 
on the PINK1 knock down cellular model. The mechanism and neuroprotective properties through 
which curcumin acts is not yet fully understood, therefore this project attempted to answer questions 
regarding the role of curcumin at a molecular level. In addition, in an attempt to study the effects of 
curcumin in patient-derived cells, South African PD patient samples were screened to identify patients 









It was postulated that decreased expression of PINK1 will result in mitochondrial functional and 
structural abnormalities that would include decreased cell viability, decreased MMP, decreased 
mitochondrial respiration and increased autophagic flux, as well as increased apoptosis and a more 
fragmented mitochondrial network. For some of these effects an additional stressor paraquat (known to 
cause mitochondrial toxicity) would be necessary for the effect to become evident or to exacerbate the 
defect. We hypothesised that curcumin exposure would be able to rescue all or some of these effects in 
a PD cellular model. Additionally, we hypothesized that copy number variation, specifically in the 
PINK1 gene, would be observed in South African patients with PD. 
 
1.8.2. Aims & Objectives 
 
The aim of the present study was to investigate the potentially protective effects of curcumin, in the 
presence or absence of paraquat, on a PINK1 siRNA-mediated knock down cellular model of PD. The 
study also aimed to identify patients with copy number changes specifically in PINK1 but also other 
PD-causing genes for further study. 
 
The objectives of this study were as follows: 
 
1. To create a PD cellular model using a PINK1 siRNA-mediated knock down approach in SH-
SY5Y neuroblastoma cells. 
2. To determine the correct dosage and time of exposure for paraquat and curcumin, and establish 
treatment groups and an appropriate timeline for the addition of each to PINK1 knock down 
cells and control cells. 
3. To determine cell viability in treatment groups. 
4. To measure levels of apoptosis through the detection of apoptotic markers cleaved PARP and 
full-length caspase 3. 
5. To determine mitochondrial membrane potential in treatment groups. 
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6. To investigate parameters of mitochondrial respiration including basal respiration, ATP 
production, maximal respiration and spare respiratory capacity, as well as levels of glycolytic 
respiration in treatment groups.  
7. To analyse mitochondrial network in treatment groups. 
8. To measure levels of autophagic flux in treatment groups. 
9. To screen South African PD patients for CNV mutations in PINK1, and other known PD-
causing genes. 
10. To compare results obtained from the SH-SY5Y cell line with fibroblasts obtained from 
patients with PINK1 CNV mutations. 
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2.1. Summary of methodology 
 
SH-SY5Y neuroblastoma cells were cultured and treated with HiPerfect transfection reagent and 
PINK1/non-silencing control siRNA. Gene and protein expression of PINK1 was then tested using 
qRTPCR and Western blotting, to verify that knock down had been successful. Thereafter, both PINK1 
siRNA cells and control cells were subdivided into four treatment groups: i. untreated, ii. treated with 
25µM paraquat for 24 hours, iii. pre-treated with 2µM curcumin for 1 hour followed by 25µM paraquat 
for 24 hours, and iv. treated with 2µM curcumin for 1 hour. Various parameters of mitochondrial and 
cellular function were measured including cell viability, apoptosis, mitochondrial respiration, 
mitochondrial membrane potential, mitochondrial network, and autophagic flux. This was performed 
to determine the effect of decreased PINK1 expression on these cells, as well as the possibly protective 
effect of curcumin treatment.  
 
An objective of this study was to repeat this method in a patient-derived fibroblast model of PD. The 
MLPA technique was used to detect CNV in the known PD-causing genes in South African PD patients. 
All results were verified by qRTPCR and Sanger sequencing.  
 
A summary of the methodology is shown in Figure 2.1. 
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PINK1 knock down cells Control cells 
Verify knock down using qRTPCR & Western blot 
Untreated 25µM PQ, 24hours 2µM Curc, 1hour 
2µM Curc, 1hour + 
25µM PQ, 24 hours 
Aspects of mitochondrial function: 
 Membrane potential: JC-1 fluorochrome flow cytometry 
 Respiration: Seahorse XF e96  Analyser 
o Mito Stress Test Kit 
o Glycolytic Stress Test Kit 
 Mitochondrial network analysis: fluorescence 
microscopy 
Aspects of cellular health: 
 Cell viability: MTT Assay 
 Apoptosis: Western blot 
o Cleaved PARP 
o Caspase 3 
 Autophagic flux: Western blot 
o LC3-II 
o P62 
Use MLPA to detect Copy Number Variation in the PINK1 gene in 210 South African patients with PD, in order to repeat functional assays 
Figure 2.1. Summary of Methodology 
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2.2. Creating a PINK1 knock down cellular model of PD 
 
The SH-SY5Y neuroblastoma cell line was ordered (European Collection of Cell Cultures, ECACC, 
UK) and cultured in a 1:1 ratio of Dulbecco’s Modified Eagle Medium (DMEM; Lonza, Switzerland) 
and Ham’s F12 Medium (Lonza, Switzerland). Added to the culture medium was 10% fetal bovine 
serum (FBS) and 1% penicillin streptomycin. Passage numbers were recorded and cells under passage 
15 were used. All cell culture protocols are recorded in Appendix I. For all knock down experiments, 
cells were seeded into 6-well plates (CoStar, Corning Incorporated, USA) and treated with siRNA when 
the cells were approximately 60% confluent.  
 
RNA interference was performed using small interfering RNA (siRNA) to determine whether the 
suppression of the PINK1 gene resulted in cellular defects compared to a control. Knock down was 
achieved using the Flexitube siRNA kits (Qiagen, Germany). Four preselected siRNAs for PINK1 were 
optimised to determine which siRNA would produce the highest decrease in PINK1 gene and protein 
expression. A non-silencing control siRNA with a scrambled sequence was included as a primary 
control for comparison. The siRNA sequences are summarised in Table 2.1. Stock siRNAs of 20µM 
were prepared by the addition of 250µl RNase-free H₂O to the siRNA, and were kept at -20°C.  
 
Table 2.1. Sequences of the four different siRNAs used for knocking down PINK1 
Gene Product name Sequence 
PINK1 
Hs_PINK1_2 Flexitube siRNA NM_032409 CTCCAGCGAAGCCATCTTGAA 
Hs_PINK1_3 Flexitube siRNA NM_032409 CCGGACGCTGTTCCTCGTTAT 
Hs_PINK1_4 Flexitube siRNA NM_032409 GACGCTGTTCCTCGTTATGAA 
Hs_PINK1_6 Flexitube siRNA NM_032409 ATGGGTCAGCACGTTCAGTTA 
 
 
SH-SY5Y cells were cultured and seeded into 6-well plates containing 2x10⁵ cells per well. For 
transfection, 0.6µl of the 20µM siRNA stock was added to 99.4µl serum-free medium and 12µl 
HiPerfect transfection reagent (Qiagen, Germany), to achieve a final concentration of 5nmol. Two 
controls were used to compare to the PINK1 siRNA – i. the non-silencing control siRNA, and ii. a mock 
transfection control which is composed of only transfection reagent and serum-free medium, but no 
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siRNA. These complexes were incubated at room temperature for 15mins. During incubation, the media 
was removed from the cells and a new volume of 2.3ml medium was added to each well. Thereafter, 
the complexes were added drop-wise to the wells.  
 
Plates were then incubated at 37°C, 5% CO₂ for 48 hours in the Forma Steri-Cycle CO2 Incubator 
(Thermo Scientific, Pierce Biotechnology, USA). Previous studies using the same siRNA kit and 
protocol have recommended that cells be continuously treated with siRNA over a longer time period 
(Gegg et al., 2009; Gegg et al., 2010). This method of knock down is specific to PINK1, as knock down 
of this protein for 48 hours is insufficient to produce significant changes to the cellular phenotype. 
Based on this knowledge, cells were treated with the siRNA and HiPerfect transfection reagent every 








Figure 2.2. The procedure for transfecting SH-SY5Y cells with PINK1 siRNA, control non-
silencing siRNA and transfection reagent. KD, knock down. 
 
2.2.1. Verification of efficient PINK1 knock down by quantitative real time 
PCR 
 
RNA extraction and cDNA synthesis 
The RNeasy Mini kit (Qiagen, Germany) was used for isolation and purification of intracellular RNA 
from the SH-SY5Y cells. After the 12 day siRNA transfection period, cells were trypsinised and 
centrifuged (Prism Microcentrifuge, Labnet, USA) to pellet the nucleic acids. The pellet was washed 
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RNA conversion into cDNA was then carried out using the Quantitect Reverse Transcription Kit 
(Qiagen, Germany) in a two-step process. This kit provides a convenient procedure for effective reverse 
transcription as well as effective genomic DNA (gDNA) elimination. The first reaction involves the 
removal of gDNA by the gDNA wipeout buffer, and the second step is a reverse transcription reaction 
prepared by the addition of reverse transcriptase (Qiagen, Germany), RT buffer (Qiagen, Germany) and 
RT primer mix (Qiagen, Germany). This results in high yields of cDNA template for use in subsequent 
qRTPCR reactions. 
  
Quantitative Real Time PCR 
qRTPCR was performed on non-silencing control cDNA, mock transfection control cDNA, and PINK1 
siRNA cDNA diluted to a concentration of 300ng/µl. Primetime Standard qPCR Assays (IDT, USA) 
were used specific to PINK1 and three housekeeping genes (HKGs) – GAPDH, B2M and RPL13A.  
Each assay was resuspended in 1000µl TE buffer (10mM Tris, 0.1mM EDTA, pH8.0) to obtain a 10X 
final stock concentration. A cocktail was made up of each assay, Master Mix (Quantifast Multiplex 
PCR kit, Qiagen, Germany) and dH₂O for each gene. A volume of 4µl was pipetted into each well of a 
384-well plate (Lasec, SA) by the epiMotion (eppendorf, Germany). Thereafter, 1µl of PINK1 siRNA 
cDNA, non-silencing control cDNA and mock-transfected control cDNA was pipetted in quadruplicate 
to each assay in the wells.  
 
The plate was centrifuged on the Centrifuge 5810R (eppendorf, Germany) at 1000rpm for 1min and 
placed in the ABI 7900HT (Applied Biosystems, USA), a fast real time PCR system, situated at the 
Central Analytical Facility’s satellite laboratory at Tygerberg. The system was run for 1 cycle at 95°C 
for 10min, and 40 cycles at 95°C for 15s, and 60°C for 45s. A dissociation melting curve was included 
at 1 cycle at 95°C for 15s, 60°C for 15s and 90°C for 15s. Results were analysed on an Excel spreadsheet 
to determine the percentage knock down for the siRNA transfected cells in comparison to the non-
silencing control siRNA and mock control. Standard curves were included in the initial run for each 
gene so as to determine the efficiency values of the assay (this value should be as close to 1 as possible). 
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2.2.2. Verification of efficient PINK1 knock down by Western blot 
 
Cell lysate extraction 
Once knock down of PINK1 had been established on a gene expression level, it was necessary to 
confirm that this was translated to a protein level. Cells were cultured in 6-well plates and transfected 
with 5nmol siRNA for the 12 day period. After knock down, 10µM CCCP (a mitochondrial uncoupler) 
was added to the cells for 6hours. This is standard protocol for the detection of the PINK1 protein by 
Western blotting, as mitochondrial depolarization causes an increase of endogenous PINK1 recruitment 
to the mitochondria, which can then be detected by the commercially available antibodies. Cells were 
then trypsinised, collected and centrifuged. Supernatant was removed and the pellet was resuspended 
in 1ml PBS (phosphate-buffered saline), transferred to a 1.5ml epi and re-centrifuged. Thereafter, the 
pellet was resuspended in 50µl cell lysis buffer (Appendix II) and kept on ice for 30min. The lysate was 
centrifuged (UEC13, United Scientific, USA) at 4°C for a further 10min, and the supernatant was 
removed and stored at -20°C for future use. 
 
Bradford protein concentration determination 
In order to calculate a standard curve of protein concentrations, 10µl of a dilution range of bovine serum 
albumin (BSA) standards ranging from 0 - 1000µg/µl was loaded into the wells of a luminometer plate 
(Nunc™, Denmark) in duplicate. A volume of 1µl of cell lysate samples was also added to the plate in 
duplicate. Thereafter, 200µl Bradford reagent (Sigma Aldrich, Germany) was added to each standard 
and lysate sample. The protein concentration of each well was determined by a Synergy HT 
luminometer (BioTek Instruments Inc., USA). Using the KC4™ v 3.4 software (BioTek Instruments 
Inc., USA), a standard curve was set up and each sample’s protein concentration was calculated. 
 
Western blot 
The Mini-PROTEAN TGX Precast Gels for polyacrylamide electrophoresis were used for all Western 
Blots (BioRad, USA). The gels were placed in a holding apparatus and container. A 1x SDS Running 
Buffer was made up from 10x SDS Running Buffer (Appendix II), and poured into the container. The 
comb was removed from the gel and 10µl of the Precision Plus Protein Kaleidoscope (BioRad, USA) 
protein ladder was loaded into the first well. Samples were mixed in a 3:1 ratio with the 4X Laemmli 
Sample Buffer dye (BioRad, USA), and denatured for 5mins at 95°C in the GeneE Thermal Cycler 
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(Techne Inc., USA). Thereafter, 50µg of each lysate was loaded onto the gel, and the gel was 
electrophoresed for approximately 40mins at 140V. 
 
The iBlot Gel Transfer Stacks and PVDF Membrane (Novex, Life technologies, USA) were used for 
transferring the gel onto a membrane. The stacks provide the necessary membrane, filter paper and 
sponge to perform a transfer. All elements were added to the iBlot Gel transfer device (Invitrogen, Life 
technologies, USA) and a roller was used to ensure no bubbles were present. The iBlot was set to voltage 
program P4, at 15 volts for 7mins. The membrane was then removed from the transfer apparatus and 
blocked with 5% fat free milk (Elite, Weigh-Less) dissolved in TBST (Tris Buffered Saline with Tween 
20, Appendix II) for 90mins on a shaker to eliminate non-specific binding of the antibodies. The 
membrane was then washed with TBST for three cycles of 15mins each. Thereafter, the primary 
antibody was diluted in 5% milk at an optimal predetermined dilution (Table 2.2). GAPDH was used 
as a loading control for all western blots. The membrane was then incubated overnight with the 
antibody-milk mixture on the shaker (Labcon, USA) at 4°C.  
 
Following the incubation period, the membrane was washed with TBST for 3X 15mins. The appropriate 
dilution of secondary antibody (Santa Cruz Biotechnology, USA) was then added to the membrane and 
placed on the orbital shaker at room temperature for 1 hour (Table 2.2). Thereafter, the membrane was 
washed with the same washing protocol used after the primary antibody incubation. In a dark room, the 
two substrate components of the SuperSignal® West Pico Chemiluminescent Substrate kit (Thermo 
Scientific, Pierce Biotechnology, USA), viz. the SuperSignal West Pico Luminol/Enhancer solution 
and the SuperSignal West Pico Stable Peroxide solution, were mixed in a 1:1 ratio. The membrane was 
incubated in this solution for 5mins and then placed inside an autoradiography cassette and covered 
with a transparent plastic sheet. Autoradiography film (Eastman Kodak Company, USA) was placed 
over the membrane and the cassette was closed. Exposure time varied from 10 seconds to 5mins, 
depending on the strength of the signal. The film was processed by the Hyperprocessor™ automatic 
autoradiography film processor (Amersham Pharmacia Biotech UK Ltd., UK). The size of the protein 
was determined when placing the film against the protein ladder on the membrane. PINK1 protein was 
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Table 2.2. Antibodies and antibody dilutions for PINK1 and GAPDH Western blot conditions.  
Ab, Antibody 
 
Quantification of Western blots 
All Western blots were quantified using the Image J software (http://imagej.nih.gov/ij/). Image J is able 
to measure the width of the band and obtain an arbitrary unit of thickness. All blots were performed in 
biological and technical triplicate. PINK1 siRNA and the mock control were normalised to the non-
silencing control siRNA. Each value was then compared relative to the GAPDH value. The final value 
was then used for statistical analysis. 
 
2.3. Creation of dosage and time curves 
 
Following the verification of PINK1 knock down at a transcriptomic and proteomic level, we aimed to 
determine the effect of curcumin on both control and PINK1 knock down cells, in the presence and 
absence of a stressor, paraquat. In order to test this, it was essential that the correct concentration of 
paraquat and curcumin were added to the cells, for the correct time period. Dosage and time curves 
were therefore performed on the cells and an MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide) assay was used to measure the number of viable cells compared to non-
viable cells.   
 
Stocks were made up for both paraquat and curcumin. A 50mM final stock concentration was made up 
of 100mg Paraquat dichloride x-hydrate pestanal (Sigma Aldrich, Germany) and 7.8ml dH₂O. For 
curcumin, a final stock concentration of 20mM was made up by adding 10mg curcumin (Sigma Aldrich, 
ANTIGEN 




















5% milk 1:500, 5% milk Goat anti-mouse 1:1000, 5% milk 63-65kDa 
GAPDH 
FL-335, sc-25778, 




5% milk 1:1000, 5% milk Goat anti-rabbit 1:7000, 5% milk 37kDa 
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Germany) to 1.36ml DMSO (dimethyl sulfoxide). For the dosage curve, dilutions of paraquat were 
made up in DMEM for final concentrations of 10µM, 25µM, 50µM, 100 µM, 200µM and 500µM. 
Dilutions of curcumin were made up in DMEM for final concentrations of 1µM, 2µM, 5µM, 10µM and 
20µM. These dilution ranges were adapted from previous studies utilising paraquat and curcumin on 
SH-SY5Y cells (Jaisin et al., 2011; Z. Liu et al., 2013; Yang and Tiffany-Castiglioni, 2008).  
 
2.3.1. MTT Assay 
 
SH-SY5Y cells were cultured in 48-well tissue culture plates (SPL Life Sciences, Korea) with a total 
of 100 000 cells seeded per well. After 24 hours, cells were then either untreated, or treated with 10µM, 
25µM, 50µM, 100µM, 200µM or 500µM paraquat. All of these experiments were performed in 
quadruplicate on the plate. After 24 hours of treatment, an MTT assay was performed to determine the 
percentage of viable cells across the dilution range. An MTT assay assesses cell metabolic activity 
through the measurement of NADPH-dependent cellular oxidoreductase enzymes. During incubation 
of the cells in an MTT solution, the presence of these enzymes reduce the yellow tetrazolium MTT dye 
to its insoluble form formazan, which is purple. This is an indication of a living and viable cell.   
 
A 10mg/ml solution of Thiazolyl Blue Tetrazolium Bromide (Sigma Aldrich, Germany) was made in 
PBS (Appendix II). The solution was covered in foil, as MTT is photosensitive, and vortexed until the 
powder had dissolved. Media was removed from the cells and 200µl of the MTT solution was added to 
each well. Cells were then incubated for 2 hours at 37⁰C, 5% CO₂. After incubation, the media in each 
well was removed and added to microfuge tubes that were centrifuged for 2mins at 4500rpm. The 
supernatant was removed and pellets were resuspended in 150µl of a detergent solution made up of a 
50:1 ratio of 1% Isopropanol/HCl and 0.1% Triton solution. This was then returned to the plate, which 
was placed in the Synergy HT plate reader spectrophotometer (Biotek, USA) and absorbance was read 
at 595nm using the KC4 software.  
 
The intention for paraquat was to stress the cells so that 50% viable cells remained. Based on the 
readings obtained, 25µM paraquat resulted in a 50% decrease in cell viability compared to the untreated 
cells, and was therefore the chosen concentration of paraquat to be used in all future experiments 
(Results, Section 3.2). The MTT assay was repeated using cells treated with 0.5µM, 1µM, 2µM, 5µM, 
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10µM and 20µM dilutions of curcumin. A concentration of 2µM curcumin was selected to be used for 
future experiments, as this was not toxic to the cells (Section 3.2).  
 
In order to determine the exposure time of the cells to paraquat and curcumin, cells were treated with 
either 25µM paraquat or 2µM curcumin in quadruplicate over different time periods including 30mins, 
1hr, 2hrs, 4hrs, 8hrs, 12hrs and 24hrs. An MTT assay was then performed. Based on the cell viability 
results, it was decided that paraquat exposure time would be 24 hours, and curcumin exposure time 
would be 1 hour. Once this was determined, a protocol was established for all of the functional assays 












        Functional assays performed 
 
Figure 2.3. Designed protocol used for all functional assay. All three transfection groups – PINK1 
siRNA, control siRNA and control ‘mock’ were transfected over a 12 day period. Thereafter, cells either 
remained as they were (untreated, blue), were treated with 25µM paraquat (PQ) for 24 hours (green), 
were pre-treated with 2µM curcumin (Curc) for 1 hour and then treated with 25µM PQ for 24 hours 
(yellow), or were treated with 2µM Curc for 1 hour only (red).  
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2.4. Cell viability  
 
PINK1 siRNA cells, control siRNA cells, and control mock transfected cells were seeded into 48-well 
plates in quadruplicate. Based on the protocol in Figure 2.3, each group was then either treated with 
paraquat, curcumin, pre-treated with curcumin then paraquat, or remained untreated. An MTT assay 
was performed to determine the percentage of viable cells after each treatment. The assay was repeated 
for three separate runs and statistical analysis was performed (Section 2.10) to determine possible 
changes between each treatment group.  
 
Results obtained from the MTT assay showed that non-silencing control siRNA and mock control cells 
exhibited no changes in cell viability. Based on this, and the expense of transfection reagent, it was 
determined that future assays would only be performed using the non-silencing control siRNA and not 
the mock control.  
 
2.5. Detection of apoptotic markers 
 
Two proteins were used as markers for apoptosis in the treatment groups of PINK1 siRNA and control 
siRNA cells – cleaved PARP and full-length caspase 3. Both proteins form part of the apoptotic cascade, 
and were detected through Western blot analysis (Section 2.2.2). Cell lysates were collected after each 
treatment condition, and their concentration was determined through Bradford protein concentration 
determination. A final concentration of 50µg for each lysate was loaded and run on Mini-PROTEAN 
TGX Precast Gels (BioRad, USA), and transferred to a membrane which was subsequently blocked in 
5% milk. Primary and complementary secondary antibodies for cleaved PARP, full-length caspase 3 
and GAPDH (loading control) were used (Table 2.3) and blots were quantified using Image J software. 
Statistical analysis was performed to determine changes in band size, and therefore changes in levels of 
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Table 2.3. Antibodies and antibody dilutions for cleaved PARP, full-length caspase 3 and GAPDH 
Western blot conditions 
Ab, Antibody 
 
2.6. Measuring mitochondrial membrane potential 
 
MMP can be measured by staining the cells with the JC-1 fluorochrome and using flow cytometric 
analyses. A stock concentration of 5mg/ml JC-1 and DMSO was made up (Appendix II) and stored at 
-20°C for future use. 
 
2.6.1. Staining cells with JC-1 
 
SH-SY5Y cells were treated with either PINK1 siRNA or control siRNA over the course of 12 days, 
and were then treated with one of the four treatment groups shown in Figure 2.3. The cells were then 
trypsinised and resuspended in 2ml DMEM. The JC-1 stock was diluted to 10µg/ml and 4µL was added 
to the resuspended cells. The cells were incubated at room temperature for 15mins and vortexed until 
the stain was properly dissolved. Cells were then centrifuged for 3mins at 1500rpm. The supernatant 
was discarded and the pellet resuspended in 500µl PBS.  
 
ANTIGEN 






















5% milk 1:1000, 5% milk Goat anti-rabbit 1:1000, 5% milk  116kDa 
Caspase 3 
CST9662, Rabbit 
polyclonal Ab to 
caspase 3, 1mg/ml 
(Cell Signalling 
Technology) 
5% milk 1:1000, 5% milk Goat anti-rabbit 1:1000, 5% milk 35kDa 
GAPDH 
FL-335, sc-25778, 




5% milk 1:1000, 5% milk Goat anti-rabbit 1:7000, 5% milk 37kDa 
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2.6.2. Flow cytometric analysis 
 
All flow cytometric analyses were performed on a FACSAria flow cytometer (Becton Dickinson 
Biosciences, USA) equipped with a 488nm Coherent Sapphire solid state laser (13-20mW), 633nm JDS 
Uniphase HeNe air-cooled laser (10-20mW) and 407nm Point Source Violet solid state laser (10-
25mW). The FACSAria is able to sort a mixture of cells based on the fluorescent signal from each cells. 
Cells for this assay were sorted based on polarisation. This was done at the Central Analytical Facility 
at Stellenbosch University, with the help of Miss. Rozanne Adams. Samples were analysed on the flow 
cytometer and a minimum of 10 000 events were collected. Fluorescence intensity signal was measured 
using the geometric mean on the intensity histogram. JC-1 aggregates in red, indicative of healthy 
mitochondria and a high MMP, were measured with the PE (Phycoerythrin) fluorochrome, whereas JC-
1 monomers in green, indicative of lowered MMP were measured with the FITC (Fluorescein 
isothiocyanate) fluorochrome. Therefore the PE/FITC ratio indicated a ratio of healthy mitochondria to 
depolarised mitochondria. 
 
2.7. Measuring mitochondrial and glycolytic respiration  
 
The XFe96 Analyser (Seahorse Bioscience, USA) enables one to measure cellular metabolism and 
mitochondrial respiration of the cells by measuring the rate of oxygen consumed by the cells, also 
known as the Oxygen Consumption Rate (OCR). Furthermore, by measuring lactic acid production via 
protons released into the medium surrounding the cells, one can measure glycolytic respiration, by the 
Extracellular Acidification Rate (ECAR). The XFe96 Analyser has a cartridge that enters each well of 
a 96-well plate. At the bottom of each cartridge are two fluorophores – one that is quenched by oxygen 
and therefore measures the mitochondrial component of respiration, and one that is quenched by 
hydrogen and measures glycolysis. A change in fluorophore emission represents a change in the levels 
of oxygen or hydrogen in the cells 
 
2.7.1. The XF Cell Mito Stress Test 
 
The XF Cell Mito Stress Test kit is designed to measure various aspects of mitochondrial respiration, 
including basal respiration, ATP production, maximal respiration and spare respiratory capacity. The 
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kit includes three drugs that are injected into the media surrounding the cells at specific time points 
through drug injection ports. The machine then measures and determines the response of the cells to 
each drug at three measurement points in real time. After three measurements of basal respiration, 
Oligomycin is injected into the media. Oligomycin is an ATP coupler that inhibits ATP synthesis by 
blocking ATP synthase (Complex V). This step enables one to determine the percentage of oxygen 
consumption devoted to ATP synthesis by calculating the difference in OCR before and after 
Oligomycin addition (Figure 2.4). The second injection is FCCP (trifluorocarbonylcyanide 
phenylhydrazone), an uncoupling agent that causes a drop in MMP, which results in a rapid 
consumption of energy and oxygen as ATP generation is halted. This enables one to determine the 
maximal respiration of the cells as well as the spare respiratory capacity, which is the difference between 
maximal OCR and basal OCR (Figure 2.4). Lastly, a combination of Rotenone and Antimycin A is 
injected which inhibit complex I and complex III respectively. This results in a decrease in OCR as 
mitochondrial respiration is shut down and an increase in ECAR as the cells switch to a glycolytic state 










Figure 2.4. The Mito Stress Test measures the fundamental parameters of mitochondrial 
respiration. These include basal respiration, ATP production, maximal respiration, and spare capacity, 
and are measured by OCR (Oxygen Consumption Rate) in real time.  
 
Cells underwent the knock down protocol (Section 2.2, Figure 2.2) and were then seeded into the 96-
well XF Analyser Cell Culture plate (Seahorse Bioscience, USA) at a predetermined seeding density of 
7500 cells per well, counted using the Scepter Handheld Cell Counter (Merck, Germany). In summary, 
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four rows of the plate had control siRNA cells (A-D), and four rows had PINK1 siRNA cells (E-H). 
The plate was placed in the incubator overnight. Thereafter, each row was treated with one of the four 












Figure 2.5. Design of the 96-well plate used for the XF Analyser Mito Stress Test. Each row of 
wells was treated based on the pre-determined protocol. The black corner wells were untreated and 
remained empty. PQ, paraquat; Curc, curcumin 
 
Three plates are utilized during the process of mitochondrial respiratory detection - the XF Analyser 
Cell Culture Plate, the Utility Plate, and the Cartridge Plate (which contains the fluorophores). Whilst 
the cells were being treated, it was necessary to hydrate the cartridge plate overnight in order to hydrate 
the fluorophores and remove excess CO₂ from the plastic, as this affects the pH of the medium. A 
volume of 200µl XF Calibrant Media (Seahorse Bioscience, USA) was added to each well of the utility 
plate, and the cartridge plate was placed over the utility plate and added to the XF Seahorse incubator 
(37⁰C, 0% CO₂) overnight. 
 
The following day, an assay medium was made up containing 42.5ml XF Assay Medium Modified 
DMEM (Seahorse Bioscience, USA), 1mM Pyruvate and 25mM Glucose and pH pf 7.4. The medium 
Control siRNA, untreated 
Control siRNA, 25µM PQ 
Control siRNA, 2µM Curc 
Control siRNA, 2µM Curc + 25µM PQ 
PINK1 siRNA, 2µM Curc + 25µM PQ 
PINK1 siRNA, 2µM Curc  
PINK1 siRNA, 25µM PQ 
PINK1 siRNA, untreated 
Blank wells 
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on the cells was removed and the cells were washed with 200µl of assay medium. This was removed 
and a further 175µl assay medium was added to the cells. The plate was then incubated in the XF 
Seahorse incubator for 1hour.  
 
The stock solutions of the three drug compounds (Oligomycin, FCCP and Rotenone + Antimycin A) 
were made up by adding each compound to DMSO for a stock concentration of 2.5µM. The optimal 
final concentrations for each compound were as follows: 1µM Oligomycin, 0.5µM FCCP, 1µM 
Rotenone + Antimycin A. This was made up by diluting the stock solutions in assay medium. These 
solutions were then vortexed and 25µl was added to the cartridge plate at specific ports via a loading 
plate. Oligomycin was added to Port A, FCCP to Port B, and Rotenone + Antimycin A to port C. The 
cartridge plate was then incubated in the XF Seahorse incubator for 5mins. Thereafter, the cartridge 
plate and utility plate were added to the XFe96 Analyser and calibrated for 20mins. The utility plate 
was then removed and the cell culture plate was placed over the cartridge plate and the run was initiated. 
Results and data were analysed on the XFe96 Wave software (www.seahorsebio.com/). 
 
2.7.2. The XF Glycolysis Stress Test  
 
The XF Glycolysis Stress Test kit makes it possible to measure glycolysis in real time while inducing 
metabolic stress in order to identify key parameters of glycolytic flux in the cells: glycolysis, glycolytic 
capacity and glycolytic reserve. The conversion of glucose to pyruvate, and subsequently to lactate in 
the cytosol, results in the production and release of protons to the extracellular medium. An increase in 
the release of protons results in an increase in the measurable ECAR, which signifies an increase in 
glycolytic activity. The kit, similar to the Mito Stress Test kit,  includes three drugs that are injected 
into the media surrounding the cells at specific time points through drug injection ports. After three 
measurements of ECAR in a glucose-free medium, a saturating concentration of glucose is injected to 
the cells (Figure 2.6), resulting in a spike of ECAR as glycolysis rates increase. Thereafter, Oligomycin 
is injected, which inhibits oxidative phosphorylation and therefore results in the maximal cellular 
glycolytic capacity. Lastly, 2-deoxy-glucose (2-DG), a glucose analogue, is injected to the cells and 
inhibits glycolysis (Figure 2.6). 
 











Figure 2.6. The Glycolysis Stress Test measures the fundamental parameters of glycolytic flux. 
These include glycolysis, glycolytic capacity and glycolytic reserve, measured in real time by the ECAR 
(extracellular acidification rate). 2-DG, 2-deoxy-glucose 
 
Cells, the utility plate and the cartridge plate were treated and plated in the same manner as was done 
in Section 2.7.1 for the Mito Stress Test (Figure 2.5). Once treated, cells were washed with 200µL 
glycolysis assay medium. This was removed and a further 175µl assay medium was added to the cells. 
The plate was then incubated in the XF Seahorse incubator for 1hour. Stocks were made up for the three 
drug compounds of the Glycolysis Stress Test Kit – Glucose, Oligomycin and 2-DG by adding the 
compound to DMSO for a stock concentration of 2.5µM. Final concentrations of 10mM Glucose, 1µM 
Oligomycin and 100mM 2-DG were then made by diluting the stock solution in the glycolysis assay 
medium. These solutions were added to the ports in the cartridge plate, and the same protocol for the 
Mito Stress Test was followed thereafter. Results and data were analysed on the XFe96 Wave software 
(www.seahorsebio.com/). 
 
2.8. Mitochondrial network analysis 
 
After the third knock down step (Figure 2.2), cells were seeded in 8-well chambered coverglass (Lab-
Tek, Nunc, Denmark) at a density of 10 000 cells per well, and incubated for 24 hours. Cells were then 
treated with siRNA and transfection reagent for a final time, incubated for 48 hours, and treated with 
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the pre-determined treatment groups as shown in Figure 2.3. MitoTracker Red (Invitrogen, Life 
Technologies, USA) which stains for the mitochondrial network, was diluted in cell culture media to 
1:1000. The Hoechst 3343 stain for the nucleus (Thermo Scientific, USA) was diluted at 1:200 in media.  
 
After treatment, the cells were stained with both MitoTracker Red and Hoechst 33342, and then were 
observed on an Olympus Cell^R system attached to an IX-81 inverted fluorescence microscope 
equipped with an F-view-II cooled CCD camera (Soft Imaging Systems). Using a Xenon-Arc burner 
(Olympus Biosystems GMBH, Germany) as light source, images were excited with the 360nm, 492nm 
or 572nm excitation filters. Emission was collected using a UBG triple-bandpass emission filter cube. 
For the image frame acquisition, an Olympus Plan Apo N 60x/1.4 oil objective and the Cell^R imaging 
software was used. Images were processed and background-subtracted using the Cell^R software. The 
images were then quantified using Image J software.  
 
Form factor (the degree of mitochondrial branching) was calculated from the measurements of 
mitochondrial perimeter and area. Aspect ratio, which represents the relationship of mitochondrial 
width and height, was determined by the ratio of the major and minor axes. The major axis is the axis 
that projects through the length of the mitochondrion, and the minor axis the width. The following 
equations were used for calculation: 
 
Form factor = P2/4πA    (P, perimeter of cell; A, area of cell) 
Aspect ratio = Major axis/ Minor axis 
 
Statistical analysis was performed and Bonferroni’s correction for multiple comparisons was utilised. 
(Section 2.10). 
 
2.9. Autophagic flux measurement and calculation 
 
Autophagy can be measured through the detection of autophagic proteins via Western blots. LC3-II is 
a protein associated with the inner and outer membrane of the autophagosome and is primarily used to 
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determine levels of autophagy in the cells. Furthermore, p62 is a second measure of autophagic flux, as 
it binds to LC3-II in the autophagosome and is rapidly degraded during autophagy. It must be noted 
that p62 is not only specific to autophagy, and is associated with other pathways which may affect the 
level of p62. Despite this, it is necessary to verify measurements of LC3-II with p62. To calculate 
autophagic flux, both LC3-II and p62 need to be measured after activation of basal autophagy in a 
starvation state, as well as after the addition of BafA1, which acts as an inhibitor of vacuolar ATPase 
and autophagosome-lysosome fusion. The difference in levels before and after BafA1 treatment is then 
defined as autophagic flux (Figure 2.7). A 20µg/ml stock solution of BafA1 was made up in ethanol 










Figure 2.7. The effect of the lysosomal inhibitor Bafilomycin A1 on autophagy. Autophagic flux is 
calculated by the difference in LC3-II and p62 before and after the addition of bafilomycin A1. 
Bafilomycin A1 inhibits vacuolar-ATPase and prevents lysosomal fusion with the autophagosomes. 
Taken from www.vivabioscience.com 
 
SH-SY5Y cells were seeded into 6-well plates and either PINK1 siRNA or control siRNA was added 
to them. In total there were 2 groups of treated PINK1 siRNA cells and 2 groups of control siRNA cells. 
After 12 days of transfection, cells were either untreated, or treated with either paraquat, curcumin or 
pre-treated with curcumin and then with paraquat according to the previously described protocol. 
Thereafter, the treatment media was aspirated and 3ml HBSS media was pipetted onto one set of PINK1 
siRNA and control siRNA cells. HBSS is a saline solution that contains 1g/L glucose and no amino 
acids – therefore it is capable of inducing nutrient starvation to the cells and a subsequent increase in 
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autophagy. Alternatively, the second set of PINK1 siRNA and control siRNA cells were treated with a 
combination of HBSS and BafA1. From the stock solution, 9.7µl BafA1 was diluted in 3ml HBSS to 
give a final concentration of 100nM. This was added to the second group of cells, and the both groups 
were incubated simultaneously at 37°C for 2hours.  
 
After incubation, the cells were lysed and protein concentration was determined through the Bradford 
method as described in Section 2.2.2. Both groups of samples that were treated with HBSS and 
HBSS+BafA1 were simultaneously run on gels and detected by Western blotting (Section 2.2.2). 
Antibodies for LC3-II, p62 and GAPDH (the loading control) were used at optimal concentrations 
(Table 2.4). It must be noted that in order to detect LC3-II, membranes were blocked in 5% BSA diluted 
in TBST. Primary and secondary antibodies were also diluted in 5% BSA compared to p62 and GAPDH 
that used 5% milk. Intensity of the bands for each protein was quantified by Image J software, and band 
intensities of LC3-II and p62 were each normalised to the corresponding band intensities of GAPDH. 
Autophagic flux was then calculated by comparing the normalised LC3-II and p62 in BafA1-treated 
versus untreated samples. These results were technically repeated three times, and replicated in three 
independent experiments. Statistical analysis was performed using GraphPad Prism software (Section 
2.10). 
 
Table 2.4. Antibodies and antibody dilutions for LC3-II, p62 and GAPDH Western blot 
conditions 
Ab, Antibody; BSA, bovine serum albumin 
 
ANTIGEN 
















monoclonal Ab to 
LC3-II, 1mg/ml (Cell 
Signalling 
Technology) 
5% BSA 1:1000, 5% BSA Goat anti-rabbit 1:1000, 5% BSA 16kDa 
P62 
AB56416, Mouse 
monoclonal Ab to 
p62, 1mg/ml 
(Abcam) 
5% milk 1:1000, 5% milk Goat anti-rabbit 1:1000, 5% milk 62kDa 
GAPDH 
FL-335, sc-25778, 




5% milk 1:1000, 5% milk Goat anti-rabbit 1:7000, 5% milk 37kDa 
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2.10. Statistical analysis 
 
All statistical analyses were performed using GraphPad Prism Software V5 
(www.graphpad.com/scientific-software/prism/). Column bar graphs were generated indicating the 
mean with standard deviation. Depending on the total number of groups being analysed, one way 
analysis of variance (ANOVA) and student t-tests were performed to determine the value of ‘p’. All 
measurements of p<0.05 were considered statistically significant. Statistical analyses were done with 
the help of Miss Moleen Zunza from the Biostatistics Unit, Stellenbosch University. 
 
2.11. Analysis of Copy Number Variation in South African PD patients 
 
This section of work was conducted in order to detect CNV in known PD-causing genes in a cohort of 
South African PD patients. We specifically aimed to identify rearrangements in the PINK1 gene, in 
order to obtain fibroblasts from these patients for use in a second model of PD. 
 
2.11.1. Patient and control selection 
 
Patients suffering from PD were recruited from the Movement Disorder clinic at Tygerberg Hospital, 
as well as the Parkinson’s Association of South Africa. The patients were examined by a movement 
disorder specialist, Professor Jonathan Carr, and met the UK Parkinson’s Disease Society Brain Bank 
Research criteria for diagnosis of PD (Gibb and Lees, 1988). Blood samples were obtained from each 
patient and gDNA was isolated by Dr. Sihaam Boolay (Appendix I). Furthermore, control blood 
samples were obtained from the Geriatric clinic at Tygerberg Hospital and the Western Province Blood 
Transfusion Services, and gDNA was isolated and stored at -4°C. This study was approved by the 
Health Research Ethics Committee at Stellenbosch University (Protocol number: 2002/C059). The 
approval is renewed annually. All study participants were recruited with informed written consent. For 
this study, a total of 210 patients from all ethnic backgrounds were analysed (Table 2.5).  
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Table 2.5. Clinical characteristics of 210 South African PD patients recruited for this study 
 Total N = 210 
AAO, mean +-SD, (range) 59.4 +- 12.3 years (20-82 years) 
AAO <= 50 years 44 (20.9%) 
Family history of PD 55 (26.2%) 
Ethnicity  
       White 75 (35.7%) 
       Afrikaner 56 (26.7%) 
       Mixed Ancestry 57 (27.1%) 
       Black 21 (10.0%) 
       Indian 1 (0.5%) 
AAO, Age at onset 
 
2.11.2. MLPA analysis 
 
The MLPA kit (MRC Holland, Netherlands) for CNV detection in PD patients consists of two separate 
kits, each with a different probe mix. These probe mixes contain oligonucleotides for ligation to the 
exons of genes known to cause PD, as well as reference probes. More specifically, probe mix 1 is 
SALSA MLPA P051 (MRC Holland, Netherlands), and contains probes for exons of PARK2, PINK1, 
SNCA, ATP13A2, LRRK2 and DJ-1. Probe mix 2, SALSA MLPA P052 (MRC Holland, Netherlands), 
contains probes for exons of PARK2, UCHL1, GCH1, CAV1 and LRRK2 (Appendix III). The MLPA 
kit also contains a SALSA MLPA EK1 Reagent Mix (MRC Holland, Netherlands) which includes the 
SALSA MLPA Buffer, Ligase-65, Ligase buffers A and B, PCR Primer mix, and SALSA polymerase. 
 
Patient and control gDNA was diluted in dH₂O to a final concentration of 30ng/µl for each MLPA 
reaction. Control gDNA included samples with no known mutations in the PD genes, and 2 controls 
were included for each run. A negative dH₂O control was also included in the runs. Reactions for probe 
mixes P051 and P052 were performed at the same time, therefore two sets of the samples were run 
parallel to each other, one containing probe mix P051, and the other P052. A volume of 5µl of gDNA 
from each sample and control sample was pipetted into 0.2ml epis, and the samples were denatured in 
the GeneAmp® PCR system 2720 Thermal Cycler (Applied Biosystems, USA) for 5min at 95⁰C and 
cooled to 25⁰C for a further 5min. The hybridisation master mix was then prepared consisting of 0.75µl 
MLPA buffer and 0.75µl probe mix (either P051 or P052). A total volume of 1.5µl of the hybridisation 
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master mix was added to each sample and mixed well by gently pipetting up and down. Samples were 
placed in the thermocycler for incubation at 95⁰C for 1min and then 60⁰C overnight for 16 hours. 
Thereafter the thermocycler was paused at 54⁰C. 
 
The following day a Ligase-65 master mix was prepared containing 12.5µl dH₂O, 1.5µl Ligase buffer 
A, 1.5µl Ligase buffer B and 0.5µl Ligase-65 enzyme. A total volume of 16µl of the Ligase-65 master 
mix was added to the samples at 54⁰C. Ligation of the probes to the sample DNA was then initiated by 
running the thermocycler for 15mins at 54⁰C, followed by heat inactivation of the ligase enzyme for 
5mins at 98⁰C and cooling at 20⁰C for 5mins. Lastly, the polymerase master mix was prepared with 
3.75µl dH₂O, 1µl SALSA PCR primer mix, and 0.25µl SALSA polymerase. Samples were removed 
from the thermocycler after ligation and 5µl polymerase master mix was added to each epi. Samples 
were placed back in the thermocycler for PCR amplification for 35 cycles of 30sec 95⁰C, 30sec 60⁰C 
and 60sec 72⁰C, followed by 20mins at 72⁰C and cooling for 5mins at 15⁰C.  
 
Fragment separation by capillary electrophoresis was performed on the PCR products at the Central 
Analytical Facility of the Department of Genetics, Stellenbosch University on the ABI 3130xl ® 
Genetic analyser (Applied Biosystems, USA).  A summary of the MLPA method is shown in Figure 
2.8. The raw data was then analysed using the Coffalyser.Net software, version .131211 
(http://coffalyser.software.informer.com/download/).  
 
The results for MLPA raw data were analysed as follows: 
 
The relative peak height (RPH) of each exon was obtained by dividing the single peak height by the 
sum of peak heights of all the internal control probes. A ratio was then generated by comparing each 
RPH to the mean value of the corresponding RPHs from a reference wild-type sample. Ratios to indicate 
mutations were set as follows: 
 
- between 0.7 and 1.3 were considered to be normal (sample contains no exon 
rearrangements) 
- between 0.3 and 0.6 indicated a heterozygous deletion  
- between 1.4 and 1.6 indicated a heterozygous duplication 
- Higher than or equal to 1.7 indicated a triplication 
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- Absence of a peak would indicate either a possible point mutation at that probe 















Figure 2.8. A summary of the MLPA procedure. The MLPA procedure can be divided into four 
major steps. 1. Denaturation of the sample DNA and hybridisation of probes to adjacent target 
sequences of DNA. 2. Ligation of the probes to the DNA. 3. Exponential amplification of the ligated 
probes during a PCR reaction. 4. Separation of the amplification products by capillary electrophoresis. 
Taken from www.mlpa.com. 
 
2.11.3. Quantitative real time PCR 
 
For verification of the MLPA results, qRTPCR was performed on the Lightcycler 96 (Roche 
diagnostics, Germany). Primers were available for all genes of interest as well as β-globulin (HBB), the 
HKG used in these experiments. All primers were diluted to 20µM, and 30ng/µl gDNA was used.  




A mastermix was prepared for each reaction consisting of 7µl dH₂O (Roche diagnostics, Germany), 
0.5µl forward primer, 0.5µl reverse primer and 10µl Lightcycler 480 SYBR Green I Master Mix (Roche 
diagnostics, Germany). A total volume of 18µl of the mastermix was pipetted into each well of a 96-
well plate (Roche diagnostics, Germany) using the epiMotion (eppendorf, Germany) to prevent manual 
pipetting errors. Thereafter, 2µl of sample or control DNA was added to each well and mixed with the 
mastermix. All sample and control reactions were performed in triplicate. The plate was centrifuged for 
1min at 1500rpm and placed in the Lightcycler 96. qRTPCR was accomplished under the following 
conditions: i. Preincubation at 95⁰C for 600sec, ii. Three step amplification for 45 cycles including 
95⁰C for 10sec, 60⁰C for 10sec followed by a touchdown to 55⁰C after the second cycle, and 72⁰C for 
10sec, iii. Melting period of 95⁰C for 10sec, 65⁰C for 60s, 97⁰C for 1sec and iv. Cooling period of 37⁰C 
for 30s. Results were analysed on the Lightcycler 96 software version 1.1 (www.roche.com), which 
calculates relative quantification. Ct values differing by more than 1 unit per triplicate were discarded. 
 
2.11.4. Direct Sequencing  
 
Results from the MLPA analysis showed that sequencing was required on samples believed to be false 
positive due to the presence of a polymorphism in the annealing site of the probe. Primer sequences 
were available on request, and PCR reactions were performed on gDNA of these samples on the 
GeneAmp® PCR system 2720 Thermal Cycler (Applied Biosystems, USA). The PCR products were 
run on a 2% agarose gel to verify the presence of the exon.  
 
A volume of 8µl of each PCR product was pipetted into a 0.2ml microcentrifuge PCR epi (Sigma-
Aldrich, USA), and this was purified with 5U of both Exonuclease I (USN Corporation, USA) and SAP 
(Shrimp Alkaline Phosphatase; Promega, USA). The samples were mixed and spun in the Hermle 
Z100M microcentrifuge (Labnet, USA) and then incubated at 37°C for 15mins followed by 80°C for 
10mins to deactivate the enzymes. Each product was diluted down to 30ng/µl for the sequencing 
reaction.  
 
The primers used for sequencing were the same primers used during the PCR amplification diluted to 
1.1µM. All automated sequencing reactions of the PCR products were performed at the Central 
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Analytical Facility of the Department of Genetics, Stellenbosch University using the BigDye terminator 
V3.1 Ready reaction kit on the ABI 3130xl ® Genetic analyser (Applied Biosystems, USA). Analysis 
of sequencing data was performed using the BioEdit Sequence Alignment Editor Version 7.0.5 software 
(Hall, 1999). 
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Section A: Creation of an siRNA-mediated PINK1 knock down 
cellular model of PD and the effect of curcumin exposure 
 
3.1. Successful knock down of PINK1 using an siRNA-mediated approach 
 
In the present study, we attempted to knock down PINK1 in an SH-SY5Y neuroblastoma cell line using 
siRNA, decreasing the expression of this gene at a transcriptional and translational level. As mentioned 
in Section 2.2, two different controls were used to test the expression of PINK1 – i. non-silencing control 
siRNA using scrambled siRNA and ii. a mock transfected control treated only with transfection reagent.  
To determine the percentage knock down and cell viability levels, both control siRNA and mock control 
cells were used. Furthermore, the optimum PINK1 siRNA chosen for subsequent knock downs was 
Hs_PINK1_6_Flexitube siRNA. 
 
Once the cells had been transfected, gene expression analysis was performed using qRTPCR and results 
confirmed a 75% decrease in the expression of PINK1 mRNA normalised to the expression levels of 
the cells treated with non-silencing control siRNA (p=0.0018, Figure 3.1). All experiments were 
performed in triplicate. The mock transfected control showed similar expression to the control siRNA 








Figure 3.1. Quantitative real time PCR (qRTPCR) analysis of PINK1 mRNA expression levels. 
Bar graph indicating qRTPCR of PINK1 cDNA. PINK1 was significantly reduced by 75% after knock 
down using PINK1 siRNA (** p<0.01). 
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In order to detect protein expression of endogenous PINK1 in vitro, SH-SY5Y cells needed to be treated 
with CCCP prior to lysate collection. CCCP depolarises the mitochondria, resulting in a lowered 
membrane potential and thus recruitment of full-length PINK1 (~65kDa) to the OMM of the 
mitochondria. Without CCCP addition, endogenous levels of PINK1 are too low to be detected by 
current commercially available antibodies (Geisler et al., 2010a). Therefore control siRNA cells, mock 
transfected cells and PINK1 siRNA cells were treated with 10μM CCCP for 6 hours. Results revealed 
a significant decrease in endogenous PINK1 expression compared to control siRNA cells (p<0.001, 
54% decrease). Comparison of the mock control to the control siRNA showed no change in PINK1 















Figure 3.2. Western Blot analysis of PINK1 protein expression. A. Image indicating the detection 
of full-length PINK1 (65kDa, top panel) and the loading control GAPDH (37kDa, bottom panel). B. 
Quantification of the blots revealed significantly decreased PINK1 protein levels (by 54%) after the 
addition of PINK1 siRNA compared to control siRNA (***p<0.001). 
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3.2. Determining dose- and time-curves for paraquat and curcumin 
 
Previous studies on the use of paraquat and curcumin in SH-SY5Y cells have used varying 
concentrations  of paraquat and curcumin over different time periods (Jaisin et al., 2011; Lantto et al., 
2009; Yang et al., 2010). Dosage and time curves were therefore established for both paraquat and 
curcumin to determine a final concentration and exposure time for each compound that would be used 
throughout all of the experiments. Initially, cells were seeded at densities of 50 000, 100 000, 120 000 
and 140 000 in 48-well cell culture plates (SPL Life Sciences, Korea) for 24 hours to determine an 
optimal density as well as to ensure that the MTT protocol was optimised correctly. The MTT assay 
has previously been used in studies to determine optimal seeding density, the ideal concentration of the 
compounds, and an applicable exposure time, and was therefore an appropriate assay to use for this 
study (Liu et al., 2013; Li et al., 2012; Section 2.3.1).  
 
As expected, the number of viable cells increased as the seeding density of the cells increased (Appendix 
IV). Based on these results, a seeding density of 100 000 cells per well was selected, as this resulted in 
approximately 80% confluency after 24 hours. Cells were incubated in the presence of paraquat and 
cell viability was measured. The optimal concentration was chosen to be 25µM, as this significantly 
reduced cell viability compared to untreated cells, but did not induce excessive toxicity to the cells 
(p<0.05, Figure 3.3A). This concentration was then used to perform a time curve where 25µM paraquat 
was added to the cells at various time points over 24 hours. Results revealed that optimal exposure time 
for 25µM paraquat is 24 hours (p=0.0145, Figure 3.3B), as this significantly reduced the cell viability.  
 
Dose- and time-curves were also established for curcumin, and results indicated an optimal 
concentration of 2µM (Figure 3.4A). Concentrations over 2µM showed a significant decrease in cell 
viability. As the mechanism of curcumin as a treatment is being tested, the concentration used should 
have no toxic effect on the cells, therefore it was decided that 2µM was appropriate. The time curve 
with 2µM curcumin showed no significant change in cell viability over various time periods, therefore 
an exposure time of 1 hour was chosen as optimal as this complemented what has been done in previous 














Figure 3.3. Determining a suitable concentration and time exposure of paraquat for SH-SY5Y 
cells. A. Dose curve indicating a significant decrease in cell viability at 25µM (*p<0.05). 
Concentrations higher than 25µM showed a highly significant decline in viability, therefore 25µM 
paraquat was used as an appropriate concentration for future experiments. B. Time curve indicating a 










Figure 3.4. Determining a suitable concentration and time exposure of curcumin for SH-SY5Y 
cells. A. Dose curve indicates an optimal concentration of 2µM curcumin for future work. B. Time 
curve showed no significant increase or decrease in cell viability, and an optimal time of 1hour curcumin 
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For the remainder of the experiments, control and PINK1 knock down cells were separated into four 
treatment groups, as explained in Figure 2.3:  
- Untreated 
- Treated with 25µM paraquat for 24 hours 
- Pre-treated with 2µM curcumin for 1 hour and then treated with 25µM paraquat for 24 
hours 
- Treated with 2µM curcumin for 1 hour 
 
3.3. Cell viability 
 
Once the paraquat and curcumin exposure protocols were optimised, various parameters of cellular and 
mitochondrial function were measured to determine the effect of PINK1 knock down, paraquat addition 
and curcumin treatment on the SH-SY5Y neuroblastoma cell line. An MTT assay was performed to 
measure cell viability. Results showed a significant decrease in cell viability (p=0.0036) in cells that 
had decreased PINK1 expression after normalising to the control siRNA (Figure 3.5). Mock control 









Figure 3.5. Decrease in cell viability in cells with decreased PINK1 expression. Results normalised 
to control siRNA indicate a significant decline in cell viability in PINK1 knock down cells (**p<0.01), 
with a total decrease of 23%. Cell viability in PINK1 knock down cells was also significantly decreased 
compared to the mock control group (**p<0.01). 
** 
** 
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Mock control cells, non-silencing control siRNA cells and PINK1 siRNA cells were then separated into 
the four previously mentioned treatment groups, and all groups were normalised to the untreated group. 
 
In the control siRNA, mock control and PINK1 siRNA cells, paraquat treatment caused a significant 
decrease in cell viability compared to the untreated cells, as was expected (Figure 3.6A, B, C, p<0.001). 
In both controls, pre-treatment with curcumin prior to the addition of paraquat showed a significant 
improvement in the cell viability (Figure 3.6A, B, p<0.01), suggesting that curcumin may have a 
protective effect against paraquat. Pre-treatment with curcumin in the PINK1 siRNA cells did not show 
a significant increase in cell viability (Figure 3.6C), indicating that curcumin was unable to protect the 
cells exposed to paraquat in a PINK1 siRNA-mediated model of PD. The addition of curcumin alone to 
all three groups showed similar cell viability compared to the untreated groups (Figure 3.6A, B, C), 
































Figure 3.6. Curcumin improves cell viability in control cells. A, B. Non-silencing control cells (A) 
and mock control cells (B) showed a significant decrease in cell viability after paraquat treatment 
(***p<0.001; 58% and 62% respectively), which was rescued when pre-treated with curcumin 
(**p<0.01; 79% and 84% respectively). C. PINK1 knock down cells showed a significant decrease in 
cell viability after paraquat treatment (***p<0.001, 60%), but no protective effect with curcumin pre-
treatment was evident. PQ, paraquat; Curc, curcumin. 
 
In summary, cell viability was decreased in a PINK1 siRNA-mediated model of PD compared to two 
separate controls, suggesting that PINK1 may play a role in the maintenance of healthy cells. 
Furthermore, paraquat decreased cell viability, and this effect was rescued by curcumin pre-treatment 
in control cells, but not in the PINK1 siRNA-treated cells. This may indicate that decreased PINK1 
expression combined with paraquat treatment may damage the cells too severely, beyond a point where 
rescue by curcumin is possible. Curcumin-only treatment did not affect cell viability in the controls or 
in the PINK1 knock down model, and was therefore not toxic to the cells.  
 
3.4. Detection of apoptosis  
 
Two markers from the apoptotic cascade were measured – namely cleaved PARP and full-length 
caspase 3 – to detect levels of apoptosis in the cells. Increased apoptosis can be shown as a combination 
of increased levels of cleaved PARP, and decreased levels of caspase 3. Due to the fact that the cell 
viability assay showed similar results for both mock control and control siRNA conditions and due to 
C 
*** 
Stellenbosch University  https://scholar.sun.ac.za
76 
 
the relatively high cost of the transfection reagent, all future experiments utilised only the non-silencing 
control (control siRNA), and not the mock control, as a comparative to the PINK1 siRNA conditions.  
 
3.4.1. Cleaved PARP 
 
Images from the Western blots conducted on cleaved PARP and the loading control GAPDH are shown 
in Figure 3.7A. When quantified, it was revealed that untreated PINK1 knock down cells had 
significantly higher levels of cleaved PARP protein compared to the untreated control cells (p=0.0144), 
indicating that there was increased apoptosis in these cells when PINK1 expression was decreased 
(Figure 3.7B).  
 
Furthermore, it was revealed that paraquat treatment significantly increased levels of cleaved PARP 
compared to the untreated group in both PINK1 siRNA cells (p<0.01, Figure 3.7C) and in control cells 
(p<0.01, Figure 3.7D). Pre-treatment with curcumin in the PINK1 siRNA cells substantially reduced 
the amount of cleaved PARP compared to paraquat treatment (p<0.001, Figure 3.7C). However, in 
control cells curcumin pre-treatment did not significantly decrease levels of cleaved PARP compared 
to paraquat only cells (Figure 3.7D). In both PINK1 siRNA and control cells, the curcumin only group 
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Figure 3.7. Detection of the apoptotic marker cleaved PARP in PINK1 siRNA and control siRNA 
cells either untreated (UT), treated with paraquat (PQ), treated with curcumin then paraquat 
(Curc+PQ) or treated with curcumin alone (Curc). A. Image from the Western blots showing the 
detection of cleaved PARP (89kDa, top panel), and the loading control GAPDH (37kDa, bottom panel). 
B. PINK1 siRNA cells had significantly increased levels of cleaved PARP compared to the control cells 
(*p=0.0144). C. PINK1 siRNA cells showed significantly increased cleaved PARP after paraquat 
treatment compared to untreated cells (**p<0.01), and this was reduced when pre-treated with curcumin 
(***p<0.001). The curcumin alone group had significantly lower cleaved PARP compared to untreated 
cells (***p<0.001). D. Control siRNA cells showed increased cleaved PARP after paraquat treatment 
(**p<0.01). No changes were observed when cells were pre-treated with curcumin, but curcumin alone 
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3.4.2. Full-length caspase 3 
 
To verify the results observed from the cleaved PARP Western blots, experiments were performed using 
the full-length caspase 3 antibody. Caspase 3 is also a marker of apoptosis, and is processed to activated, 
cleaved caspase 3 when cells are undergoing apoptosis. Therefore, decreased full-length caspase 3 is 
associated with increased apoptosis. A representative image from the blots is shown in Figure 3.8A. 
When quantified, it was revealed that untreated PINK1 siRNA cells had significantly lower levels of 
caspase 3 compared to untreated control cells (p=0.0169, Figure 3.8B), indicating increased apoptosis 
in cells with lower PINK1 expression. This result verifies the result from the cleaved PARP blots - 
PINK1 siRNA cells have increased apoptosis compared to control cells, and PINK1 may play a role in 
the prevention of cell death.  
 
Paraquat treatment appeared to reduce caspase 3 levels in PINK1 siRNA and control cells, although this 
was not significant (Figure 3.8C, D). Pre-treatment with curcumin in both PINK1 siRNA and control 
cells significantly increased caspase 3 (p<0.05, Figure 3.8C, D), verifying the results observed from the 
cleaved PARP blots. In PINK1 siRNA cells, the curcumin only group revealed significantly higher 
levels of caspase 3 compared to the untreated cells (p<0.05, Figure 3.8C), and this was also observed 
in control cells (p<0.05, Figure 3.8D). The increased levels of full-length caspase 3 indicate reduced 
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Figure 3.8. Detection of the apoptotic marker full-length caspase 3 in control siRNA and PINK1 
siRNA cells either untreated (UT), treated with paraquat (PQ), treated with curcumin then 
paraquat (Curc+PQ) or treated with curcumin alone (Curc). A. Image from a Western blot 
indicating the loading control GAPDH (37kDa, top panel), and full-length caspase 3 (35kDa, bottom 
panel). B. Graph representing quantitative values from the Western blots show a decrease in caspase 3 
in PINK1 siRNA cells compared to control siRNA cells (*p=0.0169), indicating an increase in 
apoptosis. C. In PINK1 siRNA cells, pre-treatment with curcumin significantly increased caspase 3 
levels compared to paraquat (*p<0.05), and curcumin alone significantly increased caspase 3 compared 
to untreated cells (*p<0.05). D. Similarly, curcumin pre-treatment increased caspase 3 compared to 
paraquat in control siRNA cells (p<0.01), and curcumin alone significantly increased caspase 3 
compared to untreated cells (*p<0.05). 
 
In summary, from both sets of results, it has clearly been shown that PINK1 siRNA cells have 
significantly increased apoptosis compared to control cells, as shown by the increased levels of cleaved 
PARP and decreased levels of caspase 3. This could suggest that the PINK1 protein may play a 
protective role in the cell against apoptosis-driven cell death. Secondly, paraquat appeared to increase 
apoptosis (although not significantly in the caspase 3 blots, Figure 3.8C, D), which is to be expected, 
as paraquat creates an oxidative environment in the cells. Pre-treatment with curcumin reduced 
paraquat-induced apoptosis in both PINK1 siRNA and control cells, and curcumin alone further 
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3.5. Analysis of mitochondrial membrane potential 
 
Based on the observations that curcumin protects the cells from the effects of paraquat treatment, the 
next step was to understand the mechanism of its action. It was hypothesized that curcumin may be 
working at a mitochondrial level due to its antioxidant properties. Therefore mitochondrial functional 
and structural assays were performed to test this hypothesis. 
 
MMP is measured through the use of the JC-1 dye. JC-1 is permeable to the mitochondrial membrane, 
and when membrane potential is maintained, it aggregates inside the mitochondria and emits 
fluorescence in the PE channel. When the MMP is lost and cells are depolarised, JC-1 remains in the 
cytoplasm in its monomeric form, and emits fluorescence through the FITC channel. Therefore changes 
in MMP can then be determined by calculating the ratio of PE/FITC mean intensity values. The lower 
the value, the more depolarised the MMP. 
 
Results from the flow cytometric analysis with JC-1 revealed that as per our hypothesis, the PE/FITC 
ratio (and therefore the MMP) in PINK1 siRNA cells was significantly decreased compared to control 
cells (p=0.008, Figure 3.9A). This would suggest that when PINK1 expression is decreased, 
mitochondrial dysfunction will occur. The addition of paraquat to both PINK1 siRNA and control cells 
significantly reduced the PE: FITC ratio (p<0.05, Figure 3.9B, C), and pre-treatment with curcumin 
resulted in increased PE: FITC ratio compared to paraquat treated cells (p<0.05, Figure 3.9B, C). There 
was no significant changes between curcumin only treatment and untreated groups in both PINK1 





















Figure 3.9. Mitochondrial membrane potential shown by a ratio of PE/FITC values. A. PINK1 
siRNA cells had a significantly lower ratio compared to control cells (***p=0.0008). B, C. PINK1 
siRNA (B) and control (C) cells both showed significantly decreased ratios after the addition of paraquat 
(**p<0.01, *p<0.05), and these were significantly increased when pre-treated with curcumin (*p<0.05). 
No significant differences were found after curcumin treatment alone compared to the untreated group.  
PQ, paraquat; Curc, curcumin 
 
3.6. Analysis of mitochondrial respiration and glycolysis 
 
Mitochondrial respiration was measured in PINK1 siRNA cells and compared to the non-silencing 
control siRNA cells. The effect of paraquat and curcumin treatment on mitochondrial respiration was 
also analysed. By using the Seahorse XF Analyser, it is possible to detect the rates of oxygen 
consumption for respiration (OCR, oxygen consumption rate) and proton release for glycolysis (ECAR, 
extracellular acidification rate) in the media surrounding the cells, thus determining the bioenergetic 
status of the cell. The results obtained represent an average of 11 replicates per measurement (N=11). 
 
3.6.1. OCR – The Mitochondrial Stress Test  
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i. Basal respiration 
ii. Addition of Oligomycin, a complex V inhibitor, resulting in suspended ATP synthesis and 
allowing for the calculation of overall ATP production (difference in OCR between basal 
respiration and respiration after Oligomycin addition) 
iii. Addition of an uncoupler FCCP, which results in maximal respiration and allows for the 
calculation of spare respiratory capacity (difference in OCR between maximal and basal 
respiration) 
iv. Addition of complex I inhibitor Rotenone and complex III inhibitor Antimycin A, which arrests 
respiration  
 
The point-to-point OCR data is presented in Figure 3.10A for non-silencing control siRNA cells (red 
line) and PINK1 siRNA cells (purple line) at basal levels, and after the addition of Oligomycin, FCCP 
and Rotenone + Antimycin A. Quantification before and after the addition of the drug compounds 
revealed that PINK1 siRNA cells had significantly decreased OCR at basal respiration (Figure 3.10B, 
p<0.001), decreased ATP production (p=0.002, Figure 3.10C) decreased maximal respiration (Figure 
3.10D, p=0.0015) and reduced spare respiratory capacity (Figure 3.10E, p=0.0154). In summary, these 
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Figure 3.10. PINK1 siRNA cells exhibit decreased mitochondrial respiration in comparison to 
control siRNA cells. A. Point-to-point line graph of PINK1 siRNA cells (purple line) and control 
siRNA cells (red line) after the addition of Oligomycin (Oligo), FCCP and Rotenone + Antimycin A 
(Rot + Anti A). Each measurement represents 9min 12sec interval. PINK1 siRNA cells showed 
significantly decreased oxygen consumption rate (OCR) across all conditions. B. Basal respiration, 
***p<0.0001, C. ATP production, **p=0.002, D. Maximal respiration, **p=0.0015, E. Spare 











Next, PINK1 siRNA and control cells were then either left untreated, or treated with paraquat, curcumin 
or pre-treated with curcumin followed by paraquat exposure, according to the pre-determined protocol 
(Figure 2.3). The overall mitochondrial respiration results for both the PINK1 siRNA and control cells 


















Figure 3.11. Point-by-point line graphs indicating oxygen consumption rate (OCR) in each 
treatment group in PINK1 siRNA cells (A) and control cells (B) after the addition of drug 
compounds. Each measurement represents 9min 12sec interval. N=11. Oligo, Oligomycin; Rot, rotenone; 
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No significant changes were observed in OCR in PINK1 siRNA cells at basal respiration (Figure 
3.12A). Paraquat treatment in control cells interestingly resulted in a significant increase at a basal level 
(p<0.001, Figure 3.12B), and this was further increased when cells were pre-treated with curcumin 
(p<0.001, Figure 3.12B). The curcumin alone group had no significant effect on OCR at a basal level 
in control cells (Figure 3.12B), although it appeared to keep the OCR at the same level as the untreated 
cells. These results are difficult to interpret, and it has been suggested that often readings at a basal level 
can be inaccurate (personal communication, Dr. Francois van Der Westhuizen, North West University, 
South Africa).  
 
ATP production 
In both PINK1 siRNA and control cells, there were no significant changes in OCR across all treatment 
groups, indicating no changes in ATP production (Figure 3.12C, D).  
 
Maximal respiration 
In PINK1 siRNA and control cells, paraquat treatment had no effect on OCR after the addition of the 
mitochondrial uncoupler FCCP (Figure 3.12E, F).  Pre-treatment with curcumin prior to paraquat 
treatment significantly increased OCR compared to the paraquat-only group in PINK1 siRNA cells 
(p<0.01, Figure 3.12E) and in control cells (p<0.05, Figure 3.12F). Furthermore, curcumin only 
treatment significantly increased OCR compared to the untreated group in both PINK1 siRNA cells 
(p<0.05, Figure 3.12E) and in control cells (p<0.001, Figure 3.12F). These results suggest a possible 
rescue effect of curcumin on stressed, depolarised mitochondria.  
 
Spare respiratory capacity 
No changes were observed across all treatment groups in PINK1 siRNA cells (Figure 3.12G). In control 
cells, pre-treatment with curcumin significantly increased OCR, and therefore spare capacity, compared 






















































Figure 3.12. Basal respiration, ATP production, maximal respiration and spare respiratory 
capacity in PINK1 siRNA and control cells. A. No changes were observed in basal respiration in 
PINK1 siRNA cells. B. In control siRNA cells, OCR was significantly higher in the paraquat-group 
compared to the untreated group (***p<0.001). The paraquat-curcumin group significantly increased 
OCR compared to the paraquat group (***p<0.001). C, D. No changes were observed in ATP 
production in PINK1 siRNA cells (C) or control cells (D). E, F. Pre-treatment with curcumin 
significantly increased OCR compared to paraquat treatment in PINK1 siRNA (E, **p<0.01) and 
control (F, *p<0.05) cells. Curcumin alone increased OCR compared to the untreated group in PINK1 
siRNA (E, *p<0.05) and control (F, p<0.001) cells. G. No changes in spare respiratory capacity were 
observed in PINK1 siRNA cells. H. Pre-treatment with curcumin significantly increased spare 
respiratory capacity in control cells compared to the paraquat treated cells (*p<0.05). OCR, oxygen 
consumption rate; PQ, paraquat; Curc, curcumin 
 
In summary, the above results on aspects of mitochondrial respiration show that: 
 
a) Decreased PINK1 expression, using an siRNA model, has a negative effect on basal respiration, 
ATP production, maximal respiration and spare respiratory capacity. 
b) Paraquat does not affect mitochondrial respiration at this concentration of 25µM. 
G H 
* 
Stellenbosch University  https://scholar.sun.ac.za
88 
 
c) Pre-treatment with curcumin prior to paraquat is able to increase basal respiration, maximal 
respiration and spare respiratory capacity compared to paraquat treatment in control cells, and also 
increases maximal respiration in PINK1 siRNA cells. These results suggest that when cells are 
under a certain level of stress, curcumin is able to rescue mitochondrial respiration. Despite this, 
pre-treatment with curcumin prior to the addition of paraquat was not able to rescue basal 
respiration, ATP production and spare respiratory capacity in PINK1 siRNA cells. This could 
suggest that curcumin can only rescue cells on a mitochondrial level when PINK1 is present and 
functional in these cells. 
d) Treatment with curcumin alone significantly increases maximal respiration in both control and 
PINK1 siRNA cells compared to the untreated groups, which suggests a particular function of 
curcumin in the mitochondria when they have been depolarised.  
 
 
3.6.2. ECAR – The Glycolysis Stress Test 
 
ATP is primarily produced via mitochondrial respiration and the oxidative phosphorylation pathway. 
However, glycolysis can become the primary producer of ATP when oxidative phosphorylation is 
damaged or inhibited. It is therefore important to investigate key parameters of glycolytic function in 
order to understand critical information regarding cellular energy demands. The Glycolysis Stress Test 
Kit (Seahorse Bioscience, USA) enables one to determine the rate of glycolysis, the glycolytic capacity, 
and the glycolytic reserve in cells while inducing metabolic stress.  
 
ECAR detects lactic acid production by measuring the rate that free protons are released from the cells, 
in other words, when the protons ‘acidify’ the medium. ECAR was measured under the following 
conditions: 
 
i. Basal, non-glycolytic acidification measured in glucose-free medium. 
ii. Addition of a saturating concentration of glucose, to determine glycolysis rates (difference 
between ECAR before and after glucose addition). 
iii. Addition of the ATP synthase inhibitor Oligomycin to measure the glycolytic capacity of 
the cells (difference between ECAR at basal levels and after the addition of Oligomycin). 
Glycolytic reserve can also be determined by subtracting the rates of glycolysis from the 
rates of glycolytic capacity. 
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iv. Addition of a saturating concentration of 2-DG, a glucose analogue which inhibits 
glycolysis by its actions on hexokinase. 
 
The point-by-point graph for control cells (red line) compared to PINK1 siRNA cells (purple line) is 
shown in Figure 3.13A. After quantification, it was revealed that the ECAR under basal conditions in a 
glucose-free medium was significantly lower in PINK1 siRNA cells compared to control cells (Figure 
3.13B, p<0.001). PINK1 siRNA cells also exhibited significantly lower glycolytic capacity compared 
to control cells (Figure 3.13C, p=0.0445). These results would indicate that in the absence of PINK1, 
when oxidative phosphorylation is restricted, cells are unable to produce sufficient levels of ATP due 
to inhibition of basal lactic acid production and glycolytic capacity. The ECAR rates for glycolysis and 
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Figure 3.13. Reduced ECAR observed in PINK1 siRNA cells at basal levels and glycolytic 
capacity. A.  PINK1 siRNA cells (purple line) compared to control siRNA cells (red line) after the 
addition of Glucose, Oligomycin (Oligo) and 2-DG (2-deoxy-D-glucose). Each measurement represents 
9min 12sec interval. B, C. PINK1 siRNA cells show significantly decreased ECAR compared to control 
cells at basal levels (B, ***p<0.001) and for glycolytic capacity (C, *p=0.0445). N=11. 
 
ECAR measurements for PINK1 siRNA and control cells following the treatment protocol (Figure 2.3) 
are shown in Figure 3.14A and B respectively. Quantification of these results revealed no significant 
differences between each treatment group in glycolysis rates, glycolytic capacity and glycolytic reserve 
in PINK1 siRNA and control cells (Appendix V). At a basal level, paraquat treatment significantly 
decreased ECAR in PINK1 siRNA cells compared to untreated cells (p<0.001), as did curcumin alone 
(Figure 3.14C, p<0.05). Pre-treatment of the cells with curcumin prior to the addition of paraquat 
resulted in a significantly higher ECAR compared to the paraquat-only group (Figure 3.14C, p<0.001). 
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Figure 3.14. Reduced ECAR observed at basal levels in PINK1 siRNA cells after paraquat 
treatment. A, B. Point-by-point graphs for ECAR in PINK1 siRNA cells (A) and control cells (B) after 
the addition of Glucose, Oligomycin (Oligo) and 2-DG. Each measurement represents 9min 12sec 
interval. C. In PINK1 siRNA cells, ECAR was significantly decreased after the addition of paraquat 
(***p<0.001), and this was rescued by pre-treatment with curcumin (***p<0.001). Curcumin treatment 
alone resulted in decreased ECAR compared to untreated cells (*p<0.05). D. No significant difference 
in ECAR across all treatment groups in control cells. N=11. 
 
In summary, treatment with paraquat, curcumin, or both, does not appear to have an effect on aspects 
of glycolysis. However, decreased PINK1 expression results in decreased basal acidification rates after 
paraquat-only and curcumin-only treatment, and this is rescued by curcumin pre-treatment. This may 
suggest that curcumin can activate cellular acidification only under highly stressful conditions – such 
as a combination of decreased PINK1 expression and paraquat treatment.  
 
Together, the results from mitochondrial respiration and glycolytic analysis have provided detail into 
the role of curcumin at a cellular level. As a known antioxidant, curcumin is able to increase 
mitochondrial respiration and ATP production in control cells, and this effect appears to be more 
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in PINK1 siRNA cells which could suggest that PINK1 expression may be necessary for curcumin to 
function efficiently. However, despite this, curcumin increased respiration in stressed control and 
PINK1 siRNA cells when the mitochondria were depolarized (after the addition of FCCP). Furthermore, 
in a glucose-free medium, curcumin increased the rate of extracellular acidification in stressed PINK1 
siRNA cells. These results could collectively suggest that the greater the stress on the cells (i.e. addition 
of paraquat/ FCCP/ glucose-free medium), the greater the effect that curcumin may have.   
 
3.7. Mitochondrial network analysis 
 
As mentioned in the methodology, SH-SY5Y cells were visualized using Hoechst 33342 and 
MitoTracker Red to indicate nuclear architecture and mitochondrial morphology respectively (Section 
2.8). Quantification of these images through Image J software allowed for the calculation of both form 
factor (the degree of branching) and aspect ratio (measurement of mitochondrial length) as specified in 
Section 2.8. The higher the form factor, the less fragmented the mitochondrial network. The number of 
replicates used in these experiments (N) was 3. 
  
3.7.1. Form Factor 
 
The images obtained for each treatment group in PINK1 siRNA and control cells are shown in Figure 
3.15, A-H. White arrows highlight areas of increased fusion, and yellow arrows increased 
fragmentation. Quantification of the images, calculation of form factor, and subsequent statistical 
analysis indicated that although there was a trend of increased form factor, (and therefore increased 
fusion), and the cells appeared more fused in PINK1 siRNA cells (white arrow, Figure 3.15A) compared 
to control cells (yellow arrow, Figure 3.15B), this was not significant (Figure 3.15I). In both PINK1 
siRNA and control cells, paraquat treatment resulted in significantly decreased form factor compared 
to untreated cells (Figure 3.15J, K, p<0.05), suggesting that paraquat treatment caused increased 
mitochondrial network fragmentation. Curcumin pre-treatment prior to paraquat treatment appeared to 
increase form factor compared to paraquat treated cells. This was not statistically significant in PINK1 
knock down cells (Figure 3.15J), but it was significant in control cells (Figure 3.15K, p<0.05). 
Curcumin treatment alone in PINK1 siRNA cells had a lower form factor compared to the untreated 
cells, but this was not significant (Figure 3.15J). Curcumin alone in control cells appeared to increase 
form factor more than untreated cells, but this was not significant (Figure 3.15K).  
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Figure 3.15. Fluorescence microscopy images of SH-SY5Y neuroblastoma cells stained for the 
nucleus (blue; Hoechst) and the mitochondrial network (red, MitoTracker), and quantification 
and calculation of form factor in these cells. A-H. Micrographs from all treatment groups. The 
white arrows represent areas of increased fusion, whereas the yellow arrows indicate areas of 
increased fragmentation. I. PINK1 siRNA and control cells did not show significant changes in form 
factor. J. Paraquat treatment significantly reduced form factor compared to the untreated group in 
PINK1 siRNA cells (*p<0.05). K. Paraquat treatment significantly reduced form factor in control cells 
(**p<0.01), and this was rescued by curcumin pre-treatment (*p<0.05). N=3. PQ, paraquat; Curc, 
curcumin 
 
3.7.2. Aspect ratio 
 
Aspect ratio is defined as the measurement of the ratio between the major and minor axis of the ellipse 
equivalent to the mitochondria, and is an indication of mitochondrial length. The higher the aspect ratio, 
the longer the mitochondrial length. PINK1 siRNA cells had a significantly increased aspect ratio 
compared to control cells (Figure 3.16A, p=0.0091). In PINK1 siRNA and control siRNA cells, 
paraquat treatment alone significantly decreased the aspect ratio compared to the untreated groups 
(Figure 3.16B, C, p<0.001). Pre-treatment with curcumin did not affect the aspect ratio in comparison 
with the paraquat only group in both PINK1 knock down and control cells (Figure 3.16B, C). In PINK1 





Stellenbosch University  https://scholar.sun.ac.za
97 
 
group (Figure 3.16B, p<0.001). However, in the control cells curcumin treatment alone significantly 



















Figure 3.16. Quantification and calculation of aspect ratio in SH-SY5Y neuroblastoma cells. A. 
PINK1 siRNA cells had a significantly increased aspect ratio compared to control cells (**p=0.0091). 
B. Paraquat-only and curcumin-only groups had significantly reduced aspect ratio compared to the 
untreated group in PINK1 siRNA cells (***p<0.001). C. Paraquat-only group had significantly reduced 
aspect ratio compared to the untreated group in control cells (***p<0.001), and the curcumin-only group 
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In summary, whilst there were no changes in the degree of branching in PINK1 siRNA cells compared 
to control cells, the aspect ratio was significantly increased. The aspect ratio measures the mitochondrial 
length, so if the PINK1 siRNA cells had longer mitochondria, this might have an effect on ATP 
production and oxidative stress levels. Paraquat-treated cells were more fragmented, and had lower 
aspect ratios, and were therefore shorter in length. Curcumin treatment resulted in significantly 
increased aspect ratio in control cells, and significantly decreased aspect ratio in PINK1 siRNA cells. 
These results indicate that curcumin may have an effect on the mitochondrial length, and that this effect 
may differ in the presence or absence of PINK1.  
 
3.8. Autophagic flux 
 
As previously described in the Materials and Methods, Section 2.9, autophagic flux is measured by 
assessing the difference in the levels of two markers of autophagy (LC3-II and p62), in the presence or 
absence of BafA1, an inhibitor of autophagosomal and lysosomal fusion. If LC3-II and p62 is increased 
after BafA1 treatment, there is an accumulation of autophagosomes, which is indicative of an increase 
in autophagic flux and the rate of clearance via autophagy is increased. If LC3-II is decreased after 
BafA1 treatment, then autophagic flux is decreased and there is a slower rate of autophagy and clearance 
of damaged organelles and proteins from the cell. Western blots were performed using both LC3-II and 
p62 antibodies in the presence and absence of BafA1. Differences in intensities were calculated, and 
























Figure 3.17. Western blot images detecting markers for autophagy p62 (62kDa, top panel) and 
LC3-II (16kDa, bottom panel), and the loading control GAPDH (37kDa, middle panel). A. 
Samples were not treated with BafA1 (-BafA1). B. Samples were treated with 100nM BafA1 for 2 hours 
(+BafA1). UT, untreated; PQ, paraquat; Curc, curcumin; BafA1, Bafilomycin A1 
 
3.8.1. Detection of LC3-II 
 
Blots were quantified, and the difference between before (-BafA1) and after (+BafA1) treatment was 
calculated and normalised to the loading control GAPDH. Results comparing PINK1 siRNA cells to 
control cells showed that LC3-II levels were significantly increased in PINK1 siRNA cells (Figure 
3.18A, p<0.05).  
 
Paraquat treatment in PINK1 siRNA and control cells did not result in changes in LC3-II levels (Figure 
3.18B, C). The concentration of paraquat added to the cells may be too low for there to be an effect on 
autophagic flux. Curcumin pre-treatment had no effect on the PINK1 siRNA cells (Figure 3.18B), but 
significantly increased autophagic flux compared to the paraquat-only group in the control cells (Figure 
3.18C, p<0.01). Curcumin treatment alone also significantly increased LC3-II compared to the 
untreated group in control cells (Figure 3.18C, p<0.001). These results could suggest that curcumin can 
only successfully induce autophagy in the presence of PINK1. Furthermore, this could indicate an 
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induction of autophagy when cells are treated with curcumin, and will be discussed in greater detail in 

















Figure 3.18. Quantification of LC3-II Western blots. Blots were quantified, and the difference 
between before (-BafA1) and after (+BafA1) treatment was calculated and normalised to the loading 
control GAPDH. A. Normalised results show LC3-II, and therefore autophagic flux, is significantly 
increased in PINK1 siRNA cells compared to control cells (*p=0.0152). B. No significant differences 
in autophagic flux were observed across treatment groups in PINK1 siRNA cells. C. In control cells, 
pre-treatment with curcumin prior to paraquat significantly increased LC3-II levels compared to the 
paraquat-only treated group (**p<0.01). Also, curcumin treatment alone resulted in significantly 
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3.8.2. Detection of p62 
 
Results from the p62 blots showed a significantly increased level of p62 in the PINK1 siRNA cells 
compared to the control cells (Figure 3.19A, p<0.01). This result indicates that autophagic flux was 
increased in PINK1 siRNA cells, and confirms the result shown from the LC3-II blots. In PINK1 siRNA 
cells, there was a trend decrease in p62 levels after curcumin pre-treatment, although this was not 
significant (Figure 3.19B). In control cells, there was also no significance across treatment groups 















Figure 3.19. Quantification of p62 Western blots. Blots were quantified, and the difference between 
before (-BafA1) and after (+BafA1) treatment was calculated and normalised to the loading control 
GAPDH. A. Normalised results show p62, and therefore autophagic flux, is significantly increased in 
PINK1 siRNA cells compared to control cells (**p=0.002). B, C. There were no significant changes in 
the levels of p62 across all treatment groups in PINK1 siRNA cells (B) or in control cells (C). PQ, 








It is thought that p62 may be a less reliable as a marker for autophagy than LC3-II, as it is not solely 
functional at the autophagy process. It may be interesting to identify the other pathways in which p62 
is active. Based on this observation, we believe that LC3-II is a more definitive marker for autophagic 
flux. In summary, we observed an increased autophagic flux in PINK1 siRNA cells compared to control 
cells. This may be a compensatory mechanism through which clearance of the accumulated damaged 
proteins and mitochondria is increased. Interestingly, curcumin treatment also resulted in an increase in 
autophagic flux in control cells, possibly to prevent cell death and maintain a healthy cellular 
environment.  
 
Section B: Copy number variation study on genomic DNA from PD 
patients 
 
3.9. Analysis of copy number variation in PD patients  
 
Given the interesting findings observed in the first part of this study, the second part of the study focused 
on identifying South African PD patients with CNV changes in the PINK1 gene, as comparison of our 
findings in a siRNA model to that of a patient-derived cellular model would be an important and 
necessary next step. CNV includes rearrangements such as deletions, duplications or triplications that 
potentially lead to null mutations. Patients were screened using the MLPA technique and all putative 
CNV were verified using qRTPCR. 
 
In a previous study, 229 South African PD patients were analysed for exonic rearrangements using the 
MLPA technique (Haylett et al., 2012; Keyser et al., 2009). No PINK1 CNV changes were found in any 
of these patients. In the present study, an additional 210 PD patients from different South African ethnic 
groups, including White, Afrikaner, Black, Mixed Ancestry and Indian, were recruited. This section 
will focus on the mutations found from the MLPA analysis and whether or not these mutations were 
false positives (which was determined by qRTPCR verification). 
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3.9.1. Mutations observed after MLPA technique 
 
 
Two MLPA kits were used, P051 and P052 (For a full list of the probes for each exon in both kits, refer 
to Appendix III, taken from www.mlpa.com).  Initial analysis showed a large number of individuals 
with putative CNV mutations in PINK1 exons 1, 4, 5 and 8, DJ-1 exons 1, 3 and 7, PARK2 exons 4, 5, 
9 and 11, and SNCA exon 5. However, after verification of these mutations by either repeating the 
MLPA analysis or performing qRTPCR to determine whether these mutations were true or false 
positives, it was found that the original putative mutations observed were no longer present – revealing 
that the MLPA method produced a number of false positive results. One true heterozygous PARK2 exon 
4 deletion was confirmed in patient 96.69. Where possible, samples with known CNV changes (detected 
in previous studies; Keyser et al., 2009) were included in the qRTPCR verification experiments as 
positive controls. An example of the results from a qRTPCR run on SNCA exon 5 is shown in Figure 
3.20. Due to the observation that the false positives continuously occurred in the same exons, it was 
hypothesized that there are SNPs at these probe positions affecting the binding of the probes, thus 
leading to false positive results (Section 3.9.2).  
 
 
Figure 3.20. Verification of false positives in SNCA exon 5 using qRTPCR. Results from qRTPCR 
indicated that all patients with a query SNCA exon 5 mutation did not harbour the mutation (90.03, 
92.60, 92.98, 95.26, 95.32, 11.834). The wild type control (WT, red) had the same ratio compared to 
all patients. The positive control sample, 10.044 (dark blue), is known to harbour a SNCA exon 5 
triplication. qRTPCR, quantitative real time PCR 
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The heterozygous deletion in PARK2 exon 4 was observed in patient 96.69 in both P051 (Figure 3.21A, 
ratio = 0.55) and P052 (Figure 3.21B, ratio = 0.41) probe mixes. This result was verified using qRTPCR 
(Figure 3.21C). Positive controls included a PD patient homozygous for a PARK2 exon 4 deletion 
(patient 56.45, dark blue), and a control heterozygous for PARK2 exon 4 deletion (patient 67.23, red). 
As shown in Figure 3.21C, patient 96.69 (light blue) revealed relative expression of PARK2 exon 4 
similar to that of the heterozygous control 67.23, thus confirming the presence of a heterozygous 
deletion in PARK2 exon 4 in patient 96.69. Sanger sequencing was performed in all 12 PARK2 exons 


























































































































































































































































































































































































































































































































































































Figure 3.21. MLPA results from patient 96.69 indicate a heterozygous deletion of PARK2 exon 4. 
A, B. Graphs indicating the ratio values of all exons in Mix 1 P051 (A) and Mix 2 P052 (B), with an 
arrow showing the deletion (ratio value < 0.6) for PARK2 exon 4 in both mixes. C. Real time PCR 
verified that the mutation for patient 96.69 (light blue) was present in 1 allele, similar to that of a 
heterozygous control 67.23 (red). Pos, positive; homo, homozygous; het, heterozygous 
 
3.9.2. Sequencing based on common false positives 
 
A large number of putative mutations in particular exons across every MLPA run and various samples 
led us to the hypothesis that the patients may harbour non-pathogenic SNPs at the site of the primers 
for these specific exons. These frequent occurrences are summarised in Table 3.1, and include PARK2 
exons 4, 5, 9 and 11, SNCA exon 5 and PINK1 exon 1. The ethnic breakdown was also indicated, as we 
believed that the unique ethnic background in our cohort (particularly in black and mixed ancestry 
patients) may have caused these results. Interestingly, the majority of PARK2 exon 5 putative mutations 
did occur in mixed ancestry and black individuals, and the remainder appeared spread across all ethnic 
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Table 3.1. Table indicating the number of patients associated with putative mutations in several 
exons, as well as the percentage ethnic breakdown 
 
W, White; Af, Afrikaner; MA, Mixed Ancestry; B, Black; I, Indian 
 
Sequencing performed on select patient samples indicated that there were no polymorphisms observed 
in SNCA exon 5, PINK1 exon 1 and PARK2 exon 4, 9 and 11. It was however found that patients with 
a PARK2 exon 5 deletion in P051 had a common polymorphism A574C in the annealing site of the 
MLPA P051 probe for PARK2 exon 5, resulting in an M192L amino acid change (Figure 3.22). This 










Figure 3.22. Chromatogram illustrating the M192L polymorphism in PARK2 exon 5 that caused 
false positive results in the MLPA analysis. 
Exon  Mix  
Number of patients 
with putative mutation 
Ethnic group (%) 
Deletion Duplication W Af MA B I 
PARK2 ex5  P051 13 - 0 0 69.2 30.7 0 
SNCA ex5  P051 2 9 36.4 36.4 0 27.2 0 
PINK1 ex1  P051 2 3 40 40 0 20 0 
PARK2 ex4  P052 4 9 46.1 15.4 30.8 7.7 0 
PARK2 ex9  P052 - 5 40 0 40 20 0 
PARK2 ex11  P052 1 4 60 0 20 20 0 
A>C 
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In summary, analysis using MLPA did not reveal any PINK1 CNV mutations in a total of 210 South 
African PD patients. A number of false positive mutations were identified that were not verified on 
repeated MLPA runs or qRTPCR. A common polymorphism M192L PARK2 exon 5 was identified in 
a number of patients resulting in false positive deletions in kit P051. One patient was shown to harbour 
a heterozygous deletion in PARK2 exon 4.   
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In the present study, we aimed to create a cellular model of PD by decreasing the expression of the PD-
causing gene PINK1. In doing so, this would enable us to study the role of PINK1 in the cell, as well as 
the effect of curcumin on this model. PINK1 was successfully knocked down using siRNA, and this 
was validated at both gene and protein expression levels. In summary, decreased PINK1 expression 
resulted in a number of cellular and mitochondrial alterations which included: 
 
- Decreased MMP 
- Decreased mitochondrial respiration and ATP production 
- Decreased glycolytic capacity 
- Increased apoptosis 
- Increased autophagic flux 
- Decreased cell viability 
 
These results indicate the vital role of PINK1 in the upkeep of a healthy cellular environment, as well 
as in the maintenance of functional mitochondria. In the event of a mutation resulting in decreased 
PINK1 protein function, there is an accumulation of damaged mitochondria, which may ultimately 
result in neuronal cell death.  
 
When studying the effect of curcumin on this model of PD, we attempted to answer a number of 
questions. These include, does curcumin protect these cells from cell death? Does curcumin play a role 
in mitochondrial maintenance? What is the particular mechanism behind the action of curcumin? How 
will curcumin act in the presence and absence of an additional stressor? Our results show that in general, 
paraquat or curcumin treatment on their own had the same effect on control or PINK1 siRNA cells 
(Table 4.1).  However, marked differences between the control and PINK1 siRNA cells were observed 
with curcumin pre-treatment followed by paraquat exposure. These findings can be summarized as 
follows: 
 
- Curcumin rescued the MMP in both control and PINK1 siRNA cells after paraquat 
treatment 
- Curcumin increased maximal respiration in both control and PINK1 siRNA cells 
- Curcumin increased spare respiratory capacity only in control cells with paraquat 
treatment 
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- Curcumin resulted in a less fragmented mitochondrial network only in control cells 
with paraquat treatment 
- Curcumin resulted in decreased apoptosis  in both control and PINK1 siRNA cells  
- Curcumin resulted in increased autophagic flux in control cells with paraquat treatment 
- Curcumin increased the number of viable cells in culture, but this was only seen in 
control cells and not PINK1 siRNA cells, and only with paraquat treatment 
 
Therefore, in summary, our findings show that curcumin is able to ‘rescue’ many of the damaging 
effects of paraquat but some of these protective effects were seen only in the healthy cells and not in 
the PINK1 knock down cells.  
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Table 4.1. Summary of the results observed in paraquat- and curcumin-treated control and PINK1 siRNA cells. 
 



















Mitochondrial membrane potential Decrease Increase No change Decrease Increase No change 
Mitochondrial Respiration – Basal 
Maximal 
ATP production 
Spare respiratory capacity 
Increase Increase No change No change No change No change 
No change Increase Increase No change Increase Increase 
No change No change No change No change No change No change 
No change Increase No change No change No change No change 




No change No change No change Decrease Increase Decrease 
No change No change No change No change No change No change 
No change No change No change No change No change No change 
No change No change No change No change No change No change 
Mitochondrial network - form factor 
Mitochondrial network - aspect ratio 
Decrease Increase No change Decrease No change No change 
Decrease No change Increase Decrease No change Decrease 
Apoptosis (as measured by cleaved PARP) 
Apoptosis (as measured by Caspase 3) 
Increase No change Decrease Increase Decrease Decrease 
No change Decrease Decrease No change Decrease Decrease 
Autophagic flux – LC3-II 
Autophagic flux - p62 
No change Increase Increase No change No change No change 
No change No change No change No change No change No change 
Cell viability Decrease Increase No change Decrease No change No change 
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4.1. Effects observed in a PINK1 siRNA model of PD 
 
Approximately 11 years ago, Valente and colleagues discovered that mutations in PINK1 were a cause 
of hereditary early onset PD (Valente et al., 2004). Since then, numerous studies have been performed 
to further our understanding of PINK1, and to date it has been established as a core protein (either 
directly or indirectly) in the machinery that protects the cells from death – the UPS, MQC and 
autophagy. When PINK1 is mutated, resulting in either an absent or a misfolded, dysfunctional protein, 
these processes are drastically affected and severe consequences ensue.  
 
Previous studies analysing mitochondrial function in SH-SY5Y cells after siRNA-mediated knock 
down of PINK1 revealed similar results to our study. MMP was found to be reduced when PINK1 was 
absent, resulting in depolarised mitochondria, a subsequent drop in proton movement and decreased 
ATP production (Exner et al., 2007; Gautier et al., 2008; Grünewald et al., 2009; Vives-Bauza et al., 
2010; Wood-Kaczmar et al., 2008). In terms of mitochondrial respiration, whilst our results indicated 
decreased mitochondrial respiration across all measurements (basal respiration, ATP production, 
maximal respiration, spare respiratory capacity), other studies have presented conflicting data. A study 
on iPSCs derived from individuals carrying PINK1 mutations observed increased basal respiration in 
PINK1 mutant cells (Cooper et al., 2012), and a second study in patient-derived fibroblasts with PINK1 
mutations observed no defects across all areas of mitochondrial respiration (Siuda et al., 2014). They 
hypothesized that there may be a compensatory mechanism preventing dysfunctional respiration. The 
reason for these contrasting results may be the different cell types used, or possibly technical differences 
with different XF Analysers. To date, very few studies have analysed OCR in a PINK1-deficient model 
of PD, and it is clear that mitochondrial respiration needs to be studied to a greater extent in order to 
further our understanding of the role of PINK1.  
 
After decreasing the expression of PINK1 in SH-SY5Y cells, we observed decreased cell viability and 
increased apoptosis, which has also been found in previous studies using a similar approach and 
confirmed in other cell lines including M17, HeLa and PC12 cells, and animal models of PD (Deng et 
al., 2005; Gegg et al., 2009; Geisler et al., 2010b; Poole et al., 2008; Sandebring et al., 2009; Sha et al., 
2009; Wood-Kaczmar et al., 2008). It is thought that the damage to the mitochondria results in increased 
cell death. The present study also observed elevated autophagic flux in the PINK1-deficient cells. Based 
on this finding, we hypothesized that when the cells become damaged and start to die, levels of 
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autophagy might increase in an attempt to rid the cell of the dysfunctional proteins/ mitochondria, thus 
acting as a compensatory mechanism.  
 
In agreement with this hypothesis, Dagda and colleagues observed an increase in the number of AVs, 
increased LC3-II levels and autophagic flux in PINK1-deficient SH-SY5Y cells (Dagda et al., 2009). 
Various ultrastructural studies have shown increased lysosomal content in PINK1 knock down cells 
(Marongiu et al., 2007; Wood-Kaczmar et al., 2008), and these results were also found to occur in 
Drosophila, which observed increased basal autophagy in PINK1 mutant flies (Liu and Lu, 2010). This 
suggests that autophagy may be upregulated in an attempt to protect the cell against damage caused by 
the absence of PINK1. Interestingly, levels of parkin have been shown to be increased in some PINK1 
knock down cell lines, and may also be involved in this compensatory mechanism (Cherra et al., 2010; 
Chu, 2010). It may be possible that when PINK1 expression is reduced and the amount of dysfunctional 
mitochondria increases, parkin initiates the autophagic response in an attempt to clear the mitochondria 
and reduce cell death.  
 
In contrast, other studies have found decreased levels of autophagy in the absence of PINK1. Gegg and 
colleagues used a similar 12-day knock down approach to our study, and revealed a reduced autophagic 
flux in their model (Gegg et al., 2010). Another study that reduced PINK1 expression in SH-SY5Y cells 
also revealed decreased autophagy, and this was increased when PINK1 was overexpressed (Michiorri 
et al., 2010). The different observations in PINK1-deficient cells may be due to different experimental 
settings and knock down protocols. Nevertheless, it is still essential that the role of PINK1 and parkin 
in autophagy be further studied using various models and experimental designs. Autophagy is a highly 
complex process, and it could be that current methods of detecting it are not accurate enough. Once it 
has been established how PINK1 regulates autophagy, it could result in a better understanding of other 
functions of PINK1, such as its role in fission and fusion regulation.  
 
4.2. The role of curcumin in cell viability and apoptosis   
 
This study investigated the effect of curcumin in our cellular model of PD, and to our knowledge this 
was a novel aspect of our research that has not yet been studied to date. Furthermore, we tested the 
effect of curcumin in the presence and absence of a stressor. A particularly interesting result was 
observed when curcumin pre-treatment protected the PINK1-deficient and control cells exposed to 
paraquat from apoptosis (Table 4.1).  




Various in vivo and in vitro models of PD have also shown that curcumin protects neurons and other 
cells from cell death. In a 6-OHDA rat model, Zbarsky and colleagues revealed that curcumin treatment 
protected neurons in the SNc from apoptosis, and this led to improved striatal dopamine levels (Zbarsky 
et al., 2005). A cellular model of 6-OHDA in MES23.5 cells also found that curcumin reduced 
cytotoxicity and restored cell viability (Wang et al., 2009). Curcumin prevented MPTP-induced injuries 
to dopaminergic neurons in an MPTP mouse model of PD (Pan et al., 2012), and similar effects were 
observed in cellular models. In PC12 cells, curcumin prevented cytochrome c release and PARP 
activation (Raza et al., 2008), protected MPP+-induced cytotoxicity and apoptosis (Chen et al., 2006), 
and reduced A53T α-synuclein-induced cell death (Jiang et al., 2013; Wang et al., 2010). Furthermore, 
curcumin reduced rotenone-induced cell death in SH-SY5Y cells, and alleviated PD-like symptoms in 
Drosophila (Z. Liu et al., 2013).  
 
To date, there have been several pathways that curcumin has been implicated in that protect cells from 
damage and death. Curcumin has various molecular targets including growth and transcription factors 
and their receptors, cytokines, enzymes and genes that regulate apoptosis (Aggarwal et al., 2007b). This 
causes downstream effects on pathways such as the JNK pathway. JNK is a member of the mitogen-
activated protein kinase (MAPK) family, and is activated by environmental stress and apoptotic agents. 
When upregulated, JNK causes increased cell death by translocating Bax to the mitochondria, resulting 
in the release of cytochrome c. The JNK pathway has been associated with dopaminergic neuronal 
degeneration, and it has been suggested that inhibitors of this pathway may slow the progression of PD 
(Mythri and Bharath, 2012). Activation of this pathway occurs via the phosphorylation of JNK1, JNK2 
and c-Jun. Pan and colleagues revealed that curcumin inhibited this phosphorylation in an MPTP mouse 
model of PD, thus diminishing the effects of apoptosis (Pan et al., 2012). Other studies have suggested 
that JNK may not be a direct target of curcumin, but rather that curcumin interferes with regulators 
upstream of MAPK, which in turn leads to the unresponsiveness of the JNK cascade (Chen and Tan, 
1998; Mythri and Bharath, 2012; Yu et al., 2010).  
 
Pan and colleagues also investigated the effect of curcumin on the Bcl-2/Bax heterodimer, which is the 
active component for cell death protection (Rezende et al., 2008; Zhang et al., 2004). When Bcl-2 is 
phosphorylated, it becomes inactive, allowing for the pro-apoptotic protein Bax to be released from the 
dimer complex (Biswas et al., 2007). Once freed, Bax forms pores on the OMM, resulting in increased 
mitochondrial membrane permeability and the release of cytochrome c, which promotes apoptosis 
through the activation of the caspase cascade. By preventing the phosphorylation of Bcl-2, the release 
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of Bax and induction of apoptosis could also be prevented. In an MPTP-induced mouse model of PD, 
curcumin was able to attenuate the phosphorylation of Bcl-2 proteins, strengthen the interaction 
between Bcl-2 and Bax, and prevent Bax translocation to the cytosol (Pan et al., 2012). Other studies 
have also observed that curcumin was able to induce the overexpression of Bcl-2 proteins, whilst 
decreasing the levels of Bax in cellular models of PD (Chen et al., 2006; Chen and Tan, 1998). 
Interestingly, JNK is involved in the regulation of the activation of Bcl-2 family members, further 
highlighting a role for curcumin in this pathway. Importantly, curcumin’s role in preventing apoptosis 
potentially has significant implications for its use as a neuroprotective agent in the treatment of 
neurodegenerative disorders.  
 
4.3. Curcumin’s role in maintaining healthy mitochondria 
 
When determining the effect of curcumin on mitochondrial function in PINK1-deficient cells, two 
major findings were observed: i. curcumin increased maximal respiration after paraquat treatment, and 
ii. curcumin increased MMP in these cells (Table 4.1). The maximum respiratory rate reflects an 
unstable state in the cells where the addition of a mitochondrial uncoupler stimulates increased 
respiration. Maximal respiration is indicative of the maximum activity of electron transport and 
substrate oxidation that is achievable by the cells, and a decrease in maximal respiration is a strong 
indicator of mitochondrial dysfunction (Brand and Nicholls, 2011). Therefore the observation that 
curcumin increases the maximal respiratory rate, as well as the MMP, suggests that it plays a role in 
protection of mitochondrial function in paraquat-induced and PINK1-deficient cells. To our knowledge, 
this is the second study that has assessed the effect of curcumin on OCR using the XF Analyser, the 
first of which found that curcumin reversed metabolic defects in breast epithelial cells (Vaughan et al., 
2013).  
 
Various studies on different diseases affected by mitochondrial damage have been conducted to 
determine the effect of curcumin on mitochondrial function. Mythri and colleagues used peroxynitrite 
(PN), a free radical that mediates complex I injury, to damage mouse brain mitochondria in vivo and in 
vitro. When these cells were pre-treated with curcumin, they were protected against PN damage and the 
decreased MMP, complex I injury and decreased glutathione antioxidant levels were all attenuated 
(Mythri et al., 2010, Mythri et al., 2007). Furthermore, curcumin increased the activity of all five 
complexes of the ETC and subsequently decreased mitochondrial dysfunction in rats with renal oxidant 
damage (Molina-Jijón et al., 2011) and in aluminium-treated rats (Sood et al., 2011). Rats treated with 
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curcumin prior to reperfusion injury also portrayed increased mitochondrial respiratory capacity and 
attenuated reperfusion injury damage (González-Salazar et al., 2011).  
 
Studies have shown curcumin to act as a strong antioxidant, capable of reducing the levels of oxidative 
stress and ROS, and increasing the MMP (Chen et al., 2006; Harish et al., 2010; Zhao et al., 2011). The 
effects of curcumin on the mitochondria have also been observed in models of PD. Wang and colleagues 
over-expressed α-synuclein in SH-SY5Y cells which resulted in elevated ROS levels, cytotoxicity and 
apoptosis. The addition of curcumin protected the cells from these defects (Wang et al., 2010). A second 
study demonstrated that curcumin prevented damage in a rotenone-induced SH-SY5Y model by 
reducing levels of ROS (Z. Liu et al., 2013). Our study confirms the role of curcumin in prevention of 
mitochondrial damage by increasing mitochondrial respiration, and stabilising MMP. Once the 
mitochondria are protected and functional, this leads to cellular health and reduced cell death.  
 
4.4. Curcumin’s role in autophagy 
 
Curcumin treatment resulted in significantly increased autophagic flux in control cells treated with 
paraquat, but this was not observed in PINK1-deficient cells (Table 4.1). Therefore curcumin plays a 
role in autophagic induction when cells are under stress (i.e. after the addition of paraquat), but not to 
the same extent when PINK1 expression is decreased in the cells. This could indicate that the extent of 
the damage caused to both the mitochondria and the general health of the cell without sufficient levels 
of PINK1 is too severe to be rescued by curcumin. On the other hand, this could also suggest that 
curcumin is only able to induce autophagy in the presence of PINK1. To our knowledge, this is the first 
study to look at the effect of curcumin on autophagy in a PINK1 knock down cell line. Therefore the 
action of curcumin on PINK1 will need to be studied further and in greater depth in the future. Other 
functional assays including the analysis of mitophagy or ROS levels should be performed, and this also 
needs to be studied in an in vivo PINK1 knock out model of PD.   
 
Analysis of autophagic flux is currently the gold standard for measuring autophagy. (Nelson and 
Shacka, 2013). Over the past few years, there has been much debate surrounding the role of autophagy 
in cells. Whilst some researchers firmly believe that autophagy plays a vital role in cell survival by 
removing dysfunctional proteins and organelles, others suggest that autophagy is a key promotor of 
non-apoptotic programmed cell death, by engulfing the cytoplasm. Cell damage and cell death can 
therefore either result from autophagy being too active, or too inactive (Nelson and Shacka, 2013). 
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Interestingly, curcumin appears to induce autophagy in most studies, but depending on the cell type and 
disease it can either cause autophagic cell death or cell survival. 
 
Curcumin was initially thought to have anticarcinogenic properties when it induced cell death in 
malignant cells, but not healthy cells (Karunagaran et al., 2005). Over the past decade, studies have 
shown that curcumin induces cell death through the induction of autophagy, and this has been observed 
in hepatocellular carcinoma cells (Qian et al., 2011), colon cancer cells (Basile et al., 2013; Lee et al., 
2011), malignant glioma cells (Zhuang et al., 2012), leukaemia cells (Jia et al., 2009; Wu et al., 2011) 
and oesophageal cancer cells (O’Sullivan-Coyne et al., 2009). Despite this evidence, curcumin-induced 
autophagy appears to only enhance cell death in certain tumour types, whilst mediating 
chemotherapeutic resistance in others (Wilken et al., 2011). A study performed on colon cancer stem 
cells revealed that curcumin induced proliferation and autophagic survival, permitting long term 
persistence of colorectal cancer (Kantara et al., 2014).  
 
The predominant consensus suggests that autophagy triggers cell survival in neurodegenerative 
disorders rather than autophagic cell death. Maintenance of proper autophagic function is critical to 
providing neuroprotection to non-dividing neuronal cells, as increased autophagic flux results in an 
increased  rate of clearance of damaging cellular materials and thus the regulation of a healthy cellular 
environment (Harris and Rubinsztein, 2012; Nelson and Shacka, 2013). In our study, we observed 
increased autophagic flux in curcumin-treated paraquat-induced cells, suggesting that autophagy 
resulted in cell survival rather than cell death. Very few studies have been conducted on the effect of 
curcumin on autophagy in PD. Jiang and colleagues overexpressed mutant A53T α-synuclein in SH-
SY5Y cells which resulted in impaired autophagy (Jiang et al., 2013). Curcumin treatment reduced 
A53T accumulation, recovered autophagy, and also resulted in downregulation of the mTOR 
(mammalian target of rapamycin)/ p70S6K (p70 ribosomal protein S6 kinase) pathway. A study on 
APP/PS1 double transgenic AD mice also showed that curcumin decreased mTOR expression, thus 
enhancing autophagy and resulting in increased clearance of Aβ (Wang et al., 2014). mTOR is a protein 
kinase that acts as a key regulator of autophagy. When active, mTOR inhibits autophagy, but when 
inactivated by rapamycin or nutrient starvation, autophagy is induced. Therefore by inhibiting the 
mTOR pathway, curcumin allows for induction of autophagy.  
 
A summary of the results from this section is depicted in Figure 4.1. Paraquat exposure to cells with 
either healthy PINK1 protein (control) or absent/ mutant PINK1 (PINK1 siRNA) had a negative effect, 
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and resulted in mitochondrial dysfunction and cell death. Pre-treatment with curcumin, however, 


























Paraquat exposure stresses the cells 
Decreased MMP, fragmented mitochondrial network, increased apoptosis, decreased cell viability 
Curcumin rescues the cells from the effects of paraquat 
Rescues MMP Rescues MMP 
Increases mitochondrial respiration 
(maximal respiration, spare respiratory capacity) 
Increases mitochondrial respiration 
(maximal respiration) 
No effect on glycolysis Increases basal glycolysis 
Reduces fragmentation of mitochondrial network No effect on mitochondrial network 
Increases autophagic flux No effect on autophagic flux 
Decreases apoptosis 
Rescues cell viability 
Decreases apoptosis 
No effect on cell viability 
Figure 4.1. Diagram highlighting the rescue effect of curcumin from paraquat in cells with either healthy or 
absent/ mutant PINK1  
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4.5. No PINK1 CNV mutations detected in South African PD patients 
 
The aim of this section of the study was to detect CNV primarily in PINK1, and secondarily in other 
PD-causing genes parkin, SNCA, LRRK2 and DJ-1, in a cohort of South African PD patients. Once 
detected, we could then have obtained patient’s fibroblasts, and compared the effects in these to that 
observed in our PINK1-deficient SH-SY5Y cell model. Furthermore, we could have tested the effects 
of curcumin on these fibroblasts. Fibroblasts have been known to serve as a useful primary PD cell 
model as they are readily available and obtainable from a skin biopsy, express most of the PD genes at 
relatively high levels, and they reflect cumulative cellular damage according to the age of the patient 
(Auburger et al., 2012). Unfortunately, we were unable to detect CNV in PINK1 in our patient cohort, 
and were therefore unable to repeat the study on patient-derived fibroblasts with PINK1 mutations. 
Furthermore, no CNV was detected in SNCA, LRRK2 or DJ-1. The only mutation found in our cohort 
of 210 patients screened in this study was a heterozygous deletion of parkin exon 4 in a white male 
patient with an AAO of 49 and no family history of PD. No other CNV or point mutations in parkin 
were found in this patient. 
 
Heterozygous mutations in parkin have played a controversial role in recessive genes, and it is still 
unknown whether they are pathogenic in themselves (Corti et al., 2011). Kay and colleagues screened 
over 2000 patients with PD, as well as age-matched controls (Kay et al., 2010). Interestingly, a total of 
0.95% of control subjects carried a heterozygous CNV mutation in parkin, compared to 0.86% of 
patients. This indicates that there is no compelling evidence for association of heterozygous parkin 
mutations with PD. Conversely, it has been reported in several studies that individuals who are 
heterozygous carriers of mutations in parkin can also present with PD (Bonifati et al., 2005; Hedrich et 
al., 2004; West et al., 2002). It is thought that heterozygous mutations are not sufficient to cause PD, 
but are rather associated with a higher risk of developing the disease and may play a role in a threshold 
effect for parkinsonism (Klein et al., 2007).  
 
The mutation frequency of PINK1 mutation carriers varies from 0-15% worldwide, depending on the 
population, making this gene the second most frequent cause of autosomal recessive EOPD - after 
parkin (Corti et al., 2011; Deas et al., 2009; Nuytemans et al., 2010). The majority of PINK1 mutations 
are point mutations and small insertions/deletions, whilst larger deletions and complex rearrangements 
are rare (Cazeneuve et al., 2009; Marongiu et al., 2007). To our knowledge, CNV in PINK1 using the 
MLPA kit has been reported in two studies focussed specifically at early onset cases – one heterozygous 
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deletion of exon 1 was observed in a Brazilian cohort (Moura et al., 2012) and a compound heterozygous 
deletion of exon 2 + deletion of exon 2, 3 and 4, was found in an Iranian cohort (Darvish et al., 2013). 
In both studies, the CNV in PINK1 was only observed in one patient. This highlights the rarity of exonic 
or genomic rearrangements in PINK1 in certain populations.  
 
In comparison to PINK1, parkin mutations are far more frequent, and are responsible for 10-20% of 
EOPD cases worldwide (Corti et al., 2011). Parkin mutations have been found in numerous families 
with different ethnic backgrounds, including individuals with African ancestry (Haylett et al., 2012; 
Hedrich et al., 2004; Lücking et al., 2000; Periquet et al., 2003). In a previous study, Haylett and 
colleagues aimed to assess the genetic contribution of parkin mutations (both point mutations and exon 
rearrangements) in a group of 229 South African PD patients. Seven patients (3.1%) had homozygous 
or compound heterozygous mutations in parkin, and seven patients had heterozygous sequence variants 
(Haylett et al., 2012), concluding that mutations in the parkin gene are not a major contributor to PD in 
the South African population. The results from the present study confirm that the known PD-causing 
genes are only a rare cause of PD in South African patients. A study on Zambian PD patients found one 
heterozygous parkin mutation in a cohort of 39 patients (Yonova-Doing et al., 2012). Together, these 
studies highlight a concerning situation relating to the genetic cause of PD in African individuals. It is 
clear that in comparison to other populations, mutations in the known PD-causing genes are less 
frequent in African populations, and this may be due to the hypothesis that there are still unknown 
genetic causes of PD, and these may be specific to the African population. 
 
Currently, genetic characterization of the African population remains limited, although recently the 
African Genome Variation Project (AGVP) was set up to assess genetic diversity in Africa by the WGS 
of 320 individuals (Gurdasani et al., 2015). High levels of genetic diversity are observed in African 
populations, and studying these populations in greater detail could lead to the discovery of genetic 
determinants that may contribute to the global understanding of disease (Ramsay et al., 2011). 
 
4.6. Study limitations 
 
Patient-derived dopaminergic neurons would be an ideal cell type in which to study the pathogenesis 
of PD. Unfortunately, the individual would need to be deceased before these cells can be obtained, and 
brain cells post mortem may have an altered phenotype and gene expression profile compared to when 
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the cells were still active. Therefore, an alternative method for studying PD is to create a disease model 
that can replicate dopaminergic neurons as best as possible. The SH-SY5Y cell line used in this study 
is commonly used as a cellular model for PD (Xie et al., 2010). Advantages of using this cell type 
include ease of access, culturing ability, and capacity to under or over express genes. Whilst SH-SY5Y 
cells do possess many characteristics of dopaminergic neurons, they are not derived from patients with 
PD, and were therefore a limitation of this study. As mentioned above, we would ideally have repeated 
this work in PINK1-mutant fibroblasts, but this was not available to us. From fibroblasts, one could 
then have created iPSC dopaminergic neurons, which are advantageous in that they are patient-derived 
neuronal cells. However, one must be cautious when regarding this cell type, as the characteristics of 
an iPSC-derived neuron may not mirror those of patient neurons.  
 
Experimental limitations of this study included the protein expression level of PINK1 after siRNA 
treatment. Whilst a decrease in protein expression of 54% was sufficient to induce mitochondrial and 
cellular dysfunction, this does not accurately portray the effect seen in PINK1-associated PD, where 
100% of the protein is truncated or absent. Therefore, a 100% decrease in PINK1 protein expression 
would have been preferable, but this was not possible with the methodology used in this study. 
Secondly, each experiment was performed in triplicate, and was also biologically replicated three times 
(n=3). Whilst this is considered a standard protocol, some of the results presented with large error bars 
after statistical analysis. It is thought that the statistical power of these results could have been increased 
if ‘n’ was greater than 3.  
 
This study determined one optimal concentration for paraquat and curcumin to be used in all functional 
assays. However, in order to better understand the effect of paraquat and curcumin, a dosage curve of 
varying concentrations can also be performed for each assay. One could then observe whether a higher/ 
lower concentration had a better/ worse effect on the cells compared to other doses. Furthermore, we 
could have included other treatment groups such as paraquat and curcumin combined, or post-treatment 
with curcumin (rather than only pre-treatment). Other studies have found that pre-treatment with 
curcumin before a stressor produces the best results (Mythri et al., 2010), and that was the reason for 
the chosen protocol in this study. Additionally, future experiments should verify the results from the 
MTT assay with an independent assay, such as the WST-1 or ATP assay. 
 
For Western blot detection of protein markers for apoptosis and autophagy, two markers were used for 
each process. For apoptosis, we initially aimed to use cleaved caspase 3 as a marker to verify the results 
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found from cleaved PARP. Cleaved caspase 3 is a reliable and frequently used marker of apoptosis. 
However we were unable to detect the protein in our lysates with the available antibodies, and therefore 
chose to use full-length caspase 3. Whilst these results verified the majority of the observations from 
cleaved PARP, other markers available for apoptosis such as cleaved and full-length caspase 8 and 9 
could also have been utilised in our study. As previously mentioned, the use of p62 as a marker of 
autophagy can often be regarded as unreliable, therefore other autophagy-specific markers such as Atg 
proteins or Beclin-1 should be studied and utilised in future experiments. In addition, the measurement 
of autophagic flux by Western blotting is in itself a limitation. Western blotting is able to measure a 
‘rate’, and is also a difficult method to assess small changes in LC3-II and p62 protein levels accurately 
(Loos et al., 2014). New techniques need to be established whereby flux can be measured in a highly 
sensitive, robust and well-quantifiable manner. 
 
Lastly, the polymorphisms observed in PARK2 exon 5 were only observed in Mixed Ancestry and Black 
individuals (Table 3.1), and led to false positive CNV findings. Therefore, manufacturers of MLPA kits 
need to take into account these ethnic-specific polymorphisms for the design of more appropriate 
probes.   
 
4.7. Future work 
 
As previously mentioned, we found no patients with CNV in the PINK1 gene, and were therefore unable 
to obtain fibroblasts (Section 3.10). In order to verify these results in a patient-derived cell model of 
PD, we will contact either researchers or cell banks that may have access to PINK1 mutant fibroblasts. 
Whilst studying cells with PINK1 CNV is ideal, these mutations are extremely rare, and fibroblasts with 
PINK1 point mutations may be another option. Once obtained, the various functional assays used in 
this study should be performed to determine the effect of PINK1 mutations in these cells. Additional 
assays should also be executed, such as measurement of mitophagy and the levels of ROS and 
antioxidants. 
 
Furthermore, we will aim to establish a protocol for culturing iPSCs from the fibroblasts. One option is 
that this will be performed in collaboration with researchers from the University of Cape Town in South 
Africa, as this methodology has been successfully set up in fibroblasts from patients with 
spinocerebellar ataxia (Watson et al., 2015). In addition, it would also be ideal to repeat this study in an 
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animal model of PD. Once established, we would have three models of PINK1-deficient PD – 
fibroblasts, iPSCs, and an animal model. Using this multi-tiered approach, one could study the effects 
of curcumin in each system, compare the results, and create a better understanding of its mode of action. 
Subsequent to those studies, a clinical trial could be launched for curcumin in South African patients 
suffering from PD.  
 
Accumulating various models in which to study PD is advantageous in that it enables one to study the 
effects of other compounds of interest. For example, resveratrol is an antioxidant enriched in grapes, 
and has beneficiary effects similar to that of curcumin (Bereswill et al., 2010; Sharma et al., 2007). 
Several studies performed on the effect of resveratrol in PD have found that it attenuates oxidative stress 
and exerted neuroprotection in rat models of the disease (Jin et al., 2008; Wu et al., 2011). Future work 
could focus on the effect of this compound and other natural, non-toxic antioxidants on our models of 
PD. 
 
4.8. Concluding remarks 
 
In conclusion, this study has shown that down regulation of PINK1 results in mitochondrial dysfunction 
and neuronal cell death. Mitochondria are active players in apoptosis via the intrinsic mitochondrial 
death pathway, and understanding the effects of curcumin on the mitochondria in models of PD may be 
key to develop this drug as a therapeutic option in patients with PD and related neurodegenerative 
disorders. Whilst pharmacological and surgical interventions are available, the current options exhibit 
distinct side effects with long term treatment. There is a great need to develop new treatments with i. 
less side effects and ii. that can simultaneously target the multiple pathways associated with this 
disorder.  
 
The greatest challenge facing researchers that have studied curcumin is that it is an enigma – how can 
one single molecule possess such diverse activities? In this study, we aimed to create a better 
understanding of the function of curcumin, and to determine whether it may be a potential therapeutic 
agent for patients suffering from PD. We have shown that curcumin reduced apoptosis and improved 
mitochondrial respiration and MMP in our model of PD. Curcumin did not increase autophagic flux in 
our model, but rather in control cells stressed by paraquat, speculating a possible role for curcumin in 
the PINK1/parkin pathway and mitophagy.  




Future studies on the effect of curcumin on PD are vital, as this compound may be an ideal 
neuroprotective agent. Curcumin is known to have a variety of beneficial properties including 
antioxidant and anti-inflammatory, which could lead to its ability to promote cell survival in 
neurodegenerative diseases such as PD and AD. In addition, curcumin is advantageous as it has low 
toxicity, and is already commercially available from pharmacies in the form of a concentrated capsule 
or as a component of the curry spice turmeric. Further work on clinical applications of curcumin in 
patients suffering from PD and other diseases may reveal that this compound is a key element for the 
development of therapeutic modalities aimed at preventing or halting neuronal cell death. 
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Appendix I: Laboratory protocols: 
 
1. Culturing SH-SY5Y neuroblastoma cells 
 
Flasks were labelled correctly and the work bench was prepared and cleaned with ethanol to ensure no 
contamination. Medium for SH-SY5Y cells was made up of a 1:1 ratio of DMEM: Ham’s F12, and 
treated with 10% FBS and 1% penicillin streptomycin. A volume of 1ml media was added to frozen 
stocks of cells, and this was placed in a 15ml Flacon tube and centrifuged for 3mins at 4500rpm. The 
supernatant was discarded and the pellet was resuspended in 2ml media. A volume of 4ml media was 
added to a 25cm² CellBIND flask (Corning, USA), and the resuspended cell solution was then pipetted 
directly into the flask. Flasks were incubated at 37°C, 5% CO2 until 80-90% confluency.  
 
1.1. Trypsinising the cells 
Once confluent, cells were trypsinised and relocated to either a larger 75cm2 flask, or a tissue culture 
plate specific to the experiment. Media was pipetted out of the flask, and cells were washed with 5ml 
PBS. Once removed, 5ml trypsin was added to the cells and the flask was incubated at 37°C until they 
no longer adhered to the flask surface. Thereafter, 4ml media was pipetted into the flask and mixed with 
the cells and the trypsin. This was then pipetted out of the flask and into a 15ml Falcon tube, which was 
centrifuged for 3min at 4500rpm. The supernatant was discarded and the pellet was resuspended in 
media, the volume of which was also dependent on which flask/ plate the cells would be seeded into.  
 
1.2. Freezing down procedure 
 
Freezing media was made up using 3.2ml media and 0.8ml DMSO. Once trypsinised and resuspended 
in 3ml media, a total volume of 1ml of resuspended cells was mixed with a volume of 1ml freezing 
media. Thereafter, two volumes of 1ml of the cell suspension + freezing media combination was 
aliquoted into 2X 2ml sterile cryotubes. The 2ml cryotubes were placed in the -80°C freezer for a 
minimum of 4hrs. The tubes were then carried in liquid nitrogen to the liquid nitrogen storage containers 
and placed in the boxes. One vial was thawed, put into a 25cm² flask containing 5ml culture medium 
and incubated for three days as a control to check for viability and exclude contamination (Freshney, 
2010).  





2. Genomic DNA isolation from blood samples 
 
Four 5ml blood samples in EDTA tubes were aliquoted into 2 sterile 50ml tubes. These were then filled 
to the 45ml mark with cold cell lysis buffer. Each tube was well shaken and left on ice for 10mins. The 
tubes were shaken again, after which cells were pelleted by spinning at 3000rpm for 10mins. The 
supernatant was poured off and the wash step was repeated. Thereafter a volume of 900µl sodium 
acetate (3M solution) and 100µl of 10% sodium dodecyl sulfate (SDS) was added to each pellet. The 
pellet was resuspended in this solution and 100µl of proteinase K was added to each tube. The mixture 
was incubated at 37C overnight. 
 
The following day, 2ml dH2O and 500µl 3M Na-acetate was added to each tube, after which the solution 
was mixed. A volume of 2,5ml of phenol-chloroform was added to each tube and the mixture shaken 
on a shaking platform at room temperature. The mixture was then transferred to a 10ml glass Corex 
tube and spun at 7000rpm for 12mins at a temperature of between 4 C and 10 C. The supernatant was 
then transferred to a clean Corex tube without disturbing the interphase. Thereafter, 2,5ml octonal-
chloroform was added to each tube. The tubes were sealed tightly and slowly mixed by inversion until 
the mixture turned milky. The tubes were then centrifuged without lids at 7000 rpm for 10mins in a 
Sorval centrifuge at a temperature of between 4C and 10 C. The supernatant was poured into a 12ml 
plastic tube, and 5-7ml ethanol was slowly added. The tube was closed and mixed until the DNA 
precipitated.  
 
The DNA was transferred to a 1,5ml Eppendorf tube, which was filled with 70% ethanol and centrifuged 
at 14000rpm for 3mins. The supernatant was poured off and the wash was repeated. The pellet was then 
dried at room temperature for 30mins, after which 500µl of a 1x Tris-EDTA solution was added to each 
tube. The tubes were incubated overnight at 37C. Thereafter, the solutions were mixed for three days 
on a rotating wheel at 30rpm. The concentration of the DNA solution was read by the Nanodrop and 
the sample was diluted to a concentration of 0.1-0.2µg/µl. All gDNA isolations were performed by Miss 
Ina Le Roux and Dr. Sihaam Boolay. 
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Cell lysis buffer 
5ml passive lysis buffer  
100µl 50mM PMSF 




10x SDS Running Buffer 
30g Tris base 
144g Glycine 
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100ml 10% SDS 
ddH₂O to a final volume of 1L 
 1x SDS Running Buffer 
Dilute 100ml 10x SDS Running Buffer in 900ml distilled water 
 
5% Milk for membrane blocking 
10g milk powder 
200ml TBST 




20ml 1M Tris-HCl (pH 7.6) 
1ml Tween 20 
pH 7.6 
ddH₂O to a final volume of 1L 
 





Dissolve paraformaldehyde in PBS by adding 1M NaOH and heating it to 50°C for 30mins with 
constant stirring. Adjust final pH to 7.4-7.6. 





12g Mowiol 4-88     
30g Glycerol     
30ml ddH2O       
Add 60ml of a 0.2M Tris stock solution (pH 8.5) and stir overnight at room temperature. Dissolve 
remaining Mowiol by heating to 50˚C with constant stirring. Centrifuge at 5000g for 15 min. Aliquot 
and store supernatant at -20˚C.  
<10mg anti-fading agent 
A small quantity of anti-fading agent (n-propylgallate) was dissolved in 1ml mounting media at 50°C 
for 1 hour. This was centrifuged at 5000g for 2min and stored in the dark at 4°C for up to three weeks. 
 
 2.4. Solutions for functional assays 
 
5mg/ml MTT stock solution 
10mg Thiazolyl blue tetrazolium bromide 
2ml PBS 
 
5mg/ml JC-1 stock solution 
5mg Tetraethyl benzimidazolyl carbocyanine iodide  
1ml DMSO 
 
20µg/ml Bafilomycin A1 stock solution 
100µg Bafilomycin A1 
5ml ethanol  
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Appendix III: MLPA probes and reagents list 
 
 
3.1. Mix P051 probe list (Taken from www.MLPA.com) 






3.2. Mix P052 probe list (Taken from www.MLPA.com) 
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Based on the confluency of the cells after 24 hours, it was decided to seed cells at 100 000 cells per 
well for future cell viability work. 
  
Stellenbosch University  https://scholar.sun.ac.za
133 
 









5.1. Measurements of ECAR to determine levels of glycolysis and glycolytic reserve in PINK1 siRNA 





































5.2. No significant changes were observed across treatment groups in both control and PINK1 siRNA 










Coffalyser.Net: http://coffalyser.software.informer.com/download  
GraphPad Prism: http://.graphpad.com/scientific-software/prism  
Image J: http://imagej.nih.gov/ij 
Lightcycler 96: http://roche.com 
REST: http://gene-quantification.de/rest.html 
XFe96 Wave: http://seahorsebio.com 
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